



- (51) **International Patent Classification:**
G01N33/68 (2006.01) *C07K16/12* (2006.01)
- (21) **International Application Number:**
PCT/US20 13/021381
- (22) **International Filing Date:**
14 January 2013 (14.01.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/593,654 1 February 2012 (01.02.2012) US
- (71) **Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION** [US/US]; 825 N.E. 13th Street, MS 52, Oklahoma City, OK 73104 (US).
- (72) **Inventor: SMITH, Kenneth;** c/o Oklahoma Medical Research Foundation, 825 N.E. 13th Street, MS 52, Oklahoma City, OK 73104 (US).
- (74) **Agent: HIGHLANDER, Steven, L.;** Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX 78746 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))



WO 2013/115962 A2

(54) **Title:** HUMAN STREPTOCOCCUS PNEUMONIAE ANTIBODIES AND USES THEREFOR

(57) **Abstract:** The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of *Streptococcus pneumoniae* infections. In particular, these antibodies may kill *Streptococcus pneumoniae* or limit the replication of *Streptococcus pneumoniae*. Also disclosed are improved methods for producing such monoclonal antibodies.

DESCRIPTION

HUMAN *STREPTOCOCCUS PNEUMONIAE* ANTIBODIES AND USES THEREFOR

BACKGROUND OF THE INVENTION

5

This invention was made with government support under grant numbers P20RR015577, P20RR015577-10S1, P30RR031 152, P30AR053483, and U19AI062629, and contract number HHSN266200500026C (N01-AI500026), awarded by the National Institutes of Health. The government has certain rights in the invention.

10

This application claims benefit of priority to U.S. Provisional Application Serial No. 61/593,654, filed February 1, 2012, the entire contents of which are hereby incorporated by reference.

15

The sequence listing that is contained in the file named "OMRFP0 108US_ST25 ", which is -91.8 KB and was created on January 8, 2013, is filed herewith by electronic submission and is incorporate by reference herein.

1. Field of the Invention

The present invention relates generally to the fields of microbiology, immunology and pathology. More particularly, it concerns the development of human monoclonal antibodies for use in the diagnosis, prevention and therapy of *Streptococcus pneumoniae* infections.

20

2. Background of the Invention

Streptococcus pneumoniae is a ubiquitous human pathogen causing a range of clinical infections, such as otitis media, pneumonia, meningitis, and bacteremia. The more serious manifestations are especially virulent in immunocompromised and elderly individuals. Over 90 different 5' *pneumoniae* serotypes have been characterized, each having a different capsular polysaccharide structure. These polysaccharides are immunogenic in adults, and the Pneumovax®23 vaccine consists of a cocktail of 23 of the most common and/or virulent 5' *pneumoniae* strains. The vaccine is recommended for everyone over the age of sixty, as well as all immunocompromised individuals, to ensure seroprotection against these strains.

30

The serology of the response to Pneumovax®23, as well as the conjugate vaccine Prevnar® (used to immunize children), has been studied in depth with regard to the humoral polyclonal IgG and IgA responses in both sera and saliva (Anttila *et al*, 1999; Nieminen *et al*, 1998a; Nieminen *et al*, 1998b). The memory and antibody secreting cell (ASC) response

to these vaccines has also been previously explored on a cellular level with B cell ELISpot assays and flow cytometry (Nieminen *et al.*, 1998b; Clutterbuck *et al.*, 2006), and the presence of both responses after vaccination is now well established. However, utilizing ASCs to produce human monoclonal antibodies would provide a novel way to fully elucidate the recall response to pathogen serotypes after vaccination, and even provides a window to explore the evolution of past responses.

Antibodies that cross-react to two or more pneumococcal polysaccharides are present in sera both pre- and post-immunization (Lee *et al.*, 1984; Soininen *et al.*, 2000); however, whether this is due to single antibody specificities that are capable of cross-reacting or rather due to broad polyclonal antibody specificities is not known. Although it has been reported that immunization with Pneumovax®23 in patients with SLE does not induce new auto-specificities (Elkayam *et al.*, 2005), one report has shown that kidney-binding antibodies in a patient with SLE also cross-reacted with pneumococcal polysaccharide (Chowdhry *et al.*, 2005). Thus, it is possible that antibodies produced from B cells in SLE donors may show increased poly-reactivity or auto-reactivity. It is only possible to determine such per-antibody phenomenon by the characterization of human monoclonal antibodies from SLE donors.

SUMMARY OF THE INVENTION

Thus, in accordance with the present invention, there is provided a human monoclonal antibody panel comprising a plurality of antibodies, wherein antibodies in said panel bind to at least 15 serotypes of *Streptococcus pneumoniae*. The antibodies in said panel may bind to at least 18 *S. pneumoniae* serotypes or 21 *S. pneumoniae* serotypes. At least 15 antibodies may be serotype specific, at least 17 antibodies may be serotype specific, or 19 antibodies may be serotype specific. The antibody panel may be attached to a support, such as a bead, a dipstick, a filter, a membrane, a plate, or a chip. The serotypes may be selected from 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 11B, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F and CWPS. The antibody panel may comprise an antibody that reacts with two serotypes.

In another embodiment, there is provided a method of assessing a *Streptococcus pneumoniae* in a subject comprising obtaining a first antibody-containing sample from said subject and assessing binding of antibodies in said sample to a human monoclonal antibody panel comprising a plurality of antibodies, wherein antibodies in said panel bind to at least 15 serotypes of *Streptococcus pneumoniae*. The antibodies in said panel may bind to at least 18 *S. pneumoniae* serotypes or 21 *S. pneumoniae* serotypes. At least 15 antibodies may be serotype specific, at least 17 antibodies may be serotype specific, or 19 antibodies may be serotype specific. The antibody panel may be attached to a support, such as a bead, a dipstick, a filter, a membrane, a plate, or a chip. The serotypes may be selected from 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 11B, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F and CWPS. The antibody panel may comprise an antibody that reacts with two serotypes.

The subject may be immunocompromised and/or 60 years old or older. The subject may be suspected of having a *Streptococcus pneumoniae*. The method may further comprise treating said subject with an anti- *Streptococcus pneumoniae* therapy if said first antibody-containing sample is found to be positive for one or more serotypes. The method may further comprise treating said subject with vancomycin or levofloxacin if first said antibody-containing sample is found to be positive for serotype 19A and/or 19F. The first antibody-containing sample may be blood, serum, plasma, sputum, or saliva.

The method may further comprise obtaining a second antibody-containing sample from said subject and assessing binding of antibodies in said second sample to a human monoclonal antibody panel comprising a plurality of antibodies, wherein antibodies in said panel bind to at least 15 serotypes of *Streptococcus pneumoniae*. The second antibody-containing sample may be blood, serum, plasma, sputum, or saliva. The subject may have

been treated with an *anti-Streptococcus pneumoniae* therapy after determining that said first antibody-containing sample was positive for one or more serotypes, and a reduction in antibody titer to serotypes from said first sample indicates that said *anti-Streptococcus pneumoniae* therapy is effective at treating *Streptococcus pneumoniae*. The subject may have
5 been treated with an antibiotic after determining that said first antibody-containing sample was positive for one or more serotypes, and the absence of a reduction in antibody titer to serotypes from said first sample indicates that said *anti-Streptococcus pneumoniae* therapy is ineffective at treating *Streptococcus pneumoniae*, and optionally the method may further comprise treating said subject with a different *anti-Streptococcus pneumoniae* therapy.

10 In yet another embodiment, there is provided an antibody that binds selectively to *Streptococcus pneumoniae*, wherein said antibody has heavy and light chain CDRs selected from those set forth in Table 2. The antibody may be a single chain antibody, a single domain antibody, a chimeric antibody, a Fab fragment, or an IgG. The antibody may further comprise an antibiotic linked thereto, such as one linked to said antibody through a
15 photolabile linker or through an enzymatically-cleaved linker. The antibody may be conjugated to a nanoparticle or a liposome.

In still yet another embodiment, there is provided a method of treating a *Streptococcus pneumoniae* infection in a subject comprising administering to said subject an antibody as described above. The method may further comprise administering to said subject
20 a second anti- *Streptococcus pneumoniae* treatment, which can be given at the same time as said antibody or given before and/or after said antibody. The antibody may be a single chain antibody, a single domain antibody, a chimeric antibody, a Fab fragment or an IgG.

The antibody may further comprises an antibiotic linked thereto, such one linked to said antibody through a photolabile linker or through an enzymatically-cleaved linker. The
25 antibody may be conjugated to a liposome or nanoparticle. Multiple *anti-Streptococcus pneumoniae* antibodies are administered, such as multiple *anti-Streptococcus pneumoniae* antibodies that bind to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 *Streptococcus pneumoniae* serotypes.

30 It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.

The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the

meaning of "one or more," "at least one," and "one or more than one." The word "about" means plus or minus 5% of the stated number.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed
5 description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIGS. 1A-B. Pneumovax®23 causes a massive ASC burst which can be used as a source of high affinity anti-polysaccharide antibodies. (FIG. 1A) PBMCs were harvested from four donors 7 days after vaccination with Pneumovax®23. They were stained and sorted for cells which are CD3 and CD20 negative and CD19 intermediate. The dot plots presented indicate a large ASC burst in all four donors (CD27 high, CD38 high; circular gate). Averaging the percentage of ASCs from these four donors, designated as Con1, Con2, SLE1, and SLE2, 16.3% of total B cells in the peripheral blood are ASCs. (FIG. 1B) The ASCs indicated in A. are sorted into 96-well plates. RT-PCR and several rounds of nested PCR are performed to prepare the V regions for cloning. The DNA is then cloned into expression vectors, amplified, and transfected into the HEK293 human cell line.

FIGS. 2A-C. On average, 77% of antibodies produced after vaccination with Pneumovax®23 bind to a vaccine component. (FIG. 2A) An average of 77% (Con1, 62%; Con2, 90%; SLE1, 75%; SLE2, 75%) of the antibodies expressed bind to *S. pneumoniae* capsule or cell wall polysaccharide by ELISA. (FIG. 2B) While a significant percentage of antibodies are cross-reactive (12%), most of the antibodies produced are specific to a single serotype. (FIG. 2C) 52% of the antibodies from SLE2 are poly-reactive, binding to at least two of the following five antigens: Ro, La, Sm, nRNP, or cardiolipin.

FIGS. 3A-D. An individual can produce multiple antibodies to the same serotype, some of which are specific and others of which cross-react. (FIG. 3A.) Serotypes 9N and 9V have very similar structures, yet *Conlp2D02* binds only 9N and *SLElp1EO1* binds only 9V. (FIG. 3B) Conversely, *Conlp4B03* binds to both 9N and 9V. As shown by both affinity and avidity measurements, the binding to 9N is stronger than to 9V. (FIG. 3C) *SLElp1A03* binds to 9N, but cross-reacts with 14 rather than 9V. Its affinity and avidity for both 9N and 14 are similar. (FIG. 3D) *SLE2p2D03* binds to both 19A and 19F, which also share similar structures. The affinity to 19A and 19F is similar, however,

the avidity to 19A is 4 times stronger than to 19F. Affinity ELISAs are performed by coating plates with a single purified polysaccharide using serial dilutions of the antibody. Affinities (Kd's) are expressed in molarity. Avidity chaotropic ELISAs are performed in the same manner, but a 15 minute elution step using various dilutions of ammonium thiocyanate is added. Avidity graphs are presented as percent binding retained (OD_{405} with SCN/ OD_{405} without SCN * 100) versus the log of the thiocyanate concentration. The avidity is equal to the concentration of ammonium thiocyanate causing a 50% reduction (or retention) of binding.

FIGS. 4A-C. B cells generate cross-reactive antibodies to serotypes 15B and 14, as well as 17F and 33F. (FIG. 4A) Two antibodies, *SLE2p2G06* and *SLE2p2C04* bind solely to 17F or 33F respectively. (FIG. 4B) *SLE2plC03*, however, binds to both serotypes. The affinity for 33F is an order of magnitude better than the affinity for 17F, however, their avidities are similar. (FIG. 4C) *SLE2plB01* binds to both 15B and 14. Although the affinity is almost an order of magnitude higher for 15B, it actually shows two-fold higher avidity for 14.

FIGS. 5 ASCs resulting from vaccination with Pneumovax®23 produce antibodies which are highly mutated. Each data point is the average frequency of somatic mutations (nucleotide) per sequence from each donor (*n* values in Methods). On average, the anti-polysaccharide ASCs had accumulated a similar number of mutations as anti-influenza ASCs after seasonal influenza vaccination¹⁴. GC = germinal center populations.

FIGS. 6A-B. The specificity of ASCs induced by Pneumovax®23 is determined by a donor's memory response invoked by the vaccine. (FIG. 6A) The 'anamnestic fingerprint' from the four donors. None had previously received Pneumovax®23, thus the ASC 'recall' antibodies cloned resulted from memory due to previous exposure to *S. pneumoniae*. Each donor has a unique "fingerprint" of serotypes against which they have produced antibodies. (FIG. 6B) After eliminating members of clonal pools and combining all four graphs, the donors have very different 'pneumococcal fingerprints' with only three serotypes (9V, 15B and 17F) being represented from three donors, and only two from all four (8 and 33F).

FIGS. 7A-B. Cross-reactive and poly-reactive antibodies are shown from each donor. The ELISA curves from FIG. 2A are reproduced here also showing antibodies which are (FIG. 7A) cross-reactive in red and (FIG. 7B) poly-reactive in orange. Three of

the four cross-reactive antibodies from SLE2 are also poly-reactive (but none from the other donors).

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

To explore the antibody response generated by the Pneumovax®23 vaccine, the inventor generated and characterized large numbers of high affinity human monoclonal antibodies to the *S. pneumoniae* serotypes present in the vaccine from SLE patients and healthy controls. Although human monoclonal antibodies to *S. pneumoniae* have been made in the past (Baxendale and Goldblatt, 2006; Baxendale *et al*, 2000; Zhou *et al*, 2002; Zhou *et al*, 2004), these studies have been limited by two factors: one, they employed Fab expression library screens and two, they employed random production of hybridomas. In addition, previous studies have either focused on one serotype (6B and 23F) or have utilized vaccination with the conjugate vaccine Prevnar that consists of only seven capsular serotypes. In contrast, the inventor's technique provides cross-sectional characterization of the anti-polysaccharide response at one particular point in time, seven days post vaccination; thus, every cell used to clone an antibody has arisen from a memory response to this particular vaccination. This system will inform on a number of still unanswered questions in the field of polysaccharide immune responses and autoimmunity. In particular, the data here specifically address the percentage of human monoclonal polysaccharide antibodies that cross-react between different serotypes, how an individual's ASC response to Pneumovax®23 is a result of previous exposure to *S. pneumoniae*, and how this response differs in donors with SLE. As a result, there are now available a wide range of fully human monoclonal antibodies to *S. pneumoniae* that can be applied to diagnostic, theranostic and therapeutic applications. These and other aspects of the invention are described in detail below.

II. *Streptococcus pneumoniae*

A. General

Streptococcus pneumoniae, or pneumococcus, is Gram-positive, alpha-hemolytic, bile-soluble aerotolerant, anaerobic member of the genus *Streptococcus*. A significant human pathogenic bacterium, *S. pneumoniae* was recognized as a major cause of pneumonia in the late 19th century, and is the subject of many humoral immunity studies.

S. pneumoniae can be differentiated from *Streptococcus viridans*, some of which are also alpha-hemolytic, using an optochin test, as *S. pneumoniae* is optochin-sensitive. *S. pneumoniae* can also be distinguished based on its sensitivity to lysis by bile. The encapsulated, Gram-positive coccoid bacteria have a distinctive morphology on Gram stain,

the so-called, "lancet-shaped" diplococci. They have a polysaccharide capsule that acts as a virulence factor for the organism; more than 90 different serotypes are known, and these types differ in virulence, prevalence, and extent of drug resistance.

The genome of *S. pneumoniae* is a closed, circular DNA structure that contains
5 between 2.0 and 2.1 million basepairs, depending on the strain. It has a core set of 1553 genes, plus 154 genes in its virulome, which contribute to virulence, and 176 genes that maintain a noninvasive phenotype. Genetic information can vary up to 10% between strains.

S. pneumoniae is part of the normal upper respiratory tract flora, but, as with many natural flora, it can become pathogenic under the right conditions (*e.g.*, if the immune system
10 of the host is suppressed). Invasins, such as pneumolysin, an antiphagocytic capsule, various adhesins and immunogenic cell wall components are all major virulence factors.

Community-acquired pneumonia (CAP) is becoming more and more common, and represents an important cause of mortality and morbidity worldwide. While a number of different pathogens can give rise to CAP, *Streptococcus pneumoniae* is one of the most
15 common.

CAP is often acquired via inhalation or aspiration of pulmonary pathogenic organisms into a lung segment or lobe. Less commonly, CAP results from secondary bacteremia from a distant source.

Severe CAP normally develops in patients with cardiopulmonary disease, diminished
20 splenic function, and/or pathogenic virulence, but even young and/or healthy hosts can develop severe CAP if the causative pathogen is sufficiently virulent. Complications in CAP depend on the infecting pathogen and patient health. Myocardial infarction can be precipitated by fever due to community-acquired pneumonia (CAP). Also, patients with CAP who have impaired splenic function may develop overwhelming pneumococcal sepsis,
25 potentially leading to death within 12-24 hours, regardless of the antimicrobial regimen used.

CAP morbidity and mortality are highest in elderly patients and in immunocompromised hosts. Other factors that predict an increased risk of mortality in patients with CAP include the presence of significant comorbidities, an increased respiratory rate, hypotension, fever, multilobar involvement, anemia, and hypoxia.

30

B. Related Disease States

Despite the name, *S. pneumoniae* causes many types of pneumococcal infections other than pneumonia, including acute sinusitis, otitis media, meningitis, bacteremia, sepsis,

osteomyelitis, septic arthritis, endocarditis, peritonitis, pericarditis, cellulitis, and brain abscess.

C. Multi-drug Resistance

5 A growing concern in *S. pneumoniae* therapy is the resistance of strains many to penicillin and other beta-lactams (like amoxicillin), which is increasing worldwide. The major mechanism of resistance involves the introduction of mutations in genes encoding penicillin-binding proteins. This development complicates treatment immensely, and also adds unnecessary cost when therapies fail.

10 In 2000, Whitney *et al.* examined data on invasive pneumococcal disease in patients identified from 1995 to 1998 in the Active Bacterial Core Surveillance program of the Centers for Disease Control and Prevention. During 1998, 4013 cases of invasive *Streptococcus pneumoniae* disease were reported, and isolates were available for 3475 (87%). Overall, 24% of isolates from 1998 were resistant to penicillin. Penicillin-resistant isolates
15 were more likely than susceptible isolates to have a high level of resistance to other antimicrobial agents. Serotypes included in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78% and 88% of penicillin-resistant strains, respectively. Between 1995 and 1998, the proportion of isolates that were resistant to three or more classes of drugs increased from 9% to 14%; there also were increases in the
20 proportions of isolates that were resistant to penicillin (from 21% to 25%), cefotaxime (from 10% to 14%), meropenem (from 10% to 16%), erythromycin (from 11% to 15%), and trimethoprim-sulfamethoxazole (from 25% to 29%). These trends are like to continue, putting greater pressure on clinicians to resort to drugs such as vancomycin and levofloxacin.

25 D. Diagnosis

S. pneumoniae can be differentiated from other *Streptococcus* infections based on the alpha-hemolytic test. *Streptococcus viridans*, some of which are also alpha-hemolytic, can be distinguished using an optochin test, as *S. pneumoniae* is optochin-sensitive but *S. viridans* is not. *S. pneumoniae* can also be distinguished based on its sensitivity to lysis by bile. The
30 encapsulated, Gram-positive coccoid bacteria have a distinctive morphology on Gram stain, the so-called, "lancet-shaped" diplococci. They have a polysaccharide capsule that acts as a virulence factor for the organism; more than 90 different serotypes are known, and these types differ in virulence, prevalence, and extent of drug resistance.

In terms of distinguishing serotypes, antibodies are currently available to serotypes 1, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 12F, 14, 18C, 19F and 23F (ARUP Laboratories, Salt Lake City, UT).

5 E. Treatments

Antibiotics are the treatment of choice for *S. pneumoniae* infections, with ventilation (oxygen supplement) as supportive therapy of bacterial pneumonia. The antibiotic choice depends on the the microorganisms most commonly causing pneumonia in the geographical region, as well as nature of the specific organism, the immune status and underlying health of
10 the individual, the severity of infection, and prior treatment history. In the United Kingdom, amoxicillin is used as first-line therapy in the vast majority of patients who acquire pneumonia in the community, sometimes with added clarithromycin. In North America, where the "atypical" forms of community-acquired pneumonia are becoming more common, clarithromycin, azithromycin, or fluoroquinolones as single therapy, have displaced the
15 amoxicillin as first-line therapy. Local patterns of antibiotic-resistance should always be considered when initiating pharmacotherapy. In hospitalized individuals or those with immune deficiencies, local guidelines determine the selection of antibiotics. These antibiotics are typically given through an intravenous line. Specifically, *S. pneumoniae* is treated with amoxicillin (or erythromycin in patients allergic to penicillin), and with cefuroxime and
20 erythromycin in severe cases.

III. Producing Monoclonal Antibodies

A. General Methods

It will be understood that monoclonal antibodies binding to *S. pneumoniae* will have
25 utilities in several applications. These include the production of diagnostic kits for use in detecting and diagnosing disease. In these contexts, one may link such antibodies to diagnostic or therapeutic agents, or use them as capture agents or competitors in competitive assays. Means for preparing and characterizing antibodies are well known in the art (see, *e.g.*,
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; U.S. Patent
30 4,196,265).

The methods for generating monoclonal antibodies (MAbs) generally begin along the same lines as those for preparing polyclonal antibodies. The first step for both these methods is immunization of an appropriate host or identification of subjects who are immune due to prior natural infection. As is well known in the art, a given composition for immunization

may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by coupling a peptide or polypeptide immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers. Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobencoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine. As also is well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Exemplary and preferred adjuvants include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.

The amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal). The production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization. A second, booster injection, also may be given. The process of boosting and titering is repeated until a suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate MABs.

In the case of human monoclonal antibodies, one may instead simply look for an individual already known to have generated an immune response, in this case, to have been exposed to *S. pneumoniae* or immunized with Pneumovax®23. In order to identify subjects with immunity to various *S. pneumoniae* strains, one could generally obtain blood from subjects and test them for *S. pneumoniae* antibodies. Many antibodies described in this invention were generated in this way using peripheral blood from otherwise healthy individuals previously infected with *S. pneumoniae*.

Following immunization or obtaining of cells from previously infected subjects as described above, somatic cells with the potential for producing antibodies, specifically B lymphocytes (B cells), are selected for use in the MAB generating protocol. These cells may be obtained from biopsied spleens or lymph nodes, or from circulating blood. The antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was

immunized or human or human/mouse chimeric cells. Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas).

5 Any one of a number of myeloma cells may be used, as are known to those of skill in the art (Goding, pp. 65-66, 1986; Campbell, pp. 75-83, 1984). For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-1 1, MPC 11-X45-GTG 1.7 and S194/5XX0 Bui; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2,
10 LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions. One particular murine myeloma cell is the NS-1 myeloma cell line (also termed P3-NS-1-Ag4-1), which is readily available from the NIGMS Human Genetic Mutant Cell Repository by requesting cell line repository number GM3573. Another mouse myeloma cell line that may be used is the 8-azaguanine-resistant mouse murine myeloma SP2/0 non-producer cell line.
15 More recently, additional fusion partner lines for use with human B cells have been described, including KR12 (ATCC CRL-8658; K6H6/B5 (ATCC CRL-1823 SHM-D33 (ATCC CRL-1668) and HMMA2.5 (Posner *et al.*, 1987). The antibodies in this invention were generated using the HMMA2.5 line.

Methods for generating hybrids of antibody-producing spleen or lymph node cells and
20 myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion, though the proportion may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. Fusion methods using Sendai virus have been described by Kohler and Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by Gefter *et al.* (1977). The
25 use of electrically induced fusion methods also is appropriate (Goding, pp. 71-74, 1986). The hybridomas secreting the influenza antibodies in this invention were obtained by electrofusion.

Fusion procedures usually produce viable hybrids at low frequencies, about 1×10^{-6} to 1×10^{-8} . However, this does not pose a problem, as the viable, fused hybrids are
30 differentiated from the parental, infused cells (particularly the infused myeloma cells that would normally continue to divide indefinitely) by culturing in a selective medium. The selective medium is generally one that contains an agent that blocks the *de novo* synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin,

methotrexate, and azaserine. Aminopterin and methotrexate block *de novo* synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the media is supplemented
5 with hypoxanthine. Ouabain is added if the B cell source is an Epstein Barr virus (EBV) transformed human B cell line, in order to eliminate EBV transformed lines that have not fused to the myeloma.

The preferred selection medium is HAT or HAT with ouabain. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma
10 cells are defective in key enzymes of the salvage pathway, *e.g.*, hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B cells. When the source of B cells used for fusion is a line of EBV-transformed B cells, as
15 here, ouabain is also used for drug selection of hybrids as EBV-transformed B cells are susceptible to drug killing, whereas the myeloma partner used is chosen to be ouabain resistant.

Culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by
20 single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity. The assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays dot immunobinding assays, and the like.

The selected hybridomas are then serially diluted or single-cell sorted by flow
25 cytometric sorting and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide mAbs. The cell lines may be exploited for MAb production in two basic ways. A sample of the hybridoma can be injected (often into the peritoneal cavity) into an animal (*e.g.*, a mouse). Optionally, the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection.
30 When human hybridomas are used in this way, it is optimal to inject immunocompromised mice, such as SCID mice, to prevent tumor rejection. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide MABs in high concentration. The individual cell lines could also be cultured *in vitro*, where the MABs

are naturally secreted into the culture medium from which they can be readily obtained in high concentrations. Alternatively, human hybridoma cells lines can be used *in vitro* to produce immunoglobulins in cell supernatant. The cell lines can be adapted for growth in serum-free medium to optimize the ability to recover human monoclonal immunoglobulins of high purity.

MABs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as FPLC or affinity chromatography. Fragments of the monoclonal antibodies of the invention can be obtained from the purified monoclonal antibodies by methods which include digestion with enzymes, such as pepsin or papain, and/or by cleavage of disulfide bonds by chemical reduction. Alternatively, monoclonal antibody fragments encompassed by the present invention can be synthesized using an automated peptide synthesizer.

It also is contemplated that a molecular cloning approach may be used to generate monoclonals. For this, RNA can be isolated from the hybridoma line and the antibody genes obtained by RT-PCR and cloned into an immunoglobulin expression vector. Alternatively, combinatorial immunoglobulin phagemid libraries are prepared from RNA isolated from the cell lines and phagemids expressing appropriate antibodies are selected by panning using viral antigens. The advantages of this approach over conventional hybridoma techniques are that approximately 10^4 times as many antibodies can be produced and screened in a single round, and that new specificities are generated by H and L chain combination which further increases the chance of finding appropriate antibodies.

Other U.S. patents, each incorporated herein by reference, that teach the production of antibodies useful in the present invention include U.S. Patent 5,565,332, which describes the production of chimeric antibodies using a combinatorial approach; U.S. Patent 4,816,567 which describes recombinant immunoglobulin preparations; and U.S. Patent 4,867,973 which describes antibody-therapeutic agent conjugates.

B. Antibodies of the Present Invention

Antibodies according to the present invention may be defined, in the first instance, by their binding specificity. Those of skill in the art, by assessing the binding affinity of a given antibody using techniques well known to those of skill in the art, can determine whether such antibodies fall within the scope of the instant claims.

In the context of the present invention, the antibody specificity relates to the *S. pneumoniae* serotype. There are 24 different serotypes represented by Pneumovax®23,

represented by the following designations: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F and CWPS. The CDR region sequences for representative antibodies are included in the appended sequence listing.

Another way of categorizing the antibodies of the present invention is by their activity. This could include the ability to neutralize or kill *Streptococcus pneumoniae* in the presence or absence of complement. Finally, the antibody may be defined in particular by reference to heavy/light chain variable region sequences. The present inventor provides the following antibodies that have demonstrated activity against *Streptococcus pneumoniae* in an opsonophagocytosis assay (OPA) that measures antibody mediated uptake of bacteria by a phagocytic cell line. The also can be presented by variable regions as set out in Table 2.

C. Engineering of Antibody Sequences

In various embodiments, one may choose to engineer sequences of the identified antibodies for a variety of reasons, such as improved expression, improved cross-reactivity or diminished off-target binding. The following is a general discussion of relevant techniques for antibody engineering.

Hybridomas may cultured, then cells lysed, and total RNA extracted. Random hexamers may be used with RT to generate cDNA copies of RNA, and then PCR performed using a multiplex mixture of PCR primers expected to amplify all human variable gene sequences. PCR product can be cloned into pGEM-T Easy® vector, then sequenced by automated DNA sequencing using standard vector primers. Assay of binding and neutralization may be performed using antibodies collected from hybridoma supernatants and purified by FPLC, using Protein G columns.

Recombinant full length IgG antibodies can generated by subcloning heavy and light chain Fv DNAs from the cloning vector into a second vector, such as a Lonza pConlgG1 or pConK2 plasmid vector, transfected into 293 Freestyle cells or Lonza CHO cells, and antibodies can then be collected and purified from the cell supernatants.

pCon Vectors™ are an easy way to re-express whole antibodies. The constant region vectors are a set of vectors offering a range of immunoglobulin constant region vectors cloned into the pEE vectors. These vectors offer easy construction of full length antibodies with human constant regions and the convenience of the GS System™.

Antibody molecules will comprise fragments (such as F(ab'), F(ab')₂) that are produced, for example, by the proteolytic cleavage of the mAbs, or single-chain immunoglobulins producible, for example, via recombinant means. Such antibody derivatives

are monovalent. In one embodiment, such fragments can be combined with one another, or with other antibody fragments or receptor ligands to form "chimeric" binding molecules. Significantly, such chimeric molecules may contain substituents capable of binding to different epitopes of the same molecule.

5 In related embodiments, the antibody is a derivative of the disclosed antibodies, *e.g.*, an antibody comprising the CDR sequences identical to those in the disclosed antibodies (*e.g.*, a chimeric or CDR-grafted antibody). In yet a further embodiment, the antibody is a fully human recombinant antibody. Alternatively, one may wish to make more subtle modifications, such as introducing conservative changes into an antibody molecule. In
10 making such changes, the hydrophobic index of amino acids may be considered. The importance of the hydrophobic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is accepted that the relative hydrophobic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for
15 example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.
20 As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: basic amino acids: arginine (+3.0), lysine (+3.0), and histidine (-0.5); acidic amino acids: aspartate (+3.0 \pm 1), glutamate (+3.0 \pm 1), asparagine (+0.2), and glutamine (+0.2); hydrophilic, nonionic amino acids: serine (+0.3), asparagine (+0.2), glutamine (+0.2), and threonine (-0.4), sulfur containing amino acids: cysteine (-1.0) and
25 methionine (-1.3); hydrophobic, nonaromatic amino acids: valine (-1.5), leucine (-1.8), isoleucine (-1.8), proline (-0.5 \pm 1), alanine (-0.5), and glycine (0); hydrophobic, aromatic amino acids: tryptophan (-3.4), phenylalanine (-2.5), and tyrosine (-2.3).

It is understood that an amino acid can be substituted for another having a similar hydrophilicity and produce a biologically or immunologically modified protein. In such
30 changes, the substitution of amino acids whose hydrophilicity values are within \pm 2 is preferred, those that are within \pm 1 are particularly preferred, and those within \pm 0.5 are even more particularly preferred.

As outlined above, amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity,

hydrophilicity, charge, size, and the like. Exemplary substitutions that take into consideration the various foregoing characteristics are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

5 The present invention also contemplates isotype modification. By modifying the Fc region to have a different isotype, different functionalities can be achieved. For example, changing to IgG₁ can increase antibody dependent cell cytotoxicity, switching to class A can improve tissue distribution, and switching to class M can improve valency.

10 Modified antibodies may be made by any technique known to those of skill in the art, including expression through standard molecular biological techniques, or the chemical synthesis of polypeptides. Methods for recombinant expression are addressed elsewhere in this document.

D. Single Chain Antibodies

15 A Single Chain Variable Fragment (scFv) is a fusion of the variable regions of the heavy and light chains of immunoglobulins, linked together with a short (usually serine, glycine) linker. This chimeric molecule retains the specificity of the original immunoglobulin, despite removal of the constant regions and the introduction of a linker peptide. This modification usually leaves the specificity unaltered. These molecules were
20 created historically to facilitate phage display where it is highly convenient to express the antigen binding domain as a single peptide. Alternatively, scFv can be created directly from subcloned heavy and light chains derived from a hybridoma. Single chain variable fragments lack the constant Fc region found in complete antibody molecules, and thus, the common binding sites (*e.g.*, protein A/G) used to purify antibodies. These fragments can often be
25 purified/immobilized using Protein L since Protein L interacts with the variable region of kappa light chains.

 Flexible linkers generally are comprised of helix- and turn-promoting amino acid residues such as alanine, serine and glycine. However, other residues can function as well. Tang *et al.* (1996) used phage display as a means of rapidly selecting tailored linkers for
30 single-chain antibodies (scFvs) from protein linker libraries. A random linker library was constructed in which the genes for the heavy and light chain variable domains were linked by a segment encoding an 18-amino acid polypeptide of variable composition. The scFv repertoire (approx. 5×10^6 different members) was displayed on filamentous phage and subjected to affinity selection with hapten. The population of selected variants exhibited

significant increases in binding activity but retained considerable sequence diversity. Screening 1054 individual variants subsequently yielded a catalytically active scFv that was produced efficiently in soluble form. Sequence analysis revealed a conserved proline in the linker two residues after the VHC terminus and an abundance of arginines and prolines at
5 other positions as the only common features of the selected tethers.

The recombinant antibodies of the present invention may also involve sequences or moieties that permit dimerization or multimerization of the receptors. Such sequences include those derived from IgA, which permit formation of multimers in conjunction with the J-chain. Another multimerization domain is the Gal4 dimerization domain. In other
10 embodiments, the chains may be modified with agents such as biotin/avidin, which permit the combination of two antibodies.

In a separate embodiment, a single-chain antibody can be created by joining receptor light and heavy chains using a non-peptide linker or chemical unit. Generally, the light and heavy chains will be produced in distinct cells, purified, and subsequently linked together in
15 an appropriate fashion (*i.e.*, the N-terminus of the heavy chain being attached to the C-terminus of the light chain via an appropriate chemical bridge).

Cross-linking reagents are used to form molecular bridges that tie functional groups of two different molecules, *e.g.*, a stabilizing and coagulating agent. However, it is contemplated that dimers or multimers of the same analog or heteromeric complexes comprised of different
20 analogs can be created. To link two different compounds in a step-wise manner, hetero-bifunctional cross-linkers can be used that eliminate unwanted homopolymer formation.

An exemplary hetero-bifunctional cross-linker contains two reactive groups: one reacting with primary amine group (*e.g.*, N-hydroxy succinimide) and the other reacting with a thiol group (*e.g.*, pyridyl disulfide, maleimides, halogens, *etc.*). Through the primary amine
25 reactive group, the cross-linker may react with the lysine residue(s) of one protein (*e.g.*, the selected antibody or fragment) and through the thiol reactive group, the cross-linker, already tied up to the first protein, reacts with the cysteine residue (free sulfhydryl group) of the other protein (*e.g.*, the selective agent).

It is preferred that a cross-linker having reasonable stability in blood will be
30 employed. Numerous types of disulfide-bond containing linkers are known that can be successfully employed to conjugate targeting and therapeutic/preventative agents. Linkers that contain a disulfide bond that is sterically hindered may prove to give greater stability *in vivo*, preventing release of the targeting peptide prior to reaching the site of action. These linkers are thus one group of linking agents.

Another cross-linking reagent is SMPT, which is a bifunctional cross-linker containing a disulfide bond that is "sterically hindered" by an adjacent benzene ring and methyl groups. It is believed that steric hindrance of the disulfide bond serves a function of protecting the bond from attack by thiolate anions such as glutathione which can be present in tissues and blood, and thereby help in preventing decoupling of the conjugate prior to the delivery of the attached agent to the target site.

The SMPT cross-linking reagent, as with many other known cross-linking reagents, lends the ability to cross-link functional groups such as the SH of cysteine or primary amines (*e.g.*, the epsilon amino group of lysine). Another possible type of cross-linker includes the hetero-bifunctional photoreactive phenylazides containing a cleavable disulfide bond such as sulfosuccinimidyl-2-(p-azido salicylamido) ethyl-1,3'-dithiopropionate. The N-hydroxy-succinimidyl group reacts with primary amino groups and the phenylazide (upon photolysis) reacts non-selectively with any amino acid residue.

In addition to hindered cross-linkers, non-hindered linkers also can be employed in accordance herewith. Other useful cross-linkers, not considered to contain or generate a protected disulfide, include SATA, SPDP and 2-iminothiolane (Wawrzynczak & Thorpe, 1987). The use of such cross-linkers is well understood in the art. Another embodiment involves the use of flexible linkers.

U.S. Patent 4,680,338, describes bifunctional linkers useful for producing conjugates of ligands with amine-containing polymers and/or proteins, especially for forming antibody conjugates with chelators, drugs, enzymes, detectable labels and the like. U.S. Patents 5,141,648 and 5,563,250 disclose cleavable conjugates containing a labile bond that is cleavable under a variety of mild conditions. This linker is particularly useful in that the agent of interest may be bonded directly to the linker, with cleavage resulting in release of the active agent. Particular uses include adding a free amino or free sulfhydryl group to a protein, such as an antibody, or a drug.

U.S. Patent 5,856,456 provides peptide linkers for use in connecting polypeptide constituents to make fusion proteins, *e.g.*, single chain antibodies. The linker is up to about 50 amino acids in length, contains at least one occurrence of a charged amino acid (preferably arginine or lysine) followed by a proline, and is characterized by greater stability and reduced aggregation. U.S. Patent 5,880,270 discloses aminoxy-containing linkers useful in a variety of immunodiagnostic and separative techniques.

In a particular embodiment, the antibody is a recombinant antibody that is suitable for action inside of a cell - such antibodies are known as "intrabodies." These antibodies may

interfere with target function by a variety of mechanism, such as by altering intracellular protein trafficking, interfering with enzymatic function, and blocking protein-protein or protein-DNA interactions. In many ways, their structures mimic or parallel those of single chain and single domain antibodies, discussed above. Indeed, single-transcript/single-chain
5 is an important feature that permits intracellular expression in a target cell, and also makes protein transit across cell membranes more feasible. However, additional features are required.

The two major issues impacting the implementation of intrabody therapeutic are delivery, including cell/tissue targeting, and stability. With respect to delivery, a variety of
10 approaches have been employed, such as tissue-directed delivery, use of cell-type specific promoters, viral-based delivery and use of cell-permeability/membrane translocating peptides. With respect to the stability, the approach is generally to either screen by brute force, including methods that involve phage display and may include sequence maturation or development of consensus sequences, or more directed modifications such as insertion
15 stabilizing sequences (*e.g.*, Fc regions, chaperone protein sequences, leucine zippers) and disulfide replacement/modification.

An additional feature that intrabodies may require is a signal for intracellular targeting. Vectors that can target intrabodies (or other proteins) to subcellular regions such as the cytoplasm, nucleus, mitochondria and ER have been designed and are commercially
20 available (Invitrogen Corp.; Persic *et al.*, 1997).

By virtue of their ability to enter cells, intrabodies have additional uses that other types of antibodies may not achieve. In the case of the present antibodies, the ability to interact with the MUC1 cytoplasmic domain in a living cell may interfere with functions associated with the MUC1 CD, such as signaling functions (binding to other molecules) or
25 oligomer formation. In particular, it is contemplated that such antibodies can be used to inhibit MUC 1 dimer formation.

E. Purification

In certain embodiments, the antibodies of the present invention may be purified. The
30 term "purified," as used herein, is intended to refer to a composition, isolatable from other components, wherein the protein is purified to any degree relative to its naturally-obtainable state. A purified protein therefore also refers to a protein, free from the environment in which it may naturally occur. Where the term "substantially purified" is used, this designation will refer to a composition in which the protein or peptide forms the major component of the

composition, such as constituting about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or more of the proteins in the composition.

Protein purification techniques are well known to those of skill in the art. These techniques involve, at one level, the crude fractionation of the cellular milieu to polypeptide and non-polypeptide fractions. Having separated the polypeptide from other proteins, the polypeptide of interest may be further purified using chromatographic and electrophoretic techniques to achieve partial or complete purification (or purification to homogeneity). Analytical methods particularly suited to the preparation of a pure peptide are ion-exchange chromatography, exclusion chromatography; polyacrylamide gel electrophoresis; isoelectric focusing. Other methods for protein purification include, precipitation with ammonium sulfate, PEG, antibodies and the like or by heat denaturation, followed by centrifugation; gel filtration, reverse phase, hydroxylapatite and affinity chromatography; and combinations of such and other techniques.

In purifying an antibody of the present invention, it may be desirable to express the polypeptide in a prokaryotic or eukaryotic expression system and extract the protein using denaturing conditions. The polypeptide may be purified from other cellular components using an affinity column, which binds to a tagged portion of the polypeptide. As is generally known in the art, it is believed that the order of conducting the various purification steps may be changed, or that certain steps may be omitted, and still result in a suitable method for the preparation of a substantially purified protein or peptide.

Commonly, complete antibodies are fractionated utilizing agents (*i.e.*, protein A) that bind the Fc portion of the antibody. Alternatively, antigens may be used to simultaneously purify and select appropriate antibodies. Such methods often utilize the selection agent bound to a support, such as a column, filter or bead. The antibodies is bound to a support, contaminants removed (*e.g.*, washed away), and the antibodies released by applying conditions (salt, heat, *etc.*).

Various methods for quantifying the degree of purification of the protein or peptide will be known to those of skill in the art in light of the present disclosure. These include, for example, determining the specific activity of an active fraction, or assessing the amount of polypeptides within a fraction by SDS/PAGE analysis. Another method for assessing the purity of a fraction is to calculate the specific activity of the fraction, to compare it to the specific activity of the initial extract, and to thus calculate the degree of purity. The actual units used to represent the amount of activity will, of course, be dependent upon the

particular assay technique chosen to follow the purification and whether or not the expressed protein or peptide exhibits a detectable activity.

It is known that the migration of a polypeptide can vary, sometimes significantly, with different conditions of SDS/PAGE (Capaldi *et al*, 1977). It will therefore be appreciated that
5 under differing electrophoresis conditions, the apparent molecular weights of purified or partially purified expression products may vary.

IV. Passive Immunization and Treatment of *S. pneumoniae* Infections

10 A. Formulation and Administration

Passive transfer of antibodies, known as artificially acquired passive immunity, generally will involve the use of intravenous or intramuscular injections. Such immunity generally lasts for only a short period of time, but provides immediate protection. The antibodies will be formulated in a carrier suitable for injection, *i.e.*, sterile and syringeable.
15 Thus, the present invention provides pharmaceutical compositions comprising anti-*S. pneumoniae* antibodies and antigens for generating the same. Such compositions comprise a prophylactically or therapeutically effective amount of an antibody or a fragment thereof, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the federal or a state government or
20 listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is
25 a particular carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol,
30 water, ethanol and the like.

The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Oral formulations can include standard carriers such as

pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, *etc.* Examples of suitable pharmaceutical agents are described in "Remington's Pharmaceutical Sciences." Such compositions will contain a prophylactically or therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration, which can be oral, intravenous, intraarterial, intrabuccal, intranasal, nebulized, bronchial inhalation, or delivered by mechanical ventilation.

Generally, the ingredients of compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, *etc.*, and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, *etc.*

B. Combination Therapy

In order to increase the effectiveness of the antibody therapy of the present invention, it may be desirable to combine this treatment with other agents effective at treating or preventing *S. pneumonia* infections, *e.g.*, antibiotics. This process may involve administering to the patient the antibody of the present invention and the other agent(s) at the same time. This may be achieved by use of a single pharmaceutical composition that includes both agents, or by administering two distinct compositions at the same time, wherein one composition includes the antibody of the present invention and the other includes the second agent(s).

The two therapies may be given in either order and may precede or follow the other treatment by intervals ranging from minutes to weeks. In embodiments where the other agents are applied separately, one would generally ensure that a significant period of time did

not expire between the time of each delivery, such that the agents would still be able to exert an advantageously combined effect on the patient. In such instances, it is contemplated that one may administer both modalities within about 12-24 h of each other and, more preferably, within about 6-12 h of each other. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several d (2, 3, 4, 5, 6 or 7) to several wk (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

Various combinations may be employed, the antibody treatment of the present invention is "A" and the secondary treatment is "B":

10 A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B
 B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A
 B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A

Administration of the secondary agent will follow general protocols for that drug, taking into account the toxicity, if any. It is expected that the treatment cycles would be repeated as necessary.

1. Amoxicillin and Erythromycin

Amoxicillin. Amoxicillin (INN), formerly amoxycillin (BAN), and abbreviated amox, is a moderate-spectrum, bacteriolytic, β -lactam antibiotic used to treat bacterial infections caused by susceptible microorganisms. It is usually the drug of choice within the class because it is better absorbed, following oral administration, than other β -lactam antibiotics. Amoxicillin is one of the most common antibiotics prescribed for children. This drug acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell walls of both Gram-positive and Gram-negative bacteria.

It has two ionizable groups in the physiological range (the amino group in alpha-position to the amide carbonyl group and the carboxyl group). Amoxicillin is susceptible to degradation by β -lactamase-producing bacteria, which are resistant to a broad spectrum of β -lactam antibiotics, such as penicillin. For this reason, it is often combined with clavulanic acid, a β -lactamase inhibitor, and marketed under one name. This increases effectiveness by reducing its susceptibility to β -lactamase resistance.

Amoxicillin is used in the treatment of a number of infections including: acute otitis media, streptococcal pharyngitis, pneumonia, skin infections, urinary tract infections, salmonella, lyme disease, and chlamydia infections. It is used to prevent bacterial

endocarditis in high risk people who are having dental work done, to prevent strep pneumococcus infections in those without a spleen, and for both the prevention and treatment of anthrax. It is also a treatment for cystic acne. The UK however does not recommend its use for infectious endocarditis prophylaxis. These recommendations have not appeared to have
5 changed the rates of infection.

Side-effects are as those for other beta-lactam antibiotics. Side-effects include nausea, vomiting, rashes, and antibiotic-associated colitis. Loose bowel movements (diarrhea) also may occur. Rarer, but patient-reported, side-effects include mental changes, lightheadedness, insomnia, confusion, anxiety, sensitivity to lights and sounds, and unclear thinking.
10 Immediate medical care is required upon the first signs of these side-effects.

The onset of an allergic reaction to amoxicillin can be very sudden and intense - emergency medical attention must be sought as quickly as possible. The initial onset of such a reaction often starts with a change in mental state, skin rash with intense itching (often beginning in fingertips and around groin area and rapidly spreading), and sensations of fever,
15 nausea, and vomiting. Any other symptoms that seem even remotely suspicious must be taken very seriously. However, more mild allergy symptoms, such as a rash, can occur at any time during treatment, even up to a week after treatment has ceased. For some people who are allergic to amoxicillin the side effects can be deadly. Use of the amoxicillin/clavulanic acid combination for more than one week has caused mild hepatitis in some patients. Young
20 children having ingested acute overdoses of amoxicillin manifested lethargy, vomiting and renal dysfunction.

Amoxicillin in trihydrate form is available as capsules, chewable and dispersible tablets plus syrup and pediatric suspension for oral use, and as the sodium salt for intravenous administration (although the IV formulation is not available in the United States).
25 Amoxicillin is most commonly taken orally. The liquid forms are helpful where the patient might find it difficult to take tablets or capsules.

Erythromycin. Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of
30 atypical organisms, including mycoplasma and Legionellosis. It was first marketed by Eli Lilly and Company, and it is today commonly known as EES (erythromycin ethylsuccinate, an ester prodrug that is commonly administered).

In structure, this macrocyclic compound contains a 14-membered lactone ring with ten asymmetric centers and two sugars (L-cladinose and **D**-desosamine), making it a

compound very difficult to produce via synthetic methods. Erythromycin is produced from a strain of the actinomycete *Saccharopolyspora erythraea*.

U.S. Patent 2,653,899, which covers the drug, was granted in 1953. The product was launched commercially in 1952 under the brand name Ilosone (after the Philippine region of Iloilo where it was originally collected from). Erythromycin was formerly also called Ilotycin.

Over the years since the discovery of erythromycin A and its activity as an antimicrobial, many attempts have been made to synthesize it in the laboratory. However, the presence often stereospecific carbons and several points of distinct substitution has made the total synthesis of erythromycin A a formidable task. Complete syntheses of erythromycins' related structures and precursors such as 6- deoxyerythronolide B have been accomplished, giving way to possible syntheses of different erythromycins and other macrolide antimicrobials. However, Woodward and colleagues did successfully complete the synthesis of erythromycin A in 1981.

Erythromycin is available in enteric-coated tablets, slow-release capsules, oral suspensions, ophthalmic solutions, ointments, gels, and injections. Brand names include Robimycin, E-Mycin, E.E.S. Granules, E.E.S.-200, E.E.S.-400, E.E.S.-400 Filmtab, Erymax, Ery-Tab, Eryc, Ranbaxy, Erypar, EryPed, Eryped 200, Eryped 400, Erythrocin Stearate Filmtab, Erythrocot, E-Base, Erythroped, Ilosone, MY-E, Pediamycin, Zineryt, Abbotcin, Abbotcin-ES, Erycin, PCE Dispartab, Stiemycine, Acnasol and Tiloryth.

Gastrointestinal disturbances, such as diarrhea, nausea, abdominal pain, and vomiting, are very common because erythromycin is a motilin agonist. Because of this, erythromycin tends not to be prescribed as a first-line drug. However, erythromycin may be useful in treating gastroparesis due to this pro-motility effect. Intravenous erythromycin may also be used in endoscopy as an adjunct to clear gastric contents. More serious side-effects include arrhythmia with prolonged QTc intervals including Torsades-de-Pointe and reversible deafness. Allergic reactions range from urticaria to anaphylaxis. Cholestasis, Stevens-Johnson syndrome, and toxic epidermal necrolysis are some other rare side-effects that may occur.

Exposure to erythromycin (especially long courses at antimicrobial doses, and also through breastfeeding) has been linked to an increased probability of pyloric stenosis in young infants. Erythromycin used for feeding intolerance in young infants has not been associated with hypertrophic pyloric stenosis.

Erythromycin estolate has been associated with reversible hepatotoxicity in pregnant women in the form of elevated serum glutamic-oxaloacetic transaminase and is not recommended during pregnancy. Some evidence suggests similar hepatotoxicity in other populations.

5 It can also affect the central nervous system, causing psychotic reactions, nightmares and night sweats. It may also alter the effectiveness of combined oral contraceptive pills because of its effect on the gut flora. Erythromycin is an inhibitor of the cytochrome P450 system, which means that it can have a rapid effect on levels of other drugs metabolised by this system, *e.g.*, warfarin.

10 Erythromycin displays bacteriocidal activity, especially at higher concentrations, but the mechanism is not fully understood. By binding to the 50S subunit of the bacterial 70S rRNA complex, protein synthesis and subsequent structure and function processes critical for life or replication are inhibited. Erythromycin interferes with aminoacyl translocation, preventing the transfer of the tRNA bound at the A site of the rRNA complex to the P site of
15 the rRNA complex. Without this translocation, the A site remains occupied and, thus, the addition of an incoming tRNA and its attached amino acid to the nascent polypeptide chain is inhibited. This interferes with the production of functionally useful proteins, which is the basis of this antimicrobial action.

20 2. Clarithromycin, Azithromycin, Fluoroquinolones and Cefuroxime

Clarithromycin. Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with *Chlamydia pneumoniae* or TWAR), skin and skin structure infections. In addition, it is sometimes used to treat
25 Legionellosis, *Helicobacter pylori*, and lyme disease. Clarithromycin is available under several brand names, for example Crixan, Clarac, Biaxin, Klaricid, Klacid, Klaram, Klabax, Klacid, Claripen, Clarem, Claridar, Fromilid, Clacid, Clacee, Vikrol, Infex and Clariwin, Resclar.

Clarithromycin was invented by researchers at the Japanese drug company Taisho
30 Pharmaceutical in the 1970s. The product emerged through efforts to develop a version of the antibiotic erythromycin that did not experience acid instability in the digestive tract, causing side effects, such as nausea and stomach ache. Taisho filed for patent protection for the drug around 1980 and subsequently introduced a branded version of its drug, called Clarith, to the Japanese market in 1991. In 1985 Taisho partnered with the American company Abbott

Laboratories for the international rights, and Abbott also gained FDA approval for Biaxin in October 1991. The drug went generic in Europe in 2004 and in the US in mid-2005.

Antibacterial spectrum is the same as erythromycin but it is active against *Mycobacterium avium* complex (MAV), *M. leprae* and atypical mycobacteria.

5 Clarithromycin prevents bacteria from growing by interfering with their protein synthesis. Clarithromycin binds to the subunit 50S of the bacterial ribosome and thus inhibits the translation of peptides. Clarithromycin has similar antimicrobial spectrum as erythromycin but is more effective against certain gram-negative bacteria, particularly *Legionella pneumophila*. Besides this bacteriostatic effect, clarithromycin also has
10 bactericidal effect on certain strains such as *Haemophilus influenzae*, *Streptococcus pneumoniae* and *Neisseria gonorrhoeae*.

Unlike erythromycin, clarithromycin is acid-stable and can therefore be taken orally without being protected from gastric acids. It is readily absorbed, and diffused into most tissues and phagocytes. Due to the high concentration in phagocytes, clarithromycin is
15 actively transported to the site of infection. During active phagocytosis, large concentrations of clarithromycin are released. The concentration of clarithromycin in the tissues can be over 10 times higher than in plasma. Highest concentrations were found in liver and lung tissue.

Clarithromycin has a fairly rapid first-pass hepatic metabolism. However, 14-hydroxy clarithromycin, clarithromycin's metabolite, is almost twice as active and has a half life of 7
20 hours compared to clarithromycin's 5. Clarithromycin and its metabolites main routes of elimination are urinary and biliary excretion. Of all the drugs in its class, clarithromycin has the best bioavailability at 50%, which makes it amenable to oral administration.

Most common side-effects are gastrointestinal, including diarrhea, nausea, extreme irritability, abdominal pain and vomiting, facial swelling. Less common side-effects include
25 headaches, hallucinations (auditory and visual), dizziness/motion sickness, rashes, alteration in senses of smell and taste, including a metallic taste that lasts the entire time one takes it. Dry mouth, panic and/or anxiety attacks and nightmares have also been reported albeit less frequently. In more serious cases it has been known to cause jaundice, cirrhosis, and kidney problems including renal failure. Uneven heartbeats, chest pain, and shortness of breath have
30 also been reported while taking this drug.

Adverse effects of clarithromycin in the central nervous system include dizziness, ototoxicity and headaches, but delirium and mania are also uncommon side effects. When taken along with some statins, drugs used to reduce blood serum cholesterol levels, muscle

pain may occur. There is also the risk of oral candidiasis, due to the increased yeast production in the body from the antibiotics.

Azithromycin. Azithromycin is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics, marketed in the United States
5 under the name Zithromax, and under a variety of brand names and generic labels worldwide. It is derived from erythromycin; however, it differs in chemical structure from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring, thus making the lactone ring 15-membered.

Azithromycin is used to treat or prevent certain bacterial infections, most often those
10 causing middle ear infections, strep throat, pneumonia, typhoid, and sinusitis. In recent years, it has been used primarily to prevent bacterial infections in infants and those with weaker immune systems. It is also effective against certain sexually transmitted infections, such as non-gonococcal urethritis, chlamydia, and cervicitis. Recent studies have indicated it also to be effective against late-onset asthma, but these findings are controversial and not widely
15 accepted.

Azithromycin is used to treat many different infections including acute otitis media, streptococcal pharyngitis, gastrointestinal infections such as traveler's diarrhea, respiratory tract infections such as pneumonia, cellulitis, babesiosis, bartonella, chancroid, chlamydia, cholera, donovanosis, leptospirosis, lyme disease, malaria, mycobacterium avium complex,
20 neisseria meningitis, pelvic inflammatory disease, pertussis, scrub typhus, syphilis, toxoplasmosis, and salmonella. It is used to prevent bacterial endocarditis and some sexually transmitted illnesses post sexual assault.

It has a similar antimicrobial spectrum as erythromycin, but is more effective against certain Gram-negative bacteria, in particular, *Haemophilus influenzae*. Azithromycin
25 resistance has been described and is endemic in many areas. It is notably ineffective against MRSA. Azithromycin has been shown to be effective against malaria when used in combination with artesunate or quinine; the optimal dose for this is not yet known.

Most common side-effects are gastrointestinal: diarrhea (5%), nausea (3%), abdominal pain (3%), and vomiting. Fewer than 1% of patients stop taking the drug due to
30 side-effects. Nervousness, dermatologic reactions, and anaphylaxis have been reported. As with all antimicrobial agents, pseudomembranous colitis can occur during and up to several weeks after azithromycin therapy. This drug may interfere with the effectiveness of birth control pills; other forms of contraception may be required during the treatment period.

Azithromycin suspension has an objectionable taste, so can be difficult to administer to young children, *i.e.*, 2-5 years, who may spit it out.

Occasional patients have developed cholestatic hepatitis or delirium. Accidental intravenous overdosage in an infant caused severe heart block, resulting in residual
5 encephalopathy.

Azithromycin prevents bacteria from growing by interfering with their protein synthesis. Azithromycin binds to the 50S subunit of the bacterial ribosome, and thus inhibits translation of mRNA. Nucleic acid synthesis is not affected.

Unlike erythromycin, azithromycin is acid-stable and can therefore be taken orally
10 with no need of protection from gastric acids. It is readily absorbed, but its absorption is greater on an empty stomach. Time to peak concentration in adults is 2.1 to 3.2 hours for oral dosage forms and one to two hours after a dose. Due to the high concentration in phagocytes, azithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations of azithromycin are released. The concentration of azithromycin in the tissues
15 can be over 50 times higher than in plasma. This is due to ion trapping and the high lipid solubility (Volume of distribution is too low).

Azithromycin's half-life allows a large single dose to be administered and yet maintain bacteriostatic levels in the infected tissue for several days. The new extended-release formulation of azithromycin "Zmax," A-Max is a liquid oral suspension that releases
20 the drug in a single 2-g dose. With the macrolide technology of Zmax, this allows the drug to bypass the stomach, reducing gastrointestinal side-effects of high-dose azithromycin.

Azithromycin is commonly administered in tablet or oral suspension (a one-dose version was made available in 2005). It is also available for intravenous injection and in a 1% ophthalmic solution. Tablets come in doses of 250 mg and 500 mg. Oral suspension comes in
25 strengths of 100 mg/5 mL and 200 mg/5 mL. The 250 mg tablets are often dispensed in packages of six and commonly referred to as a "Z-Pak," whereas the 500 mg tablets are commonly available commercially in a pack of three tablets, or "Tri-Pak," intended as a three-day treatment. A common dose of oral azithromycin therapy consists of a "double dose" of medication on the first day of treatment and subsequent treatment for four or five
30 additional days. With the "Z-Pak," this means two 250 mg tablets (a total of 500 mg) on the first day and one 250 mg tablet once daily for the next four days.

Pfizer brand-name, *i.e.*, Zithromax, azithromycin tablets are mottled pink, unscored, film-coated, modified-oval-shaped tablets containing azithromycin monohydrate and the following inactive ingredients: butylated hydroxytoluene, calcium phosphate, carmine,

colloidal silicon dioxide, FD&C red # 40 lake, FD&C yellow # 6 lake, hypromellose (2910, 15cP), lactose monohydrate, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.

Fluoroquinolones. The quinolones are a family of synthetic broad-spectrum antibiotics. The term quinolone(s) refers to potent synthetic chemotherapeutic antibacterials. The first generation of the quinolones begins with the introduction of nalidixic acid in 1962 for treatment of urinary tract infections in humans. Nalidixic acid was discovered by George Leshner and coworkers in a distillate during an attempt at chloroquine synthesis. They prevent bacterial DNA from unwinding and duplicating.

Quinolones, in comparison to other antibiotic classes, have the highest risk of causing colonization with MRSA and *Clostridium difficile*. For this reason, a general avoidance of fluoroquinolones is recommended based on the available evidence and clinical guidelines. The majority of quinolones in clinical use belong to the subset fluoroquinolones, which have a fluorine atom attached to the central ring system, typically at the 6-position or C-7 position. Debates are still taking place as to whether or not the effectiveness of fluoroquinolones for the treatment of respiratory disorders is similar to that of other antibiotic classes.

Fluoroquinolone use for pneumonia is increasing, and with it so is bacterial resistance to fluoroquinolones. The majority of the prescribing of fluoroquinolones is inappropriate, with less than four percent of people prescribed quinolones being appropriate according to clinical guidelines. Clinical guidelines in Canada recommend fluoroquinolones only for outpatient treatment of pneumonia in a small number of patients, such as those with certain comorbid conditions, *e.g.*, patients with a history of COPD, or those with recent use of antibiotics. For severe forms of community-acquired pneumonia, the fluoroquinolones are associated with improved treatment rates, but with no differences found in mortality between other antibiotic classes.

Fluoroquinolones are not recommended as first-line antibiotics for acute sinusitis, as this condition is usually self-limiting, and the risks outweigh the benefits in comparison to other antibiotic classes.

Antibiotics including fluoroquinolones can be effective in some cases of bronchitis. However, only about 5-10% of bronchitis cases are caused by a bacterial infection; most cases of bronchitis are caused by a viral infection and are self-limiting and resolve themselves in a few weeks. It has been recommended that antibiotics are limited in most cases to those whose symptoms fail to resolve on their own.

Fluoroquinolones are often used for genitourinary infections; in general they are recommended only after other antibiotic regimens have failed. However, for serious acute cases of pyelonephritis or bacterial prostatitis where the patient may need to be hospitalised, fluoroquinolones are recommended as first-line therapy. Prostatitis has been termed "the waste basket of clinical ignorance" by prominent Stanford University urologist Dr. Thomas Stamey. Campbell's Urology, the urologist's most authoritative reference text, identifies only about 5% of all patients with prostatitis as having bacterial prostatitis, which can be "cured" at least in the short term by antibiotics. In other words, 95% of men with prostatitis have little hope for a cure with antibiotics alone, since they do not actually have any identifiable bacterial infection.

In general, fluoroquinolones are well tolerated, with most side effects being mild to moderate. On occasion, serious adverse effects occur. Some of the serious adverse effects that occur more commonly with fluoroquinolones than with other antibiotic drug classes include CNS and tendon toxicity. The currently marketed quinolones have safety profiles similar to those of other antimicrobial classes. Fluoroquinolones are sometimes associated with an QTc interval prolongation and cardiac arrhythmias, convulsions, tendon rupture, torsade de pointes and hypoglycemia.

These adverse reactions are a class effect of all quinolones; however, certain quinolones are more strongly associated with increased toxicity to certain organs. For example, moxifloxacin carries a higher risk of QTc prolongation, and gatifloxacin has been most frequently linked to disturbed blood sugar levels, although all quinolones carry these risks. Some quinolones were withdrawn from the market because of these adverse events (for example, sparfloxacin was associated with phototoxicity and QTc prolongation, thrombocytopenia and nephritis were seen with tosufloxacin, and hepatotoxicity with trovafloxacin). Simultaneous use of corticosteroids is present in almost one-third of quinolone-associated tendon rupture. The risk of adverse events is further increased if the dosage is not properly adjusted, for example if there is renal insufficiency.

The serious events may occur during therapeutic use at therapeutic dose levels or with acute overdose. At therapeutic doses, they include: CNS toxicity, cardiovascular toxicity, tendon/articular toxicity, and, rarely, hepatic toxicity. Caution is required in patients with liver disease. Events that may occur in acute overdose are rare, and include renal failure and seizure. Susceptible groups of patients, such as children and the elderly, are at greater risk of adverse reactions during therapeutic use. Adverse reactions may manifest during, as well as after fluoroquinolone therapy has been completed.

The CNS is an important target for fluoroquinolone-mediated neurotoxicity. Adverse event reporting in Italy by doctors showed fluoroquinolones among the top three prescribed drugs for causing adverse neurological and psychiatric effects. These neuropsychiatric effects included tremor, confusion, anxiety, insomnia, agitation, and, in severe cases, psychosis.

5 Moxifloxacin came out worst among the quinolones for causing CNS toxicity.

The basic pharmacophore, or active structure, of the fluoroquinolone class is based upon the quinoline ring system. The addition of the fluorine atom at C6 is what distinguishes the successive-generation fluoroquinolones from the first-generation quinolones. The addition of the C6 fluorine atom has since been demonstrated to not be required for the
10 antibacterial activity of this class (*circa* 1997).

Various substitutions made to the quinoline ring resulted in the development of numerous fluoroquinolone drugs available today. Each substitution is associated with a number of specific adverse reactions, as well as increased activity against bacterial infections, whereas the quinoline ring, in and of itself, has been associated with severe and even fatal
15 adverse reactions.

Cefuroxime. Cefuroxime is a second-generation cephalosporin antibiotic that has been widely available in the USA as Ceftin since 1977. GlaxoSmithKline sells the antibiotic in the United Kingdom (and other countries, such as Australia, Turkey, Israel, Bangladesh, Thailand, Hungary and Poland) under the name Zinnat.

20 As for the other cephalosporins, although as a second-generation it is less susceptible to beta-lactamase and so may have greater activity against *Haemophilus influenzae*, *Neisseria gonorrhoeae* and Lyme disease. Unlike other second generation cephalosporins, cefuroxime can cross the blood-brain-barrier.

Cefuroxime is generally well tolerated and side effects are usually transient.
25 Cefuroxime, if ingested with food, is both better absorbed and less likely to cause its most common side effects of diarrhea, nausea, vomiting, headaches/migraines, dizziness and abdominal pain.

Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, recent assessments have shown no increased risk for cross-allergy for
30 cefuroxime and several other 2nd generation or later cephalosporins.

3. Vancomycin and Levofloxacin

Vancomycin. Vancomycin (INN) is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been

reserved as a drug of "last resort," used only after treatment with other antibiotics had failed, although the emergence of vancomycin-resistant organisms means that it is increasingly being displaced from this role by linezolid (Zyvox) available PO and IV and daptomycin (Cubicin) IV and quinupristin/dalfopristin (Synecid) IV.

5 Vancomycin was first isolated in 1953 by Edmund Kornfeld (working at Eli Lilly) from a soil sample collected from the interior jungles of Borneo by a missionary. The organism that produced it was eventually named *Amycolatopsis orientalis*. The original indication for vancomycin was for the treatment of penicillin-resistant *Staphylococcus aureus*. One advantage that was quickly apparent is that staphylococci did not develop
10 significant resistance despite serial passage in culture media containing vancomycin. The rapid development of penicillin resistance by staphylococci led to the compound's being fast-tracked for approval by the FDA in 1958. Eli Lilly first marketed vancomycin hydrochloride under the trade name Vancocin and as COVANC from Nucleus, India.

Vancomycin never became the first-line treatment for *Staphylococcus aureus* for
15 several reasons. First, it possesses poor oral bioavailability. Also, it must be given intravenously for most infections. In addition, β -Lactamase-resistant semi-synthetic penicillins such as methicillin (and its successors, nafcillin and cloxacillin) were subsequently developed, which have better activity against non-MRSA staphylococci.

An oral form of vancomycin was originally approved by the FDA in 1986 for the
20 treatment of *Clostridium difficile-induced* pseudomembranous colitis. It is not orally absorbed into the blood and remains in the gastrointestinal tract to eradicate *C. difficile*. This product is currently marketed by ViroPharma in the USA.

Vancomycin biosynthesis occurs via different nonribosomal protein synthases (NRPSs). The enzymes determine the amino acid sequence during its assembly through its 7
25 modules. Before Vancomycin is assembled through NRPS, the amino acids are first modified. L-tyrosine is modified to become the β -hydroxychlorotyrosine (β -hTyr) and 4-hydroxyphenylglycine (HPG) residues. On the other hand, acetate is used to derive the 3,5-dihydroxyphenylglycine ring (3,5-DPG).

Nonribosomal peptide synthesis occurs through distinct modules that can load and
30 extend the protein by one amino acid through the amide bond formation at the contact sites of the activating domains. Each module typically consists of an adenylation (A) domain, a peptidyl carrier protein (PCP) domain, and a condensation (C) or elongation domain. In the A domain, the specific amino acid is activated by converting into an aminoacyl adenylate enzyme complex attached to a 4'phosphopantetheine cofactor by thioesterification. The

complex is then transferred to the PCP domain with the expulsion of AMP. The PCP domain uses the attached 4'-phosphopantethein prosthetic group to load the growing peptide chain and their precursors. In the biosynthesis of Vancomycin, additional modification domains are present, such as the epimerization (E) domain, which is used isomerizes the amino acid from one stereochemistry to another, and a thioesterase domain (TE) is used as a catalyst for
5 cyclization and releases of the molecule via a thioesterase scission.

After the linear heptapeptide molecule is synthesized, Vancomycin has to undergo further modifications, such as oxidative cross-linking and glycosylation, in trans, by distinct enzymes, referred to as tailoring enzymes, in order to become biologically active. To convert
10 the linear heptapeptide, eight enzymes are used. With the help of these enzymes, β -hydroxyl groups are introduced onto tyrosine residues 2 and 6, and coupling occurs for rings 5 and 7, rings 4 and 6, and rings 4 and 2. In addition, a haloperoxidase is used to attach the chlorine atoms onto rings 2 and 6 via an oxidative process.

Vancomycin acts by inhibiting proper cell wall synthesis in Gram-positive bacteria.
15 Due to the different mechanism by which Gram-negative bacteria produce their cell walls and the various factors related to entering the outer membrane of Gram-negative organisms, vancomycin is not active against Gram-negative bacteria (except some non-gonococcal species of *Neisseria*).

The large hydrophilic molecule is able to form hydrogen bond interactions with the
20 terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Under normal circumstances, this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents cell wall synthesis in two ways. It prevents the synthesis of the log polymers of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) that form the backbone strands of the bacterial cell wall, and it prevents the backbone polymers that do manage to
25 form from cross-linking with each other.

Although vancomycin levels are usually monitored, in an effort to reduce adverse events, the value of this is not beyond debate. Peak and trough levels are usually monitored, and, for research purposes, the area under the curve is also sometimes used. Toxicity is best monitored by looking at trough values. Common adverse drug reactions (> 1% of patients)
30 associated with IV vancomycin include: local pain, which may be severe and/or thrombophlebitis.

Damage to the kidneys and to the hearing were a side-effect of the early impure versions of vancomycin, and these were prominent in the clinical trials conducted in the mid-1950s. Later trials using purer forms of vancomycin found that nephrotoxicity is an

infrequent adverse effect (0.1-1% of patients), but that this is accentuated in the presence of aminoglycosides.

Rare adverse effects (<0.1% of patients) include: anaphylaxis, toxic epidermal necrolysis, erythema multiforme, red man syndrome (see below), superinfection,
5 thrombocytopenia, neutropenia, leucopenia, tinnitus, dizziness and/or ototoxicity (see below).

It has recently been emphasized that vancomycin can induce platelet-reactive antibodies in the patient, leading to severe thrombocytopenia and bleeding with florid petechial hemorrhages, ecchymoses, and wet purpura.

Vancomycin must be given intravenously (IV) for systemic therapy, since it does not
10 cross through the intestinal lining. It is a large hydrophilic molecule that partitions poorly across the gastrointestinal mucosa. The only indication for oral vancomycin therapy is in the treatment of pseudomembranous colitis, where it must be given orally to reach the site of infection in the colon. Following oral administration, the fecal concentration of vancomycin is around 500 µg/mL (sensitive strains of *C. difficile* have a mean inhibitory concentration of
15 ≤ 2 µg/mL)

Inhaled vancomycin has also been used (off-label), via nebulizer, for treatment of various infections of the upper and lower respiratory tract.

The caustic nature of vancomycin makes IV therapy using peripheral lines a risk for thrombophlebitis. Ideally, central lines, PICCs, or infusion ports should be used.

Vancomycin has traditionally been considered a nephrotoxic and ototoxic drug, based
20 on observations by early investigators of elevated serum levels in renally impaired patients that had experienced ototoxicity, and subsequently through case reports in the medical literature. However, as the use of vancomycin increased with the spread of MRSA beginning in the 1970s, it was recognised that the previously reported rates of toxicity were not being
25 observed. This was attributed to the removal of the impurities present in the earlier formulation of the drug, although those impurities were not specifically tested for toxicity.

Subsequent reviews of accumulated case reports of vancomycin-related nephrotoxicity found that many of the patients had also received other known nephrotoxins, in particular, aminoglycosides. Most of the rest had other confounding factors, or insufficient
30 data regarding the possibility of such, that prohibited the clear association of vancomycin with the observed renal dysfunction. The most methodologically-sound investigations indicate that the actual incidence of vancomycin-induced nephrotoxicity is around 5-7%. To put this into context, similar rates of renal dysfunction have been reported for cefamandole and benzylpenicillin, two reputedly non-nephrotoxic antibiotics.

In addition, evidence to relate nephrotoxicity to vancomycin serum levels is inconsistent. Some studies have indicated an increased rate of nephrotoxicity when trough levels exceed 10 µg/mL, but others have not reproduced these results. Nephrotoxicity has also been observed with concentrations within the "therapeutic" range as well. In essence, the
5 reputation of vancomycin as a nephrotoxin is over-stated, and it has not been demonstrated that maintaining vancomycin serum levels within certain ranges will prevent its nephrotoxic effects, when they do occur.

Attempts to establish rates of vancomycin-induced ototoxicity are even more difficult due to the scarcity of quality evidence. The current consensus is that clearly related cases of
10 vancomycin ototoxicity are rare. The association between vancomycin serum levels and ototoxicity is also uncertain. While cases of ototoxicity have been reported in patients whose vancomycin serum level exceeded 80 µg/mL, cases have been reported in patients with therapeutic levels as well. Thus, it also remains unproven that therapeutic drug monitoring of vancomycin for the purpose of maintaining "therapeutic" levels will prevent ototoxicity.

15 Another area of controversy and uncertainty concerns the question of whether, and, if so, to what extent, vancomycin increases the toxicity of other nephrotoxins. Clinical studies have yielded variable results, but animal models indicate that there probably is some increased nephrotoxic effect when vancomycin is added to nephrotoxins such as aminoglycosides. However, a dose- or serum level-effect relationship has not been
20 established.

Levofloxacin. Levofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class and is used to treat severe or life-threatening bacterial infections or bacterial infections that have failed to respond to other antibiotic classes. It is sold under various brand names, such as Levaquin and Tavanic, the most common. In form of
25 ophthalmic solutions it is known as Oftaquix, Quixin and Iquix.

Levofloxacin is a chiral fluorinated carboxyquinolone. Investigation of ofloxacin, an older drug that is the racemic mixture, found that the 1 form [the (-)-(S) enantiomer] is more active. This specific component is levofloxacin. Levofloxacin is available in tablet form, injection, oral solution, as well as used in prescription eye and ear drops.

30 Levofloxacin interacts with a number of other drugs, as well as a number of herbal and natural supplements. Such interactions increase the risk of cardiotoxicity and arrhythmias, anticoagulation, the formation of non-absorbable complexes, as well as increasing the risk of toxicity.

Levofloxacin is associated with a number of serious and life-threatening adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Such reactions may manifest long after therapy had been completed and in severe cases may result in life-long disabilities. Hepatotoxicity has also been reported with the use of levofloxacin.

5 As of 2011 the FDA has added two Black box warnings for this drug in reference to spontaneous tendon ruptures and the fact that levofloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Such an adverse reaction is a potentially life-threatening event and may require ventilatory support.

10 Levofloxacin is used to treat a number of infections including: respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, endocarditis, meningitis, pelvic inflammatory disease, and traveler's diarrhea.

In the adult population Oral and I.V. levofloxacin is limited to the treatment of proven serious and life-threatening bacterial infections such as Urinary Tract Infections, Community-acquired pneumonia, Skin and Skin Structure Infections, Nosocomial Pneumonia, Chronic
15 bacterial prostatitis, Inhalational Anthrax, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, and Acute Pyelonephritis.

Oral and I.V. Levaquin are not licensed by the FDA for use in children other than the exception (inhalational anthrax), due to the risk of reversible or irreversible injury to the musculoskeletal system. Although claimed to be effective, levofloxacin is not to be
20 considered a first line agent for inhalational anthrax in the pediatric population due to severe adverse reactions involving the musculoskeletal system and other serious adverse reactions, including fatalities.

The CDC revoked its recommendation regarding the use of fluoroquinolones (ciprofloxacin) as a first-line agent in treating anthrax (in part) due to the risk of adverse
25 reactions documented within the Antimicrobial Postexposure Prophylaxis for Anthrax study (aka Cipro 60-day study). However, the fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK.

Serious adverse events occur more commonly with fluoroquinolones than with any other antibiotic drug classes. In most adverse reactions are mild to moderate; however, on
30 occasion, serious adverse effects occur. There have been a number of regulatory actions taken as a result of such adverse reactions, which included published warnings, additional warnings and safety information added to the package inserts, which includes Black Box Warnings together with the issuance of "Dear Doctor Letters" concerning the recent addition of the Black Box Warnings.

In 2004, the FDA requested new warning labels to be added to all of the Fluoroquinolones, including levofloxacin, regarding peripheral neuropathy (irreversible nerve damage), tendon damage, heart problems (prolonged QT Interval/torsades de pointes), pseudomembranous colitis, rhabdomyolysis (muscle wasting), Stevens-Johnson Syndrome, as well as concurrent usage of NSAIDs contributing to the severity of these reactions. Subsequent to this, on June 25, 2007, the FDA required the manufacturer to add an additional warning to the package inserts that stated that "Other serious and sometimes fatal events, some due to hypersensitivity, and some due to uncertain etiology, have been reported in patients receiving therapy with quinolones, including levofloxacin."

Serious visual complications have also been reported to occur with ophthalmic fluoroquinolone therapy, which may also occur with levofloxacin eye drops, especially corneal perforation, but also evisceration and enucleation. This increased incidents of corneal perforation may be due to fluoroquinolones causing alterations in stromal collagen, leading to a reduction in tectonic strength. As noted previously permanent double vision (diplopia) has also been reported.

Levofloxacin is the L-isomer of the racemate ofloxacin, a quinolone antimicrobial agent. In chemical terms, levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. The chemical name is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate. The empirical formula is $C_{18}H_{20}FN_3O_4 \cdot \frac{1}{2}H_2O$, and the molecular weight is 370.38. Levofloxacin is a light-yellowish-white to yellow-white crystal or crystalline powder.

Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Levofloxacin is rapidly and, in essence, completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for LEVAQUIN Tablets when equal doses (mg/mg) are administered. Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously. Glucuronidation and hydroxylation have been cited as one of the major metabolic pathways for levofloxacin hydrochloride. However the drug card for levofloxacin (DB01 137) states that the biotransformation information is not available.

Specific information regarding biotransformation does not appear to be readily available within the package inserts.

Levofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase iv, which is an enzyme necessary to separate replicated DNA, thereby
5 inhibiting cell division.

The fluoroquinolones interfere with DNA replication by inhibiting an enzyme complex called DNA gyrase. This can also affect mammalian cell replication. In particular, some congeners of this drug family display high activity not only against bacterial
10 topoisomerases but also against eukaryotic topoisomerases, and are toxic to cultured mammalian cells and *in vivo* tumor models. Although the quinolone is highly toxic to mammalian cells in culture, its mechanism of cytotoxic action is not known. Quinolone-induced DNA damage was first reported in 1986.

15 V. Antibody Conjugates

Antibodies of the present invention may be linked to at least one agent to form an antibody conjugate. In order to increase the efficacy of antibody molecules as diagnostic or therapeutic agents, it is conventional to link or covalently bind or complex at least one
20 desired molecule or moiety. Such a molecule or moiety may be, but is not limited to, at least one effector or reporter molecule. Effector molecules comprise molecules having a desired activity, *e.g.*, cytotoxic activity. Non-limiting examples of effector molecules which have been attached to antibodies include toxins, antibiotics, therapeutic enzymes, radionuclides, anti-cancer agents, antiviral agents, chelating agents, cytokines, growth factors, and oligo- or polynucleotides.

By contrast, a reporter molecule is defined as any moiety which may be detected
25 using an assay. Non-limiting examples of reporter molecules which have been conjugated to antibodies include enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, photoaffinity molecules, colored particles or ligands, such as biotin.

Antibody conjugates are generally preferred for use as diagnostic agents. Antibody
30 diagnostics generally fall within two classes, those for use in *in vitro* diagnostics, such as in a variety of immunoassays, and those for use *in vivo* diagnostic protocols, generally known as "antibody-directed imaging." Many appropriate imaging agents are known in the art, as are methods for their attachment to antibodies (see, for *e.g.*, U.S. Patents 5,021,236, 4,938,948,

and 4,472,509). The imaging moieties used can be paramagnetic ions, radioactive isotopes, fluorochromes, NMR-detectable substances, and X-ray imaging agents.

In the case of paramagnetic ions, one might mention by way of example ions such as chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II),
5 neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and/or erbium (III), with gadolinium being particularly preferred. Ions useful in other contexts, such as X-ray imaging, include but are not limited to lanthanum (III), gold (III), lead (II), and especially bismuth (III).

In the case of radioactive isotopes for therapeutic and/or diagnostic application, one
10 might mention astatine²¹¹, ¹⁴carbon, ⁵¹chromium, ³⁶chlorine, ⁶⁰cobalt, ⁵⁸cobalt, copper⁶⁷, ¹⁵²Eu, gallium⁶⁷, ³hydrogen, iodine¹²³, iodine¹²⁵, iodine¹³¹, indium¹¹¹, ⁵⁹iron, ³²phosphorus, rhenium¹⁸⁶, rhenium¹⁸⁸, ⁷⁵selenium, ³⁵sulphur, technetium^{99m} and/or yttrium⁹⁰. ¹²⁵I is often being preferred for use in certain embodiments, and technetium^{99m} and/or indium¹¹¹ are also often preferred due to their low energy and suitability for long range detection. Radioactively
15 labeled monoclonal antibodies of the present invention may be produced according to well-known methods in the art. For instance, monoclonal antibodies can be iodinated by contact with sodium and/or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent, such as lactoperoxidase. Monoclonal antibodies according to the invention may be labeled with technetium^{99m} by ligand exchange
20 process, for example, by reducing pertechnetate with stannous solution, chelating the reduced technetium onto a Sephadex column and applying the antibody to this column. Alternatively, direct labeling techniques may be used, *e.g.*, by incubating pertechnetate, a reducing agent such as SnCl_2 , a buffer solution such as sodium-potassium phthalate solution, and the antibody. Intermediary functional groups which are often used to bind radioisotopes which exist as
25 metallic ions to antibody are diethylenetriaminepentaacetic acid (DTPA) or ethylene diaminetetracetic acid (EDTA).

Among the fluorescent labels contemplated for use as conjugates include Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein
30 Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, TAMRA, TET, Tetramethylrhodamine, and/or Texas Red.

Another type of antibody conjugates contemplated in the present invention are those intended primarily for use *in vitro*, where the antibody is linked to a secondary binding ligand

and/or to an enzyme (an enzyme tag) that will generate a colored product upon contact with a chromogenic substrate. Examples of suitable enzymes include urease, alkaline phosphatase, (horseradish) hydrogen peroxidase or glucose oxidase. Preferred secondary binding ligands are biotin and avidin and streptavidin compounds. The use of such labels is well known to those of skill in the art and are described, for example, in U.S. Patents 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241.

Yet another known method of site-specific attachment of molecules to antibodies comprises the reaction of antibodies with hapten-based affinity labels. Essentially, hapten-based affinity labels react with amino acids in the antigen binding site, thereby destroying this site and blocking specific antigen reaction. However, this may not be advantageous since it results in loss of antigen binding by the antibody conjugate.

Molecules containing azido groups may also be used to form covalent bonds to proteins through reactive nitrene intermediates that are generated by low intensity ultraviolet light (Potter and Haley, 1983). In particular, 2- and 8-azido analogues of purine nucleotides have been used as site-directed photoprobes to identify nucleotide binding proteins in crude cell extracts (Owens & Haley, 1987; Atherton *et al*, 1985). The 2- and 8-azido nucleotides have also been used to map nucleotide binding domains of purified proteins (Khatoun *et al*, 1989; King *et al*, 1989; Dholakia *et al*, 1989) and may be used as antibody binding agents.

Several methods are known in the art for the attachment or conjugation of an antibody to its conjugate moiety. Some attachment methods involve the use of a metal chelate complex employing, for example, an organic chelating agent such a diethylenetriaminepentaacetic acid anhydride (DTPA); ethylenetriaminetetraacetic acid; N-chloro-p-toluenesulfonamide; and/or tetrachloro-3a-6a-diphenylglycouril-3 attached to the antibody (U.S. Patents 4,472,509 and 4,938,948). Monoclonal antibodies may also be reacted with an enzyme in the presence of a coupling agent such as glutaraldehyde or periodate. Conjugates with fluorescein markers are prepared in the presence of these coupling agents or by reaction with an isothiocyanate. In U.S. Patent 4,938,948, imaging of breast tumors is achieved using monoclonal antibodies and the detectable imaging moieties are bound to the antibody using linkers such as methyl-p-hydroxybenzimidate or N-succinimidyl-3-(4-hydroxyphenyl)propionate.

In other embodiments, derivatization of immunoglobulins by selectively introducing sulfhydryl groups in the Fc region of an immunoglobulin, using reaction conditions that do not alter the antibody combining site are contemplated. Antibody conjugates produced according to this methodology are disclosed to exhibit improved longevity, specificity and

sensitivity (U.S. Patent 5,196,066, incorporated herein by reference). Site-specific attachment of effector or reporter molecules, wherein the reporter or effector molecule is conjugated to a carbohydrate residue in the Fc region have also been disclosed in the literature (O'Shannessy *et al.*, 1987). This approach has been reported to produce diagnostically and therapeutically promising antibodies which are currently in clinical evaluation.

VI. Immunodetection Methods

In still further embodiments, the present invention concerns immunodetection methods for binding, purifying, removing, quantifying and otherwise generally detecting *S. pneumoniae*. While such methods can be applied in a traditional detection sense, a more specific use will involve the generation of an antibody panel that is capable of distinguishing a single *S. pneumoniae* serotype from most of the serotypes listed above. By identifying the specific serotype responsible for an infection, one can better assess the need and type of therapy. Also, protective immunity is primarily attributed to serotype-specific IgG. Measurement of specific pneumococcal antibodies are clinically useful in two settings: (1) to determine protective status of a patient, and (2) to assess B-cell functionality in a patient with recurrent infection. Use of antibodies in accordance with the present invention in a competitive format will facilitate this type of assay as well.

Some immunodetection methods include enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, and Western blot to mention a few. In particular, a competitive assay for the detection and quantitation of antibodies in samples also is provided. The steps of various useful immunodetection methods have been described in the scientific literature, such as, *e.g.*, Doolittle and Ben-Zeev (1999), Gulbis and Galand (1993), De Jager *et al.* (1993), and Nakamura *et al.* (1987). In general, the immunobinding methods include obtaining a sample suspected of containing *S. pneumoniae*, and contacting the sample with a first antibody in accordance with the present invention, as the case may be, under conditions effective to allow the formation of immunocomplexes.

These methods include methods for purifying *S. pneumoniae* or related antigens from a sample. The antibody will preferably be linked to a solid support, such as in the form of a column matrix, and the sample suspected of containing the *S. pneumoniae* or antigenic component will be applied to the immobilized antibody. The unwanted components will be washed from the column, leaving the *S. pneumoniae* antigen immunocomplexed to the

immobilized antibody, which is then collected by removing the organism or antigen from the column.

The immunobinding methods also include methods for detecting and quantifying the amount of *S. pneumoniae* or related components in a sample and the detection and
5 quantification of any immune complexes formed during the binding process. Here, one would obtain a sample suspected of containing *S. pneumoniae* or its antigens, and contact the sample with an antibody that binds *S. pneumoniae* or components thereof, followed by detecting and quantifying the amount of immune complexes formed under the specific conditions. In terms
10 of antigen detection, the biological sample analyzed may be any sample that is suspected of containing *S. pneumoniae* or *S. pneumoniae* antigen, such as a tissue section or specimen, a homogenized tissue extract, a biological fluid, including blood and serum, or a secretion, such as feces or urine.

Contacting the chosen biological sample with the antibody under effective conditions and for a period of time sufficient to allow the formation of immune complexes (primary
15 immune complexes) is generally a matter of simply adding the antibody composition to the sample and incubating the mixture for a period of time long enough for the antibodies to form immune complexes with, *i.e.*, to bind to *S. pneumoniae* or antigens present. After this time, the sample-antibody composition, such as a tissue section, ELISA plate, dot blot or Western blot, will generally be washed to remove any non-specifically bound antibody species,
20 allowing only those antibodies specifically bound within the primary immune complexes to be detected.

In general, the detection of immunocomplex formation is well known in the art and may be achieved through the application of numerous approaches. These methods are generally based upon the detection of a label or marker, such as any of those radioactive,
25 fluorescent, biological and enzymatic tags. Patents concerning the use of such labels include U.S. Patents 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241. Of course, one may find additional advantages through the use of a secondary binding ligand such as a second antibody and/or a biotin/avidin ligand binding arrangement, as is known in the art.

30 The antibody employed in the detection may itself be linked to a detectable label, wherein one would then simply detect this label, thereby allowing the amount of the primary immune complexes in the composition to be determined. Alternatively, the first antibody that becomes bound within the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the antibody. In these cases, the second binding

ligand may be linked to a detectable label. The second binding ligand is itself often an antibody, which may thus be termed a "secondary" antibody. The primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under effective conditions and for a period of time sufficient to allow the formation of secondary immune complexes. The secondary immune complexes are then generally washed to remove any non-specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complexes is then detected.

Further methods include the detection of primary immune complexes by a two step approach. A second binding ligand, such as an antibody that has binding affinity for the antibody, is used to form secondary immune complexes, as described above. After washing, the secondary immune complexes are contacted with a third binding ligand or antibody that has binding affinity for the second antibody, again under effective conditions and for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes). The third ligand or antibody is linked to a detectable label, allowing detection of the tertiary immune complexes thus formed. This system may provide for signal amplification if this is desired.

One method of immunodetection uses two different antibodies. A first biotinylated antibody is used to detect the target antigen, and a second antibody is then used to detect the biotin attached to the complexed biotin. In that method, the sample to be tested is first incubated in a solution containing the first step antibody. If the target antigen is present, some of the antibody binds to the antigen to form a biotinylated antibody/antigen complex. The antibody/antigen complex is then amplified by incubation in successive solutions of streptavidin (or avidin), biotinylated DNA, and/or complementary biotinylated DNA, with each step adding additional biotin sites to the antibody/antigen complex. The amplification steps are repeated until a suitable level of amplification is achieved, at which point the sample is incubated in a solution containing the second step antibody against biotin. This second step antibody is labeled, as for example with an enzyme that can be used to detect the presence of the antibody/antigen complex by histoenzymology using a chromogen substrate. With suitable amplification, a conjugate can be produced which is macroscopically visible.

Another known method of immunodetection takes advantage of the immuno-PCR (Polymerase Chain Reaction) methodology. The PCR method is similar to the Cantor method up to the incubation with biotinylated DNA, however, instead of using multiple rounds of streptavidin and biotinylated DNA incubation, the DNA/biotin/streptavidin/antibody complex is washed out with a low pH or high salt buffer that releases the antibody. The resulting wash

solution is then used to carry out a PCR reaction with suitable primers with appropriate controls. At least in theory, the enormous amplification capability and specificity of PCR can be utilized to detect a single antigen molecule.

5 **A. ELISAs**

Immunoassays, in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art. Immunohistochemical detection using tissue sections is also particularly useful. However, it will be readily appreciated that
10 detection is not limited to such techniques, and western blotting, dot blotting, FACS analyses, and the like may also be used.

In one exemplary ELISA, the antibodies of the invention are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the *S. pneumoniae* or *S. pneumoniae* antigen
15 is added to the wells. After binding and washing to remove non-specifically bound immune complexes, the bound antigen may be detected. Detection may be achieved by the addition of another anti-X *pneumoniae* antibody that is linked to a detectable label. This type of ELISA is a simple "sandwich ELISA." Detection may also be achieved by the addition of a second anti- *S. pneumoniae* antibody, followed by the addition of a third antibody that has binding
20 affinity for the second antibody, with the third antibody being linked to a detectable label.

In another exemplary ELISA, the samples suspected of containing the *S. pneumoniae* or *S. pneumoniae* antigen are immobilized onto the well surface and then contacted with the anti-X *pneumoniae* antibodies of the invention. After binding and washing to remove non-specifically bound immune complexes, the bound anti-X *pneumoniae* antibodies are detected.
25 Where the initial anti-S. *pneumoniae* antibodies are linked to a detectable label, the immune complexes may be detected directly. Again, the immune complexes may be detected using a second antibody that has binding affinity for the first anti-X *pneumoniae* antibody, with the second antibody being linked to a detectable label.

Irrespective of the format employed, ELISAs have certain features in common, such
30 as coating, incubating and binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described below.

In coating a plate with either antigen or antibody, one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period of hours. The wells of the plate will then be washed to remove incompletely adsorbed

material. Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with regard to the test antisera. These include bovine serum albumin (BSA), casein or solutions of milk powder. The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background
5 caused by nonspecific binding of antisera onto the surface.

In ELISAs, it is probably more customary to use a secondary or tertiary detection means rather than a direct procedure. Thus, after binding of a protein or antibody to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the biological sample to be tested under
10 conditions effective to allow immune complex (antigen/antibody) formation. Detection of the immune complex then requires a labeled secondary binding ligand or antibody, and a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or a third binding ligand.

"Under conditions effective to allow immune complex (antigen/antibody) formation"
15 means that the conditions preferably include diluting the antigens and/or antibodies with solutions such as BSA, bovine gamma globulin (BGG) or phosphate buffered saline (PBS)/Tween. These added agents also tend to assist in the reduction of nonspecific background.

The "suitable" conditions also mean that the incubation is at a temperature or for a
20 period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 hours or so, at temperatures preferably on the order of 25°C to 27°C, or may be overnight at about 4°C or so.

Following all incubation steps in an ELISA, the contacted surface is washed so as to remove non-complexed material. A preferred washing procedure includes washing with a
25 solution such as PBS/Tween, or borate buffer. Following the formation of specific immune complexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immune complexes may be determined.

To provide a detecting means, the second or third antibody will have an associated label to allow detection. Preferably, this will be an enzyme that will generate color
30 development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact or incubate the first and second immune complex with a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immune complex

formation (*e.g.*, incubation for 2 hours at room temperature in a PBS-containing solution such as PBS-Tween).

After incubation with the labeled antibody, and subsequent to washing to remove unbound material, the amount of label is quantified, *e.g.*, by incubation with a chromogenic
5 substrate such as urea, or bromocresol purple, or 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid (ABTS), or $\frac{3}{4}$ ($\frac{3}{4}$, in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generated, *e.g.*, using a visible spectra spectrophotometer.

In another embodiment, the present invention contemplates the use of competitive
10 formats. This is particularly useful in the detection of *S. pneumoniae* antibodies in sample. In competition based assays, an unknown amount of analyte or antibody is determined by its ability to displace a known amount of labeled antibody or analyte. Thus, the quantifiable loss of a signal is an indication of the amount of unknown antibody or analyte in a sample.

Here, the inventor proposes the use of labeled *S. pneumoniae* monoclonal antibodies
15 to determine the amount of *S. pneumoniae* antibodies in a sample. The basic format would include contacting a known amount of *S. pneumoniae* monoclonal antibody (linked to a detectable label) with *S. pneumoniae* antigen or particle. The *S. pneumoniae* antigen or organism is preferably attached to a support. After binding of the labeled monoclonal antibody to the support, the sample is added and incubated under conditions permitting any
20 unlabeled antibody in the sample to compete with, and hence displace, the labeled monoclonal antibody. By measuring either the lost label or the label remaining (and subtracting that from the original amount of bound label), one can determine how much non-labeled antibody is bound to the support, and thus how much antibody was present in the
25 sample.

B. Western Blot

The Western blot (alternatively, protein immunoblot) is an analytical technique used to detect specific proteins in a given sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or denatured proteins by the length of the polypeptide
30 (denaturing conditions) or by the 3-D structure of the protein (native/ non-denaturing conditions). The proteins are then transferred to a membrane (typically nitrocellulose or PVDF), where they are probed (detected) using antibodies specific to the target protein.

Samples may be taken from whole tissue or from cell culture. In most cases, solid tissues are first broken down mechanically using a blender (for larger sample volumes), using

a homogenizer (smaller volumes), or by sonication. Cells may also be broken open by one of the above mechanical methods. However, it should be noted that bacteria or environmental samples can be the source of protein and thus Western blotting is not restricted to cellular studies only. Assorted detergents, salts, and buffers may be employed to encourage lysis of
5 cells and to solubilize proteins. Protease and phosphatase inhibitors are often added to prevent the digestion of the sample by its own enzymes. Tissue preparation is often done at cold temperatures to avoid protein denaturing.

The proteins of the sample are separated using gel electrophoresis. Separation of proteins may be by isoelectric point (pi), molecular weight, electric charge, or a combination
10 of these factors. The nature of the separation depends on the treatment of the sample and the nature of the gel. This is a very useful way to determine a protein. It is also possible to use a two-dimensional (2-D) gel which spreads the proteins from a single sample out in two dimensions. Proteins are separated according to isoelectric point (pH at which they have neutral net charge) in the first dimension, and according to their molecular weight in the
15 second dimension.

In order to make the proteins accessible to antibody detection, they are moved from within the gel onto a membrane made of nitrocellulose or polyvinylidene difluoride (PVDF). The membrane is placed on top of the gel, and a stack of filter papers placed on top of that. The entire stack is placed in a buffer solution which moves up the paper by capillary action,
20 bringing the proteins with it. Another method for transferring the proteins is called electroblotting and uses an electric current to pull proteins from the gel into the PVDF or nitrocellulose membrane. The proteins move from within the gel onto the membrane while maintaining the organization they had within the gel. As a result of this blotting process, the proteins are exposed on a thin surface layer for detection (see below). Both varieties of
25 membrane are chosen for their non-specific protein binding properties (*i.e.*, binds all proteins equally well). Protein binding is based upon hydrophobic interactions, as well as charged interactions between the membrane and protein. Nitrocellulose membranes are cheaper than PVDF, but are far more fragile and do not stand up well to repeated probings. The uniformity and overall effectiveness of transfer of protein from the gel to the membrane can be checked
30 by staining the membrane with Coomassie Brilliant Blue or Ponceau S dyes. Once transferred, proteins are detected using labeled primary antibodies, or unlabeled primary antibodies followed by indirect detection using labeled protein A or secondary labeled antibodies binding to the Fc region of the primary antibodies.

C. Immunodetection Kits

In still further embodiments, the present invention concerns immunodetection kits for use with the immunodetection methods described above. As the *S. pneumoniae* antibodies are generally used to detect *S. pneumoniae* or *S. pneumoniae* antigens, the antibodies will be included in the kit. The immunodetection kits will thus comprise, in suitable container means, a first antibody that binds to *S. pneumoniae* or *S. pneumoniae* antigen, and optionally an immunodetection reagent.

In certain embodiments, the antibody may be pre-bound to a solid support, such as a column matrix, dipstick, membrane, particle (*e.g.*, bead or nanoparticle) or well of a microtitre plate. The immunodetection reagents of the kit may take any one of a variety of forms, including those detectable labels that are associated with or linked to the given antibody. Detectable labels that are associated with or attached to a secondary binding ligand are also contemplated. Exemplary secondary ligands are those secondary antibodies that have binding affinity for the first antibody.

Further suitable immunodetection reagents for use in the present kits include the two-component reagent that comprises a secondary antibody that has binding affinity for the first antibody, along with a third antibody that has binding affinity for the second antibody, the third antibody being linked to a detectable label. As noted above, a number of exemplary labels are known in the art and all such labels may be employed in connection with the present invention.

The kits may further comprise a suitably aliquoted composition of the *S. pneumoniae* or *S. pneumoniae* antigens, whether labeled or unlabeled, as may be used to prepare a standard curve for a detection assay. The kits may contain antibody-label conjugates either in fully conjugated form, in the form of intermediates, or as separate moieties to be conjugated by the user of the kit. The components of the kits may be packaged either in aqueous media or in lyophilized form.

The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which the antibody may be placed, or preferably, suitably aliquoted. The kits of the present invention will also typically include a means for containing the antibody, antigen, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.

VII. Examples

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well
5 in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

10

EXAMPLE 1 - MATERIALS AND METHODS

Immunization and donors. Donors received Pneumovax®23 (Merck, Whitehouse Station, NJ) as standard of care vaccination based upon their age or SLE status. Healthy
15 donors Con1 and Con2 were both Caucasian, age 62 and 61 respectively. Lupus donor SLE1 was an African American, age 47, SLE2 was a Caucasian, age 45. All protocols were approved by the IRB and patients consented to participate in this study. Blood was drawn (-40-60 ml) into ACD tubes (BD, Franklin Lakes, NJ) by venipuncture seven days post vaccination and were stored no longer than 18 hours before processing.

20

Cell isolation and flow cytometry. Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood using lymphocyte separation medium (Cellgro, Manassas, VA) and suspended in 2% inactivated fetal calf serum in PBS. Cells were then counted and stained within two hours of the isolation. Antibodies used for the staining were anti-CD3 and anti-CD20 conjugated to FITC, anti-CD38 conjugated to APC-Cy5.5, anti-CD27 conjugated
25 to PE, anti-CD19 conjugated to PE-Alexa610 (all from Invitrogen/Caltag, Carlsbad, CA), anti-IgG conjugated to APC (BD Biosciences, San Jose CA), and anti-IgM conjugated to biotin (Southern Biotech, Birmingham, AL) followed by streptavidin-PE-Cy7 (Invitrogen/Caltag). The B cells were bulk sorted (CD3/CD20^{neg}, CD19^{low}, CD38^{high},
CD27^{very high}, IgG^{positive}) using a Becton-Dickinson FACS Aria cytometer (BD Biosciences,
30 San Jose, CA) and then single cell sorted into 96-well PCR plates with a Cytomation MoFlo cytometer (Dako, Carpinteria, CA).

Single cell RT-PCR and PCR of antibody variable region genes. As detailed in prior studies (Smith *et al*, 2009; Wrammert *et al*, 2008), the plates receiving the single cells sorted above contain 10 microliters of a hypotonic buffer consisting of 10 mM Tris-HCl with

40 U/ μ I of RNase inhibitor (Promega, Madison, WI) in each well. After the sort, plates were immediately frozen on dry ice and stored at -80°C . A One-Step RT-PCR kit (Qiagen, Valencia, CA) was used to amplify V_H and V_K message using a cocktail of sense primers to the leader regions of each of the gene families and antisense primers to the constant regions
5 of the heavy and kappa chains. One microliter of the RT-PCR mixture was then amplified in separate heavy and kappa chain PCR reactions to first obtain sequences, and another microliter was used for the final PCR reactions to incorporate restriction sites for further cloning. The variable regions were then cloned into expression vectors (containing full length IgG α heavy or kappa constant regions), maxi-prepped (Roche, Indianapolis IN), and
10 co-transfected into the HEK293A cell line using polyethyleneimine (PEI) (Polysciences, Warrington, PA). The transfected cells were allowed to secrete antibodies into serum-free DMEM supplemented with 1% Nutridoma (Roche, Indianapolis, IN) for five days. The antibodies were then purified using protein A-agarose beads (Pierce, Rockford, IL). Antibody purity and integrity were verified by SDS-PAGE and concentrations were obtained
15 with a Nanodrop spectrophotometer (Fisher, Pittsburg, PA).

Polysaccharide affinity and avidity ELISAs. To screen for binding, ELISAs were first performed by coating plates with cocktails of five or six *S. pneumoniae* polysaccharides, screening all 23 (ATCC, Manassas, VA) in this manner. Positive binders in this cocktail assay were then re-screened against each of the individual polysaccharides. As cell wall
20 polysaccharide (CWPS) is an impurity in nearly all of the coat polysaccharides (Xu *et al*, 2005), antibodies that bound to all four groups were further tested on purified cell wall polysaccharide (CWPS) (Miravista Labs, Indianapolis, IN) to confirm CWPS binding. Wells were coated with 10 μg of each polysaccharide (or total mixed polysaccharide), blocked with 20% FCS and developed with anti-human IgG-HRP (Jackson ImmunoResearch, West Grove,
25 PA) and Super Aqua Blue substrate (EBiosciences, San Diego CA). The absorbance was measured at 405nm on a microplate reader (Molecular Devices, Sunnyvale, CA). Antibody affinities (Kd) were calculated by curve fitting analysis of individual ELISA curves plotted from a dilution series of 16 two-fold dilutions of antibody beginning at 10 $\mu\text{g}/\text{ml}$. For avidity ELISAs, one concentration of antibody was used (1 $\mu\text{g}/\text{ml}$) and an elution step was added
30 before the addition of the conjugate. This elution step used varying concentrations of ammonium thiocyanate (3M to 0.06M, 8 total dilutions) in PBS, as well as PBS alone. The percent of binding retained was calculated for each dilution of ammonium thiocyanate. These values were graphed versus thiocyanate concentration and the concentration of

thiocyanate which caused 50% retention (or loss) of binding was calculated by fitting the data with a dose-response/sigmoidal curve with hillslope correction.

Autoantigen ELISAs. All antibodies were also tested for binding to five autoantigens, Ro, La, Sm, nRNP, and cardiolipin. For each, except cardiolipin, 1 unit of antigen (ImmunoVision, Springdale, AR) was coated per well on high bind plates. Plates were blocked with 0.1% BSA in PBS, antibodies were added at 1 µg/ml and developed as per polysaccharide ELISAs above. For anti-cardiolipin ELISAs, cardiolipin solution at ~5 mg/ml (Sigma, St. Louis, MO) was diluted 1 to 1000 in ethanol and 50 µl/well was allowed to evaporate in medium bind plates. Plates were blocked with 0.5% adult bovine serum in PBS and antibodies were screened at 10 µg/ml and developed as above.

Analysis of sequences and curve fitting. All curve fitting was performed using the GraphPad Prism software, with background subtraction or percent retention values calculated and averaged using Excel. Variable region sequences were analyzed using the International Immunogenetics Information System (IMGT, Montpellier, France), as well as with in-house software and/or Vector NTI (Invitrogen, Carlsbad, CA). Clonally related antibodies were defined as those having the same VDJ/VJ usage in the heavy and light chains respectively, as well as highly related V_HD_H, D_HJ_H, and V_KJ_K junctions. Average nucleotide somatic hypermutation values were obtained by analyzing sequences (using IMGT) for the number of nucleotide changes from germline in each antibody sequence. Resulting per-antibody values were then averaged to obtain average mutation rates per donor. The *n* value for these analyses included: naive cells from six donors (*n* = 18, 42, 21, 34, 15, 36); IgM germinal center/memory cells from 17 donors (*n* = 56, 158, 18, 91, 17, 10, 16, 30, 19, 28, 11, 36, 29, 13, 22, 20, 64); IgG germinal center/memory cells from 13 donors (*n* = 110, 37, 19, 28, 174, 40, 25, 15, 21, 18, 22, 24, 19, 71); anti-influenza ASCs from 11 donors (*n* = 63, 18, 33, 46, 49, 11, 36, 11, 30, 35, 25). These donors were previously described in (Wrarmert *et al*, 2008). The anti-polysaccharide ASC sequences are from the four donors in this study (Con1, 39; Con2, 49; SLE1, 24; SLE2, 25).

EXAMPLE 2 - RESULTS

Pneumovax®23 induces a strong ASC response which is more robust in healthy controls as compared to SLE patients. Four individuals were immunized with Pneumovax®23. Blood was drawn seven days post vaccination and PBMCs were isolated by Ficoll gradient. The cells were then stained and CD38^{high}/CD27^{very high} cells were

enumerated. The inventor's previous results using these techniques after influenza vaccination (Wrammert *et al*, 2008) showed an ASC burst ranging from 1% to 16% of total peripheral blood B cells at day seven (average 6.4%). Pneumovax®23 induces an even more robust ASC response (FIG. 1A), with the two healthy donors having ASCs representing
5 22.8% to 24.7% of their total peripheral blood B cells, especially as this is a primary vaccination for each donor. Although both SLE donors had half as many ASCs as the healthy donors, the overall percentages (10.6% and 7.1%) are still quite high. This strong anamnestic response is likely due to the fact that *S. pneumoniae* is a ubiquitous organism that causes both clinical and subclinical disease among the general population. FIG. 1B shows a
10 schematic representation of the process for making human monoclonal antibodies from antibody secreting cells. This technique has been previously described in detail (Smith *et al*, 2009; Wrammert *et al*, 2008). In total, including non-binding antibodies, 137 antibodies were produced and characterized (Con1, n = 39; Con2, n = 49; SLE1, n = 24; SLE2, n = 25).

A large majority of polysaccharide antibodies produced from the ASCs bind to a single serotype. Polysaccharide ELISA curves are shown in FIG. 2A, where each curve represents one antibody. A cutoff of an OD₄₀₅ of 1.5 was used as an arbitrary separation between high to moderate affinity antibodies and low to non-binding antibodies. Percentages were calculated using this cutoff as a means to determine which antibodies had significant binding. Averaged across the four donors, 76% of the antibodies (Con1, 62%; Con2, 90%;
15 SLE1 75%; SLE2, 75%) bound to *S. pneumoniae* serotype polysaccharide or cell wall polysaccharide from the vaccine. Of the hmAbs generated, SLE donors showed no significant difference in the number of high-affinity antibodies isolated. A list of all antibodies with positive binding is shown in Table 1, which details serotype bound, number of total clonal siblings characterized, as well as V_H and V_K usage. Of the antibodies which
20 bound to polysaccharide (76% of the total), an average of 88% of the antibodies characterized from the four donors are serotype specific (FIG. 2B) (Con1, 88%; Con2, 90%; SLE1 94%; SLE2, 80%). The observation that 88% of the antibodies currently in the serum bind to carbohydrate epitopes in a manner specific even among very closely related structures reinforces the well known specificity of the antibody repertoire.
25

Table 1 - Summary of anti-*S. pneumoniae* antibodies (SEQ ID NOS:1 through 126)

Ab	# of Clones	Serotype(s)	Kd (wd*)	OPA **	VH gene	JH gene	Heavy CDR3	VK gene	JK gene	Kappa CDR3
Con1 p2 C01	3	20	1.1E-08	5/12	VH3-66	JH6	AKGVTSEFDY	VK3-20	JK4	QQFGSSPPDT
Con1 p2 C04	1	1	2.2E-10	none	VH3-23	JH4	ARDPGRNGMGV	VK2-30	JK1	MQVTHWPRT
Con1 p2 D02	1	9N	3.9E-10	256	VH3-23	JH4	AKAHRGDWNNFFDY	VK3-11	JH4	QQSGDWPLT
Con1 p2 D03	1	19F/19A	1.2E-08	1024/none	VH4-59	JH3	AREWSGFDF	VK3-20	JK1	QQYGLPRT
Con1 p2 E01	3	8	7.7E-11	512	VH3-7	JH4	ARGQWLAF	VK2-30	JK2	MQGTHWPYT
Con1 p3 C02	1	2	1.4E-10	4096	VH3-7	JH4	ARGRNNFRH	VK1-33	JK3	QQFESFPRT
Con1 p3 C03	1	22F	1.8E-10	32	VH3-66	JH4	ARELGVFHSGDQWLGLDLC	VK3-15	JK3	HQYKNWPPMGT
Con1 p3 G01	2	2	1.4E-10	2048	VH3-49	JH4	RWTGGVSFGAY	VK1-5	JK1	QQYDIYLT
Con1 p3 G06	1	8	2.1E-08	16	VH3-74	JH4	ARDYYHSVDY	VK2-30	JK2	MQGTHWPYT
Con1 p4 B01	2	33F	4.0E-08	256	VH4-59	JH4	ARGPDAHKTGY	VK4-1	JK1	QQYAAATPWT
Con1 p4 B03	1	9N/9V	5.6E-10	128/128	VH3-74	JH4	ARDSYTSPTY	VK2-30	JK4	MQGSHWPLT
Con1 p4 C01	1	8	9.5E-10	128	VH3-15	JH3	TTDNGVKAFDI	VK4-1	JK3	HQYTTTFFA
Con1 p4 G01	1	6B	3.1E-10	256	VH3-74	JH4	TRGGSGATINY	VK1-39	JK4	QQSHSSPLT
Con1 p6 C01	1	9V	3.0E-08	256	VH4-61	JH4	ARDRAGIDGYNFYDY	VK1-5	JK2	QQYYSFYT
Con1 p6 D04	1	CWPS	4.2E-08	none	VH1-46	JH4	AREVAEKGAFDY	VK4-1	JK4	QQYYPPLT
Con1 p6 E03	1	3	8.9E-10	128	VH3-7	JH3	ARGQSYPGI	VK3-15	JK1	QQYNNWPRT
Con1 p6 E06	1	17F/33F	9.4E-09	8/none	VH4-59	JH4	AGRAYSSGYYLYDY	VK3-15	JK2	QHYHNPPT
Con2p3 C04	3	CWPS	7.9E-11	none	VH3-30	JH4	AKGCSNGGNCFLIDY	VK4-1	JK4	QQYNNAPLT
Con2p3 C05	1	4	1.8E-10	256	VH3-23	JH3	AKGGYYESGTMRAFDI	VK3-11	JK4	QQRSNWPAT
Con2p3 F03	2	2	1.5E-10	4096	VH3-7	JH4	ARGESNFY	VK1-33	JK3	QQFVSFPRT
Con2p3 G05	9	18C	2.8E-10	64	VH3-7	JH4	ARDSTSPARFGY	VK3-20	JK2	QHYGTSPPRYT
Con2p4 B03	1	1	3.4E-08	none	VH3-53	JH4	ATGGMTSSWYGY	VK4-1	JK2	QQYYSTPYT
Con2p4 C02	5	9N/9V	2.7E-10	512/8	VH1-46	JH4	SMGPPYCTGGSCYSACDF	VK3-20	JK2	QRYGNSPPYT
Con2p4 D06	5	9V	2.6E-10	2048	VH3-15	JH5	TTDIGKGWYTHYPDL	VK4-1	JK4	LQYRSAPFT
Con2p5 A06	2	CWPS	5.1E-10	none	VH3-30	JH4	VKEYSWGYYRTADY	VK1-5	JK1	QQYSTYPWT

Con2p5 B06	3	1	1.4E-10 none	VH3-74	JH4	ARSPGGYFDY	VK3-15	JK1	QQYSTWLWT
Con2p5 C04	1	8	2.3E-08 32	VH3-15	JH4	TTDDLKN	VK1-39	JK2	QQRYPYPS
Con2p5 E05	1	2	2.8E-10 2048	VH3-48	JH6	ARGRDCYGCNCVYFHYGGLDV	VK2-28 JK2		MRALQTPYT
Con2p6 B03	3	CWPS	6.4E-11 none	VH3-30	JH4	VKESATGWYRTADY	VK1-5	JK1	HQYNKYPT
Con2p6 C05	1	33F	3.3E-09 none	VH3-66	JH3	ARDIPTFFGIGEAFDI	VK1-5	JK1	QQYYSWGT
Con2p6 G04	1	22F	4.4E-10 128	VH1-46	JH4	ARDDSAFDY	VK2-24	JK1	MQASQSTWT
Con2p7 D03	1	CWPS	1.8E-09 none	VH3-30	JH6	AKCGSENGCFYMDD	VK4-1	JK4	QQCYNAPLT
Con2p8 B01	1	22F	2.3E-08 none	VH1-46	JH4	TREIGAVWDATSLGWLYFDY	VK3-15 JK1		QQYNNWPPVT
Con2p8 B05	2	15B	1.7E-10 none	VH3-7	JH4	AGWGRTQD	VK2-30	JK2	MQYTFWPH
Con2p8 E03	1	23F	3.3E-08 none	VH3-30	JH3	TKEGAPPGKYAFDI	VK3-11	JK3	QHRGEWPPGAT
Con2p8 F05	1	11A	1.8E-10 none	VK3-72	JH3	LKDSSQYSFDA	VK1-9	JK4	QQFKGYPLT
SLE1 p1 A02	3	5 5.	1E-10 1024	VH4-59	JH4	ARGDGYNFF	VK1-9	JK2	QQINSYPRT
SLE1 p1 A03	1	14/9N	1.7E-10 512/32	VH3-30	JH5	AKCGAEDSTTVLNLWFDP	VK3-11 JK4		QQRADWPLT
SLE1 p1 B05	3	5	9.5E-10 none	VH3-23	JH4	AKPNYFGSGSPDY	VK3-11	JK2	LQCSNWPMYT
SLE1 p1 C04	1	5	2.8E-10 2048	VH4-59	JH4	VKEQDYGYYRTADH	VK1-6	JK2	QQYDKYPWT
SLE1 p1 E01	2	9V/9N	6.2E-11 512/256	VH3-20	JH3	VRVAVPAATYTRGNDAFDI	VK1-17 JK1		LQHSSFPWT
SLE1 p1 F02	1	14	1.0E-09 none	VH3-15	JH4	TTAHGPVGDH	VK4-1	JK5	QQYTTTSPIT
SLE1 p1 G05	1	15B	1.6E-10 none	VH3-7	JH4	ARAGCSSTRCHTTPGFDY	VK4-1 JK5		QQYTTTTPIT
SLE1 p2 A02	1	5	1.4E-10 512	VH4-39	JH3	ASLSGTNAFDI	VK3-11	JK1	QQRSSGRT
SLE1 p2 D04	1	8	7.4E-09 256	VH3-23	JH4	AKPRGYSYGYFDY	VK3D-20	JK2	QQYGISPRT
SLE1 p3 A02	1	17F	2.7E-09 none	VH3-7	JH4	APPARRLDY	VK2-29	JK1	MQGTHHPWT
SLE1 p3 A04	1	4 3.	8E-08 none	VH3-74	JH4	ARSNAGHEA	VK4-1	JK4	QQYYSTPLT
SLE1 p3 B03	1	20	1.5E-09 none	VH1-46	JH4	ARDIPHANLDY	VK1-17	JK1	LQHTTTPWT
SLE1 p3 C03	1	33F	1.1E-09 128	VH3-23	JH4	VKDRVPPGDVPGDF	VK3-11	JK5	QQRRTWPPLT
SLE2p1 A01	2	23F	2.5E-09 none	VH3-48	JH6	ATLLLRDNQLDV	VK2-30	JK1	MQGTHWRT
SLE2p1 A06	1	CWPS	7.9E-10 none	VH3-33	JH4	VKEQG FGYRTADY	VK1-5	JK1	HQYDKYPWT
SLE2p1 B01	2	15B/14	2.0E-10 256/256	VH4-59	JH3	ARRNDFNI	VK3-20	JK3	QQYGSSPFT
SLE2p1 C03	1	17F/33F	2.9E-10 none	VH3-23	JH4	SIWWGTSVQYPLVLDY	VK3D-15 JK5		QQYSKWPPIT
SLE2p1 C04	1	CWPS	2.0E-09 none	VH3-30	JH5	VKEQDYGYYRTADH	VK1-5	JK1	QQYDKYPWT
SLE2p1 D02	5	5	2.0E-10 none	VH4-61	JH4	ARGHGFNAY	VK3-20	JK1	QQYGNPRT

SLE2p1 D04	1	6B	8.8E-1 1 512	VH3-15	JH4	TTVRNMADLSLNH VK3-20	JK1	QQYDDSRWT
SLE2p2 A01	1	18C	4.2E-09 none	VH3-48	JH4	ATGNRGLPRR VK2D-28	JK2	MQALRSPYT
SLE2p2 C04	1	33F	4.9E-09 none	VH3-7	JH4	VRDGWDTFFDS VK2-30	JK2	MQGRYWPYT
SLE2p2 D03	1	19A/19F	1.1E-09 none/81 92	VH3-74	JH4	VNFQLG VK3-20	JK1	QQYGNSPRT
SLE2p2 E04	1	8	5.1E-10 1024	VH3-30-3	JH5	ARAEYCSPGDCFLIDT VK2-30	JK1	MQGTHWRT
SLE2p2 F01	1	CWPS	9.6E-10 none	VH3-33	JH4	LRGNPPSSPTDY VK1-16	JK4	QQYNSYPLT
SLE2p2 G01	1	5	1.4E-09 none	VH3-23	JH6	AKWYSRPPMDV VK1 D-39	JK1	QQSYSTPWT
SLE2p2 G06	1	17F	4.8E-1 1 128	VH3-7	JH4	ARASRETGEPEY VK2-30	JK1	MQATHWPWT

*Calculated ELISA affinities, averaged for the clonal family. The affinity listed from cross-reactive antibodies is for the serotype which is most strongly bound (the serotype listed first in the serotype column).

** Opsonophagocytosis assay (OPA) measures antibody mediated uptake of bacteria; values 4 or less are considered negative ("none").

The number of clones indicates the total number of members of the clonal family

Table 2 - Selected Heavy and Light Chain Sequences from Antibodies of Table 1 (SEQ ID NOS. 127-252)

Con1 Heavy	Seq ID No:	
Con1p2-c01h	127	GAGGTGCAGCTGTTGGAGTCGGGGGAGGCTTGGTACAGCCTGGGGGTCCCTGAGAGTCTCCTGTGCAGC CTCTGGATTACCTTTAGCAACTCTGGCATGAGTTGGTCCGCCAGGCTCCAGGGAAGGGCTGGAGTGGGT CTCAGGTAATGGTGGTGGTAGTGCATACAGCAGACTCCCGTGAAGGGCCGGTTCACCAATCTCCAG AGACAATTCCAAAGAACACGCTGTATCTACAAATGAACAATTTGAGAGCCGAGGACACGGCCGTATACTACT GTGCGAAAGGAGTTACCAGTTTGGACTACTGGGGCCAGGGAATCCTGGTCAACCGTCTCCICA
Con1p2-c04h	128	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCAACCTCAGTAGCGACTATATGAGTTGGTCCGCCAGGCTCCAGGGAAGGGCTGGAGTGGGTC TCAGTTATGTATAGCGGGGTAGCACATACTACGACAGCCGTGAAGGACAGATTCACCAATCTCCAGAGA CAATTCCAAAGAAATATACTGTATCTTCAAATGAACAGCTGAGAGCCGAGGACACGGCCGTTTATTACTGTGC GAGATCCCGGGATAAGGAACGGTATGGCCGTCTGGGGCCAAAGGACACCGTCAACCGTCTCCICA
Con1p2-d02h	129	GAGGTGCAGCTGTTGGAGTCTGGGGGAGCCTTGGTACAGCCGGGGGTCCCTGAGACTTCTCCTGTGCAGCC TCTGGATTCAACCTTTACCAGCTTGGCATGGGTCGCCAGGCTCCAGGGAAGGGCTGGAGTGGGTC TCAGCTGTGACTGGCAGTGGTTATTACAAAATATGCAGACTCCCGTGAAGGGCCGGTTCACCAATCTCCAGA GACAATTCAGCAATACTCTATCTGCAATGAACAGCCTGAGAGGGGACACAGCCCTATATTACTGT GCGAAAGCACATAGAGTGTGACTGGAATACTTCTTTGACTATTGGGGCCAGGGAACCCCTGGTCAACCGTCTCC TCA
Con1p2-d03h	130	CAGGTGCAGCTGCAGGATCGGGCCAGGACTAGTGAAGCCTTCGGAGACCCCTGTCCCTCAACCTGTCTGTG TCTGTGACTCCTTCACTCAAGTGGAGTGGATCCGGCAGCCCGCCAGGAAAGGACTGGAATGGATT GGATATATCTATCCAGTGGGAACACCAACTACAACCCCGCTCAAGAGTCGAGTCAACCATATCACTGGAC ACGTCCAAGAAATCAGGTCTCCCTGAGGCTGAGCTCTGTGGCCGCTGCGGACACGGCCATGTATTACTGTGCG AGAGAGTGGAGTGGTTTTGATTTCTGGGGCCAAAGGAACAATGGTCAACCGTCTCCICA
Con1p2-e01h	131	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCAACCTTTACTAATACTATTGATGAGCTGGTCCGCCAGGCTCCAGGGAAGGGCTGGAGTGGGTC GCCAATAAAGCAAGATGGACGTGAGACATACTATGTGACTCTGTGAAGGGCCGATTCACCAATCTCCAG AGACAACGCCAAGAACTCAGTGTCTTACAGATGAGTAGCTGAGAGCCGAGGACACGGCCGTGTATTACT GTGCGGAGGGCAGTGGTGGCTTCCGGGGCCAGGGAACCCCTGGTCAACCGTCTCCICA
Con1p3-e02h	132	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGATTTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCAACCTTTAGTACCTATTGGATGAGCTGGGTCGCCAGGCTCCAGGGAAGGGCTGGAGTGGGTC GCCAGCATAAAGGAGGATGGAAGTGAAGATACTATGTGACTCTGTGAAGGGCCGATTCACCAATCTCCAG AGACAACGCCAAGAACTCAGTGTCTTACAGATGAGTAGCTGAGAGCCGAGGACACGGCCGTGTATTACT GTGCGGAGGGCAGTGGTGGCTTCCGGGGCCAGGGAACCCCTGGTCAACCGTCTCCICA
Con1p3-e03h	133	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCCGCATCAGTGGTAACTACATGAGTTGGTCCGCCAGGCTCCAGGGAAGGGCTGGAGTGGGTC

Con1 Heavy	Seq ID No:	
Con1p3-g01h	134	<p>TCACTTATTTATGGACTGATGACACAGTCTAGCGAGACTCCGTGAAGGGCAGATTCCACCATCTCCAGGGAC GTCTCCAAAGAACATGGTGCATCTTCAAATGACAGCCTGAGACTCGAGGACACCGCTGTTTATTACTGTGCG AGAGAAATAGGTGTTTTTTCATTCAGGGGGGACCAAGTGGCTGGGCCCTTAGACTGCTGGGGCCAGGGAAACC CTGGTCAACCCGTCCTCA</p>
Con1p3-g06h	135	<p>GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTTCAAGCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCAACCTTCACTAGCTGGATGCACCTGGTCCGCCAAGCTCCAGGGAAGGGGTGGTGGTCTCA CATATTAATACTGATGGAGTAGCACAAGTACCGGACTCCGTGAAGGGCCGATTCCACCATCTCCAGAGAC AACGCCAAGAAACACGCTGTATCTGCAAATGAAACAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGC AAGAGATTATTACACTCCGTTGACTAGTGGGCCAGGAAACCTGGTCAACCGTCTCCTCA</p>
Con1p4-b01h	136	<p>CAGGTGCAGCTGCAGGAGTCCGGGCCAGGAAATGGTGAAGCCTTCGGAGACCCCTGTCCCTCAATCTGCAGTGT TCTGGTGCCTCCGTCAGTCTGACCACTGGAGCTGGATCCGCCAGTCCAGGGAAGGGACTGGAGTGGATT GTCTATAATAAACAAGTGAAGCATCGAATACAATCCCTCCCTCAAGAGTGAAGTCAACATATCCGTAGAC ACGTCCAAAGAACAGGTCTCCCTGACAGTACTTCTGTGACCGTGCAGACACGGCTTCTATTACTGTGCG CGAGGGCCAGATGCCACAAAACCTGGTACTGGGGCCCGGAAACCCCTGGTCAACCGTCTCCTCA</p>
Con1p4-b03h	137	<p>GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTTCAAGCTGGGGGTCCCTGAGACTCTCCTGGCCAGC CTCTGGATTCAACCTTCAAGTAACTCTGGATGTACTGGTCCGCCAAGTTCAGGGAAGGGCTGGTGGCGT CTCACGTATTAATAGAGTGGAGTATCAATTTAGCCGGACTCCGTGAGGGCCGATTCCACCATCTCCAG AGACAACGCCAAGAACACCGTGTATCTGCAAATGAACAGTCTGAGTCTGAGGACACCGCTGTGTATTACT GTGCAAGAGATTCCCTATACAGCCCTGACTACTGGGGCCAGGGACCCCTGGTCAACCGTCTCCTCA</p>
Con1p4-c01h	138	<p>GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTTCAAGCTGGGGGTCCCTGAGACTCTCCTGTGCAGC CTCAGGATTAACCTTCAAGTAACTTGGATGGATGAGTGGTCCGCCAGGCTCCAGGGAAGGGCTGGAGTGG TTGGGGCTTTAAAACAAGCCTGATGGTGAACAACAGACTACGACACCCCGTGAAGGGCAGATTCAACC ATCTCAAGAGATGATTCAAAACCAACCGCTGTATCTGAAAATGAACAGCCTGAAAGTCAAGGACACAGCCGT GTATTACTGTACCACAGATAACGGAGTCAAGGCTTTTGATATCTGGGGCCAAAGGGACAATGGTCAACCGTCTC TTCA</p>
Con1p4-g01h	139	<p>GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTTCAAGCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCAACCTTCAAGTAACTTGGATGCACTGGTCCGCCAAGTTCAGGGAAGGGCTGGTGGTGGTGC TCACGTTATTCATCTGTGGAGTAAACAAGCCTACCGGACTCCGTGAAGGGCCGATTCCACCATCTCCAGA GACAACGCCAAGAACACCGTGTATCTGCAAATGAATAGTCTGAGAGTCAAGGACACCGCTTTTATTATTGT ACAAGAGGGGTTCCGGGGTACGATCAATTAATGGGGCCAGGGAATCTGGTCAACCGTCTCCTCA</p>
Con1p6-c01h	140	<p>CAGGTGCAGCTGCAGGAGTCCGGGCCAGGGCTGGTGAAGCCTTCAAGACCCCTGTCCCTCAACCTGCAGTGT TCTGGTGGCTCCATCAGCGGTGGTACTTACTCTGGACCTGGATCCGGCAGCCCGGGGAAGGGACTGGAG TGGATTGGGGCTATTTTTGCTAGTGGGAGCACCAACTACAATCTCCCTCAAGAGTCAAGTCAACCATTTTAG</p>

Con1 Heavy	Seq ID No:	
Con1p6-d04h	141	TAGACAGTCCAAAGAACCCTGTTCTCCCTGAGCCTGAGCTGTGACCGCCGCGAGACACGGCCATGTATTACTGTGCGAGAGATCGAGCCGGTATAGATGGCTACAATTACTACTTTGACTACTGGGGCCAGGGAAACCCCTGGTCA CCGTCTCCCTCA
Con1p6-e03h	142	AGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCAACCTTTAGTAGCTATTGGATGAGCTGGTCCGCCAGGCTCCAGGGAAGGACTGGAGTGGGTG GGCAAAATAAAGGAAGACGGAAAGTGAGAAATACTATGTGGACTCTGTGAAAGGGCCGATTCCGCCATCTCCAG AGACAACGCCAAGAACTCCCTGTCTCTGCAAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACT GTGCGAGAGGTCAATCATAATCCGGGAATTTGGGGCCAAGGACAATGGTCACCCGTCTCTTCA
Con1p6-e06h	143	CAGGTGCAGCTGCAGGAGTCCGGCCAGGACTGGTGAAGCCTTCGGAGACCCCTGTCCCTCACCTGCACCTGTC TCTGGTGGCTCCATCACTAATTAATACTACTGGGGTGGATCCGGCAGCCCCAGGGGAGGACTGGAGTGGATT GGTATACTATTACAGTGGAAAGCACCACACTACAACCCCTCCCTCAAGAGTCAAGTCAACATATCAGTAGAC ACGTCCAAAGAACCAGTTCTCCCTAAAGCTGACCTCTGTAAACCGCCGACACACGGCCGTGTATTACTGTGCGG GGTCCGGCTTACAGTAGTGGTTACTACTACCTAATTGACTACTGGGGCCAGGGAACCCCTGGTCACCCGTCTCC TCA
Con1 Kappa	Seq ID No.	
Con1p2-c01k	144	GAAAATTGTGTTGACGCAGTCTCCAGGCACCCCTGTCTTTGTCTCCAGGGGAAAAGAGCCACCCCTCTCCTGCAGG GCCAGTCAAGAGTGTACCTACTTAGCCTGGTACCAGCAGAAAACCTGGCCAGGCTCCAGGCTCCTCTTCTAT GGTACATCCAGCAGGGCCACTGGCATCCAGACAGGTTCAAGTGGCAGTGGGTCTGGGACAGACTTCACTCTC ACCATCAGCAGAGTGGAGCCCTGAAGATTTTGCAGTGTATTACTGTCAAGCAGTTTGGCAGCTCACCTCCGGAC ACTTCCGGCGGAGGACCAAGGTGGAATCAAA
Con1p2-c04k2	145	TTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCAACCCCTGGACAGCCGGCCCTCCATCTCCTGCAGGGCTAG TCAAGGCCCTCGAACACAGTGTGGAACACCTACTTGTGTTTCCAGCAGAGGCCAGGCCGATCTCCCCG GCGCCTAATTTATAAGGTTTCTAACCCGGACTCTGGGTCCAGACAGATTCAGTGGCAGTGGGTCAAGGCAC TGAATTCACACTGGAATCACCCAGGTTGAGGCTGAGGATTTGGAGTTTATTACTGCATGCAAGTTACACA CTGGCCGAGGACGTTCCGGCCAAGGACCAAGGTGGAATCAAA
Con1p2-d02k	146	GAAAATTGTGTTGACACAGTCTCCAGGCACCCCTGTCTGTCTCCAGGGGAAAAGAGCCACCCCTCTCCTGCAGG GCCAGTCAAGATATTAGTCCCACTTGGCTGGTACCACAGAAAACCTGGCCAGTCTCCAGGCTCCCTCATA TATGATGCATCCAAACAGGGCCACTGGCATCCAGCCAGGTTCAAGTGGCAGTGGTGGACAGACTTCACT CTCAGCATCAGCAGCCTAGAGCCGTGAAGATTTGCAAGTTTACTGTTCAGCAGAGTGGCGACTGGCCCTCTC ACTTCCGGCGGAGGACCAAGGTGGAATCAAA
Con1p2-d03k3	147	GAAAATTGTGTTGACGCAGTCTCCAGGCACCCCTGTCTTTGTCTCCAGGGGAAAAGAGCCACCCCTCTCCTGCAGG

Con1 Kappa	Seq ID No.	
Con1p2-e01k	148	<p>GCCAGTCAGAGTGTTTACAGCATCTACTTCGGCTGGTACAGCAGAAACCCGGCCAGGCTCCCAGGCCCTC ATTTATGGTGTCTCCAACAGGGCCACTGGCATCCCAACAGAGTTACAGTGGCAGTGGGTCTGGGACAGACTTC ACTCTCACCATCAGCAGACTGGAGCCAGAAATTTTGCAGTGTATTTACTGTCAGCAGTATGGGTAGTTACCT CGGACGTTCCGGCCAGGGACCAAGGTGGAATCAAA</p>
Con1p3-c02k	149	<p>TTGTGATGACTCAGTCCCACTCTCCCTGCCCTCACCCCTTGGACAGCCGGCCCTCCATCTCCCTGCAGGTCTAG TCGAAGCCTCGTATACAGTGTAGGAGCCACTACTTGAATGGTTTCAGCAGAGGCCAGCCAAATCTCCAAG GCGCCTAATTTGGCACGTTTCTAACCGGACTCTGGGTCACAGACAGATTACAGCGGCAATGGGTCCAGGCAC TGATTCACACTGAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGTTTATTACTGCATGCAAGGTACACA CTGGCCTTACACTTTGGCCAGGGACCAAGGTGGAATCAAA</p>
Con1p3-c03k	150	<p>GACATCCAGATGACCCAGTCTCCATCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAACCATCACTTGGCCAG GCGAGTCAGGACATAGGAAGCTTTAAATTTGGTATCAGCAGAGACCAGGAAAGCCCTAACCTCCTGTGATC TACGATGCATCCAAATTTGGAAACAGGGGTCCCATCAAGGTTCAAGTGGAAAGTGGATCTGGGACACATTTTAGT TTCACCATCACAGCCTGCAGCCTGAAGATATTGCAACATATTACTGTCAACAGTTTGAAGTTTCCCTCGCA CCTTCGGCCTGGACCAAGTGGATATCAAA</p>
Con1p3-g01k	151	<p>GAAATAGTGTGACGCAGTCTCCAGCCACCCCTGTCTGTCTCCAGGGAAACAGCCACCCCTCTCCTGCGCAGG GCCAGTCAGAGTGTAAACAGCTTCTTAGCCTGGTACCAGCAAAACCTGGCCAGGCTCCAGGCTCCTCATC TATGTCTCATCCACCCAGGGCCACTGGTGTCCAGCCAGGTTCAAGTGGCAGTGGGTCTGGGACAGAGTTCACT CTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTACTACTGTCAACAGTATAAAAAACTGGCCCTCGG ATGGGCATTTCCGGCCCTGGACCAAGTGGATATCAAA</p>
Con1p3-g06k	152	<p>GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCTGCAGCCCTGGACAGCCGGCCCTCCATCTCCCTGCAGGTCTAG CCAGTCAGAAATATGGTGTCTCCTTGGCCTGGTATCAGCAGAAACAGGGAAAGCCCTAACCTCCTGTATCT ATAAGGCGTCTTATTAAGAAAGGGGGTCCCATCAAGGTTCAAGCGGCAATGGGATCTGGGACAGAAATCACTC TCACCATCAGCAGCCTACAGCCTGATGATTTTGGCAACTTATTATTTGCCAACAGTATGATATTTATTGACATT CGGCCAAGGACCAAGGTGGAATCAAA</p>
Con1p4-b01k	153	<p>TTGTGATGACTCAGTCCCACTCTCCCTGCCCTGCAGCCCTGGACAGCCGGCCCTCCATCTCCCTGCAGGTCTAG TCAAAGTCTCGCACACAGTGTGGAATACCTACTTGAATGGTTTCAGCAGAGGCCAGGCCAAATCTCCAAG GCGCCTAATTTATAAGGTTTCTAACCGGACTCTGGGTCCCAGACAGATTCAAGCGGCAATGGGTCCAGGCAC TGATTCACACTGAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGTTTATTACTGCATGCAAGGTACACA CTGGCCGTACACTTTGGCCAGGGACCAAGGTGGAATCAAA</p>
Con1p4-b03k2	154	<p>GACATCGTGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGCGAGAGGGCCACCATCAACTGCAAG TCCAGCCAGAGTGTTTATACAGCCCAACAATAAGAAATTAAGTGTGGTTCAGCAGAGGCCAGGCCAAATCTCCCGG CCTCTAAATTAATTAAGTGTCTACTGGCATCTATCCGGACTCCGGGTCCCTGACCCGATTCAAGTGGCAGCGGT CTGGACAGATTTCACTCTCAGCCTCAGCTGCAAGTGTGAGGCTGACGATGTGGCAGTTTATTACTGTCAAGCAAT ATGCTGCTACTCCGTGACGTTCCGGCCAAAGGACCAAGGTGGAATCAAA</p>
		<p>TTGTGATGACTCAGTCTCCACTCTCCCTGCCCTGCAGCCCTGGACAGCCGGCCCTCCATCTCCCTGCAGTTCTAG TCAAAGCCTCGTATACAGTGTGGAACAACCTACTTGAATGGTTTCAGCAGAGGCCAGGCCAAATCTCCCGG GCGCCTAATTTATAAGGTTTCTAACCGGACTCTGGGTCCCAGACAGATTCAAGCGGCAATGGGTCCAGGCAC TGATTCACACTGAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGTTTATTACTGCATGCAAGGTTCACA CTGGCCGCTCACTTTCCGGGGAGGGACCAAGGTGGAATCAAA</p>

Con1 Kappa	Seq ID No.	
Con1p4-c01k	155	GACATCGTGATGACCCAGTCCAGACTCCCTGGCTGTGTCTCTGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCTGAGTGTTTATCCAGCTCCCAATAATGAGAACTACTTAGCTTGGTACCAGCAGAAACCCAGGACAGCCTCTAAGCTGCTCAATTTACTGGCATCTACCCGGGATCCCGGGTCCCTGGCCGATTCAAGTGGCAGGGGCTCTGGACAGATTTCACTCTCACCATCAGCCTGAGGCTGAAGATGTGGCAGTTTATTACTGTCAACATATTATACTCCCTCGCTTCGGCCCTGGGACCAAAAGTGGATATCAAA
Con1p4-g01k	156	GACATCCAGATGACCCAGTCCCTGCTCCCTGCTGCATCTGTGGAGACAGTGTCAACCATCACCATTGCCGGGCAAGTCCAGAGATTAGCAGCTATTTAAATTGGTATCACCAAAACCAAGGAAAGCCCTAAACTCCTGATCTATGGTGCATCCACTTTGCAAAAGTGGGTCCCATCAAGTTCTGGTGCAGTGGATCTGGACACAGATTTCACTCTCACCATCAGCAGTCTGCAACTGACGATTTTGGCAACTTACTACTGTCAACAGAGTCCAGATTTCCCTCTCACTTTCCGGGAGGGACCAAGGTGGAGATCAAA
Con1p6-c01k	157	GACATCCAGATGACCCAGTCCCTTCCACCCTGTCTGCCTCTGTAGGAGACAGAGTCAACCATCACCATTGTCCGGGCCAGTCTGGTAGCTGGTGGCTGGTATCAGCAGAGCCAGGAAAGCCCTAAGCTCCTGATCTATAAGGCGTCTACTTTAGAAAAGTGGGTCCCATCACGGTTCAGCGGCAGTGGATCTGGACACAGAAATTCACCTCACCATCAGCAGCCTGACGCTGATGATTTTGGCAACTTATTACTGCCAACAGTATTATAGCTTCTACACTTTGGCCAGGGGACCAAGGTGGAAATCAAA
Con1p6-d04k	158	GACATCGTGATGACCCAGTCCAGACTCCCTGGCTGTGTCTCTGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTCTTTCTACAGTTCCAAACAAGAAGA ACTACTTAGCTTGGTACCAGCAGAAAGCCAGGACAGCCTCTAACTGATCAATTTACTGGGCATCTACCCGGGAAATCCCGGGTCCCTGACCATTCAAGTGGCAGGGGCTCTGGGACAGATTTCACTCTCACCATCACCAGCCTGCGGGCTGAAGATGTGGCAGTTTATTACTGTCAACATATTATACTCCCTCCTCACATTCGGCGGAGGACCAAGGTGGAAATCAAA
Con1p6-e03k	159	GAAATAGTGATGACGCACTCCAGCCCTGTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCGAGGGCCAGTCTAGCGGCGACTTAGTCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAAGGCTCCTCATCTATGGTGCCACCACCAGGGCTCTGGTGTCCAGCCAGGTTCAAGTGGCAGTGGGTCTGGGACACAGATTTCACTCACCATCAGCAGCCTGCACTGAGATTTTGGCAATTTTATTACTGTCAAGCAGTATAATAACTGGCCCCCGACGTTCCGGCCAAAGGACCAAGGTGGAAATCAAA
Con1p6-e06k	160	GAAATAGTGATGACGCACTCCAGCCCTGTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCGAGGGCCAGTCTAGCGGCGACTTAGTCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAAGGCTCCTCATCTATGGTGCCACCACCAGGGCTCTGGTGTCCAGCCAGGTTCAAGTGGCAGTGGGTCTGGGACACAGATTTCACTCACCATCAGCAGCCTGCACTGAGATTTTGGCAATTTTATTACTGTCAAGCAGTATAATAACTGGCCCCCGACGTTCCGGCCAAAGGACCAAGGTGGAAATCAAA
Con1p6-e09k	161	GAAATAGTGATGACGCACTCCAGCCCTGTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCGAGGGCCAGTCTAGCGGCGACTTAGTCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAAGGCTCCTCATCTATGGTGCCACCACCAGGGCTCTGGTGTCCAGCCAGGTTCAAGTGGCAGTGGGTCTGGGACACAGATTTCACTCACCATCAGCAGCCTGCACTGAGATTTTGGCAATTTTATTACTGTCAAGCAGTATAATAACTGGCCCCCGACGTTCCGGCCAAAGGACCAAGGTGGAAATCAAA
Con2 Heavy	Seq ID No.	
Con2p3-e04h	161	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGGCTGGTCCAGCCTGGGAGGTCCC TGAGACTCTCCTGTGCAGCCCTCTGGATTCAACCTCAGCAACCATGGCATGCCTGGCTCCGCCAGACTCCAGCAAGGGGCTGGAGTGGGTGGCAGTCAATTCATATGATGGAAAGTACCAATACTATGCAGACTCCCTGAAAGGGCCGATGCACCCTCTCCAGA GACAAATCCAAAGGAAACGGTGTCTTCTGCAAAATGAACAGCCTGAGACCTGAGGACACCGGCTGTGTATTATTGTGCGAAAGGGTGTCTTAATGGTGGTAACTGCTTTTGTGATTGACTACTGGGGCCCGGAAACCCCTGGTCAACCCGTC

Con2 Heavy	Seq ID No.	
Con2p3-c05h	162	GAGGTGCAGCTGTGGAGTGGGGGGGAGACTTGGTGCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCCGACTTCAGTATTTATGGCATGAACCTGGTCCGCCAGGCTCCAGGAAAGGGGCTTGAATGGGTC TCAGTTATTAGTGGTGGTGGCAGTATATATACTACGAGACTCCGTGAAGGGCCGGTTCAGTACTCTCCAGA GACAAATCCAAAGAACACACTGTTTTGCAAGTGAACAGCGTGAAGAGCCGAGGACACGGCCGTATATTACTGT GCGAAGGGGGCTACTATGAATCGGGGACTATGCGGGCTTTTGGATATCTGGGGCCAAAGGGACAATGGTCCAC CGTCTCTTCA
Con2p3-f03h	163	GAGGTGCAGCTGTGGAGTGGGGGGGAGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCC AGCCTCTGGATACACCTTTAGTAGTTATCAATGAGTTGGTCCGCCAGGCTCCAGGAAAGGGGCTGGAGTG GGTGGCCAGCATTAAGCCAGAAGGAAGTGAAGAAATCTATGTGGACTCTGTGAAGGGCCGATTCACTACTCTC CAGAGACAACGCCAAGAACTCACTGTATCTGCAATGAACAGCCTGAGAGGGGAGGACACGGCTGTCTACT ACTGTGCGAGAGGGGAATCTAATTTCCGATACTGGCACCCAGGAAACCCCTGGTCAACCCTCTCCTCA
Con2p3-g05h	164	GAGGTGCAGCTGTGGAGTGGGGGGGAGCCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACTTTCAGTAACTCTTGGATGGCTGGTTCGCCAGGCTCCAGGAAAGGGGCTGGAGTCCGTG GCCAAATAAAACCAGATGGAAGTGAAGAAATCCATGTGGACTCTGTGAAGGGCCGATTCAACCATCTCCAG AGACAACGCCGAGAACTCACTGTATCTGTGATGAACAGCCTGAGAGCCGAGGACACGGCTGTCTATTACTG CGGAGAGATAGCACTTCCCGGCCCTTTTGGGTACTGGGGCCAGGAAACCCCTGGTCAACCCTCTCCTCA
Con2p4-b03h	165	GAGGTGCAGCTGTGGAGTGGGGGGGAGCCTTGGTCCAGCCTGGGGGGTCCCTGAGGCTCTCCTGTGCAGCC CTCTGGGTTAAACCGTCAATACTACTACATGAAGTGGTCCGCCAGGCTCCAGGAAAGGGGCTGGAGTGGGT CTCAGTTATTTATAGCGTGGTGGCACAATACTACGAGACTCCGTGAGGGCCGATTCACTACTCCAGAGA CAATCCAGGAACGGCTTTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGATTAATCTGTG GACGGCGGGATGACCAAGTGGTACCGCTACTGGGGCCAGGAAACCCCTGGTCAACCCTCTCCTCA
Con2p4-c02h	166	AGGTGCAGCTGTGGAGTGGGGGGGAGGTTGATGAAGCCTGGGGCTCAGTGAAGGTTTCCCTGCAAGGCA TCTGAATACACTTTCATACTAACTACTTGTGTCTGGTGGCAGAGCCCTGGACAAGGGCTTGAGTGGATG GGAGAAATGAACCCCACTCGTGGAGCACAAGTACCCACAGAAATCCAGGGCAGAGTCCACCATGACCCAG GGACACGTCCACGAGCACAGTCTACATGGAGTTGAGCAGCCTGAGATCTGACGACACGGCCGTTTATTACTG CTCCATGGTCCGCCCTATTGTACTGGTGAAGCTGTACTCCGCCCTGTGATTTCTGGGGCCCGGGAACCCCTG GTCACCGTCTCCTCA
Con2p4-d06h	167	GAGGTGCAGCTGTGGAGTGGGGGGGAGGCTTGTATGAACCTGGGGGGTCCCTTAGACTCTCCTGTGCAGTC TCTGGGTTCACTTTCATAACGCTGGCTGAGTGGTCCGCCAGCCTCCAGGAAAGGGGCTGGAGTGGGT GGCCGTGCTTACAGCAGTCTGGCGTTGGACAATGGACTACTTTCACCCCTGAGGGGCAGATTACCCATC ACAAGAGACGATTCAAATAAACACACTGTATCTGCAAAATGAACAACCTGAAACCCGAGGACACAGCCGTGTA TTACTGTACCACAGATATTGGCAAAGGCTGGTACAGCAGTACTTCCCTGACCTCTGGGGCCAGGGAAACCCCTGGT CACCGTCTCCTCA
Con2p5-a06h	168	CAGGTGCAGCTGTGGAGTGGGGGGGAGGCTGGTCCAGCCTGGGAAGTCCCTCAGACTCTCCTGTGTAGCC TCTGGATTCACTTAAAGTACCTGTGGCATGCACTGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTG GCAGTTACAACAATATGATGGAGTCGTAATAATAATGTAGACTCCGTGAAGGGCCGATTCAACCATCTCCAGA GACAAATCCAAAGAACACCGTGTATCTGCAAAATGGACGGCTCAAAGCCGAGGACACGGCTGTGTACTACTG TGTGAAGAATAATAGTTGGGGTACTACAGAACTGCGGACTACTGGGGCCAGGGAAACCCCTGGTCAACCCTCTC

Con2 Heavy	Seq ID No.	
Con2p5-b06h	169	GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTAGCCGGGGGGTCCC TGAGACTCTCCTGTGTAGCC TCTGGATTCAACCTCAGTACTTACTGGATGCATGGGTCCGCCAACCTCCGGGGAAGGGCTGGTGGGTC TCACGTATTAATCTGTATGGCAGTAGCACAAACTACGGCGACTCCCGTGAACGGCCGATTCACCACTCCAGA GACAAACCGCAAGAACACCGCTGTATCTTGAATGAAACAGTTTGAGAGTCGAGGACACAGCTCTCTATTACTGT GCAAGAAGTCTCGGGGTTACTTTGACTACTGGGCCACAGACCTGTTACCCGTCCTCTCA
Con2p5-e04h	170	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGAAGCCTGGGGGTCCCTTACACTCTCCTGTGCAGTC TCTGGATTCACTTTCACTACCGGTGGATGAGCTGGTCCGCCAGGCTCCAGGAAAGGGCTGGACTGGGTT GGCCGTATTAAGCAAACTGCTGGTGGACAAACAGACTATGTCACCCGTGAAAGACAGATTCACCAT CTCAAGAGATGATTCAAAAAACACCGCTGTATCTGCAACTGACAGCCTTAAACCCGAGGACACAGCCGCTGT ATTACTGTACCACAGATGACTGAAAAAAGCTGGGCCAGGAAACCTGTTACCCGTCCTCTCA
Con2p5-e05h	171	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCGGGGGTCCCTGAGACTCTCCTGTGCAGC CTCTGGATTCACTTCACTTCACTAGTATAGCATGAAGCTGGGTCCGCCAGGTCCTCCGGGAAAGGGCTGGAGTGGGT CTCATACAAAGTACTAAAAGTGATATCAAAATACTACGGGACTCTGTGGAAGGCCGATTCACCAATTTCCAG AGACAATGCCAAGAACTCAATTGTATCTGCAAAATGAACAGCCTGAGAGACGAAAGACACGGCTGTCTATTATG TGGAGAGGACGAGATTGTTATGGGGTAACTGCGTCACTACTTCCACTACTACCGGTTTGGACGCTGTGGGG CCAAAGGACCAACCGTCAACCGTCTCTCTCA
Con2p6-b03h	172	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGTAGTC TCTGGATTCAACCTCAGTTCCTGTGGCATGCATGGGTCCGCCAGTCTCCAGGCAAGGGCTGGAGTGGCTG TCAGTTAGCACCTATGATGGAGATGGCAATCAGAAATACTATGCGGCCCTCCGTGAAGGCCGATTCCTCATC TCCAGAGACACTTCGAAGAACACCGTGTATCTCCATATGAACAGCCTGACAGCTGAGGACACGGCTCTATAT TATTGTGAAAGAGAGTGGCACTGGCTGGTATCGCACCCGCTGATTACTGGGGCCAGGGAACCCCTGGTCAAC GTCTCTCTCA
Con2p6-e05h	173	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCAACCGTCACTAGCATATTCATGAGCTGGTCCGCCAGGCTCCAGGCAAGGGCTGGAGTGGGTC TCAGTCACTATACCGATGGAACAAACATATTATGCAACTCCGTGGAGGCCGATTCACCATCTCCAGAGAC GATCCCAAGAAATGGTGTATCTTCAATTGAGCAGCCTGAGAACTGAGGACACCGGCTGTTTATTACTGTGGC AGAGATATCCCAACGACATTTGGAATAGGTGAAGCTTTTGATATCTGGGGCCAGGGGACAAATGGTCAACCCGTC TCTCTCA
Con2p6-g04h	174	AGGTGCAGCTGGTGCAGTCTGGGGTGAAGTGAAGAACCCCTGGGGCTCAGTGAAGCTTTCCCTGCAAGACA TCTGGATACTCCTTCAACAGCAACTATTGCACTGGGTGCAGACGGCCCTGGACAAGGACTTGAGTGGATG GGAATGGTCTACCCAAATGATGGTACTACAACCTACGCTCAGAAGTTTCAGGGCAGAGTCAACCATGACCCAGT GAGACGTCCACACACCAATCTACATGGACCTGAGCGGCTGACATCTGAGGACACGGCCATATATTACTGT GCTAGACGATTCGGGCTTTGACTACTGGGGCCAGGAAACCTGGTCAACCGTCTCTCTCA
Con2p7-d03h	175	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGTCCCTGAGACTCTCCTGTGAAGC CTCTGGATTCACTTCACTAGCAATGGCATGCATGGTCCGCCAGGCTCCAGGCAAGGGCTGGAGTGGGTC GGCAGTTATATCACTGTATGGAGTAGAGATACATGACAGACTCAATGAAGGCCGATTCACCATCTCCAG AGACAACCTCAAAGAACAGCTGTATCTGCAATGAAACAGCCTGAGAGCTGACGACACCGGCTGTCTATTACTG TGGCAAGGCTGTAGTGGTGAATAATTGCTTCTATATGGACGACTGGGGCCAAAGGACACCGGTCACCCGTCCTC CTCA

Con2 Heavy	Seq ID No.	
Con2p8-b01h	176	AGGTGCAGCTGGTGCAGTCTGGGGGTGAGGTGAAGAAGCCTGGGGCCTCACTGAAGGTCTCCTGCAAGGCA TCTGGATACACCTTCAGACAGAACTATTTCCACTGGGTGCAGACAGCCCTTGACAAAGGCTTGAAGTGGATG GGAGTAATCAACCCGAGTGGTAGTACAAAGTTCCACAGAAAGTTCCAGGGCAGATCAGCATGACCCAG GGACACGTCCACGAGCACAGTTTACATGGACCTGACAGTCTGACATCTGAGGACACGGCCGCTATTATTG TACGAGAGATCGGCCGAGTGGTAGTAGTACGTACGTGGGTGGGTGGGCTACTTTGACTACTGGGG CCAGGAAACCTTGGTCAACCTCTCCCTCA
Con2p8-b05h	177	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCCGGGGGTCCCTGAGTCTCTCCTGTGAAGCC TCTGGATTAACCTTCAGTGGTACTGGATGAACCTGGTCCGCCAGGCTCCAGGAAAGGGCTGGAGTGGGTG GCCAACAATAATCCAGAAGAAAGTGAAGAGATACGTGGAGTCTGTCAGGGCCGATTCAACCTCTCCAG AGACAACCCGAAGAACACCCCTGATTTGCAAAATGAACAGCCTGAGAGTCGAGGACACGGCTCTGTATTACT GTGGGGCTGGGGGAGAACCCAGGACTGGGGCCAGGAGCCCTGGTCAACCTCTCCCTCA
Con2p8-e03h	178	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGACTCACCTTCAGCAATATGGCATGCACCTGGGTCCGCCAGGCTCCAGGAAAGGGCTGGAGTGGGT GCAGTTGTGTCGGCAAGGGAGGAACTACATAATATGCAGACTCCCTGTAAGGGCCGATTCAACATCTCCAGA GACAAATCCAAAGAACACCGATGTCTCTGCAAAATGAACGGCCTGAGACCTGACGACACGGCTGTGTATTTTTGT ACGAAAGAGGAGCACACCTGGAAAATATGTCTTTGATACTGGGGCCAAAGGGACAAATGGTCAACCGTCTC TTCA
Con2p8-f05h	179	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGAGGATCCCTGAGACTCTCCTGGCCAGCC TCCGGATTCACCTTCAGTACTACCGCATGGACTGGGTCCGCCAGGCTCCAGGAGGGGGTGGAGTGGATT GCCCGTATTAGACACAGAGATGCAAGGCTATAGCACAGAAATACCCCGCTGTGTAGGGGGCAGATTCACCGT CTCAAGAGATGACTCACAGATACACTGTACCTGCAGATGAACAGCTTGAAGCCGACACACGGCCGTGT ATATTTGTCTTAAAGATTCTTCGCAATACTCTTTTGTGATGTCGCTGGGGCCAAAGGGACAAATGGTCAACCGTCTCTC A
Con2 Kappa	Seq ID No.	
Con2p3-c04k	180	GACATCGTGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGGAGAGGGCCACCATCAACTGCAAG TCCAGTCAAGAGTATTTTATCCAGATCCAAACAATAAGAACTACTTAGCCTGGTACCAGCAGAAACCCAGGACAG CCTCCTAAATTGCTCCTTTATTTGGGCACTACCCGGGAATCCGGGGTCCCTGACCCGATTCAGTGTCAAGCGGT CTGGTCAAGATTCACTCCACCATCAGTAGCCTGCAAGGCTGAGGATGTGGCAGTTTATTACTGTGTCAGCAGT ATTATAATGCTCCCCTCACTTTCGGGGAGGACCAAGGTGGAGATCAAA
Con2p3-c05k	181	GAAAATTGTGTTGACACAGTCTCCAGCCACCTGTCTTTGTCTCCAGGGGAAAAGGGCCACCCCTCCTGTCAGG GCCAGTCAAGACTGTAGCAGGTACTTAGCCTGGTACCAACAAGCCCTGGCCAGGCTCCAGGCTCCCTCATC TATGCTGCATCCAACAGGGCCACTGGCATCCCAACCCAGGTTCAAGTGGCAGTGGGTCTGGGACAGACTTCACT CTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAATTTTATTACTGTGTCAGCAGCAGTGAACAACCTGGCCGTC ACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA
Con2p3-f03k	182	GACATCCAGATGACCCAGTCTCCTCCTCCTGCTGCATCTGTAGGAGACAGTGTCAACCATCACTTGGCCAGG CGAGTCAAGACATTAGAGACCGTTAAATTGGTATCAGCAGAAAGCCAGGAAAGCCCTAACCTCCTGATCT ACGATGCATCAAGTTTGGAAACAGGGGTCCCATCAAGGTTCAAGAGGAAAGTGGATCTGGGACAGATTTTACTT

Con2 Kappa	Seq ID No.	
		TCACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACATATTACTGTCAACAGTTTTGTTAGTTTCCCTCGAAC TTTTCCGGCCCGGGACCAAAAGTGGATATCAAA
Con2p3-g05k	183	GAAATTGTGTGAGGCAGTCTCCAGGCATCTGTCTTTGTCTCCAGGGGAAAGGCCACCCCTCTCCTGCAGG GCCAGTCAGAGTGTAGCAGCAGGTCTTGTCTCTGTACCAGAGAGACCTGGCTGGCTCCAGGCTCCTC ATCTATGTGCATCCAGCAGGCGCTGTACCCCAAGGTTCACTGCCAGCGGGTCTGGGACAGACTTC ACTCTACCATCAGCAGTCTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAAGCACTATGGTACCTCACCTC CGAGGTACACTTTTGGCAGGGACCAAGTGGAGATCAAA
Con2p4-b03k	184	GACATCGTGTGATGACCCAGTCCCCAGACTCCCTGGTGTCTCTGGCGGAGAGGGCCACCATCAACTGCAAG TCCAGCCAGAGTGTTTACACAGCTCCAACAATAAGAACTACTTGTCTTGTACCAGCAGAAACCCAGGACAG CCTCTAAGCTGCTCATTCACCTGGCATCTACCCGGCATCCCGGGTCCCTGACCGATTCACTGGCAGCGGG TCTGGACAGATTTCACTCTACCATCAGCAGCCTGCAGGCTGAAGATGTGACAATTTATTACTGTCAAGCAA TATTATAGTACTCCGTACACTTTTGGCCAGGGACCAAGTGGAAATCAAA
Con2p4-c02k	185	GAAATTGTGTGACGCAGTCTCCAGGCACCCCTGTCTTTGTCTCCAGGGGAAAGGCCACCCCTCTCCTGCAGG GCCAGTCCGAGTCTTGACAGCGCTACTTAGCCTGGTACCAGCAGAAAGCCTGGCCAGGCTCCAGGCTCCTC ATCTATGGTGCATCCTCCAGGGTCACTGGCATCCCCAGATAGGTTCAGTGGCAGTGGTCAAGGACAGACTTC ACTCTACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTACTACTGTCAAGCGGTATGGTAACTCACCT CCGTACACTTTTGGCCAGGGACCAAGTGGAGATCAAA
Con2p4-d06k	186	GACATCGTGTGATGACCCAGTCTCCAGACTCCCTGGTGTGTCTCTGGCGGAGAGGGCCACCATCAGCTGCAAG TCCAGCCAGAGTCTTTTATACAGTTCAGCAATAAAGAACTACTAGCTTGGTCCAGCAGAAACCCAGGACAG GCTCCTAAGTTGCTCAATTTACTGGCATCTACCCGGAAATCCCGGGTCCCTGACCGATTCACTGGCAGCGGG TCTGGACAGATTTCACTCTACCATCAGCAGCCTGCAGACTGAAGATGTGGCAGTTTATTATTGTCTGCAAT ATCGTAGTCTCCGTTCACCTTCCGGGGAGGGACCAAGTGGAGATCAAA
Con2p5-a06k	187	GACATCCAGATGACCCAGTCTCCTTCCACCCAGTCTGCATCTGTAGGAGACAGAGTCAACCATCCTTGCCTGG GCCAGTCAGAGTATTAGTAGTGGTGGCTGGTATCAGCAGAAACCCAGGAAAGCCCTAAGGTCTCTGATC TATGGGTGTCTAGTTTGAAGAGTGGGTCCCATCAAGGTTCAAGGTCAGCGGCAGTGGATCTGGGACAGAAATCACT CTCACCATCAGCAGCCTGCAGCCTGAGGATTTTGCAGTATTACTGCCAACAAATATAGTACTTATCCCTGGA CGTTCGGCCAGGGACCAAGTGGAAATCAAA
Con2p5-b06k	188	GAAATAGTGTGACGCAGTCTCCAGCCTCCCTGTCTGTGTCTCCAGGGGAAACAGCCACCCTCTCCTGCAGG GCCAGTCAGAGTGTGGCAGCACCCTTAGCCTGGTACCAGCAGAAAGCCCGCCAGGCTCCCAAGGCTCCTCATC TATAATGTATTCACAGGGCCGCTGGTGTCCAGCCAGGTTCACTGGCAGTGGTCTAGGACGGAGTTCACT CTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTATTACTGTCAAGCAGTATAGTACCTGGCTGTGGA CGTTCGGCCAGGGACCAAGTGGAAATCAAA
Con2p5-c04k	189	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAACCATCCTTGCCTGG GCAAGTCAGCGCATTAGCAGCTACTTGAATTTGGTATCAGCAGAAACCCAGGAAAGCCCTTAACTCCTCTGATC TACGCTGACGCCAGTTTGCATGATGGGTCCCATCAAGGTTCAAGTGGCAGTGGATCTGGGACAGATTTCACT CTCACCATCAGCAGTCTGCAACTGAAGATTTTGCAGTATTACTGTCAACAGCGGTTACAGAAATCCCGGTACA GTTTTGGCCCGGGACCAAGTGGAGATCAAA
Con2p5-e05k	190	GATATTGTGATGACTCAGTCTCCACTCTCCCTGTCTCCCTGTCAGCCCTGGAGAGCCCGGCTCCATCTCCTGCAGGT CTAGTCAGAGCCCTCTTCAAGGTAAATGGACACAACACTATTTGGATTGGTACCTGCAGAAAGCCAGGACAGTCTC

Con2 Kappa	Seq ID No.	
		CCAGTCAGGGCA TTGATACTCGTTTGATCTGGTATCAACAAGAACAGCCAGGGGAAGCCCTAAGCTCCTGATCT ATGAAGCATCCACTTTGCAAAAGTGGGCCCCATCAAGTTCAAGCGGCAAGTGGATTCGGGACAGAATTCACCTC TCACAATCAGCAGCTGCAGCCTGAAGACTTTGCAACTTATTACTGTCAACAGTTTAAAGGTTACCCCGCTCAC TTTCGGCGGGGGACCAAGTGGAGATCAAA
SLE1 Heavy	Seq ID No.	
SLE1p1-a02h	199	CAGGTGCAGCTGCAGGAGTCGGGCCAGGACTGGTGAAGCCCTTCGGAGACCCCTGTCCCTCACCTGCACCTGTC TCTGGTGGCTCCATCAGTAGTCACTACTGGAGCTGGATCCGGCAGCCCCAGCGAAGGGACTGGAGTGGATT GGGTATATCTATCACAGTGGATGACCAACTACAACCCCTCCCTCAAGAGTCGAGTCAACCATATCAATAGAC ACGTCCAAGAACCAGTTCTCCCTGAAGTTGAGCTCTGTGACCCGCTGGGACACGGCCGTGTATTACTGTGGC AGAGTGTGGCTACAATTTCTTCTGGGCCAGGGAACGCTGGTCAACCCGTCCTCA
SLE1p1-a03h	200	CAGGTGCAGCTGGTGGAGTCTGGGGAGGGCTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGC GTCTGGACTCACGTTACGTAACCAAGATTTCCACTGGTCCGCCAGGCTCCAGGCAAGGGGTGGAATGGGT GGCATTTATACGTTATGATGGAGGTTTTAAAACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAG AGACAATTTCCAGAAAATGCTGTATCTGCAAAATGGACAGCTGAGAGTTGAAGACACACGGCTGTATTACTG TCGGAAGTGGCGGCAGAGGACTTACTACTGTCTGGCTGAATTTGGTTCGACCCCTGGGGCCAGGGAACCCCT GGTCAACCGTCTCCTCA
SLE1p1-b05h	201	GAGGTGCAGCTTGGAGTCTGGGGAGGGCTTGGTAGAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTAGCAGCTATGCCATGAGTGGTCCGCCAGGCTCCAGGAAAGGGCTGGAGTGGGTG TCAGCTATTAGTGACAGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGTTACCATCTCCAGA GACAAGTCCAAGAACACGCTGTATCTGCAAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTG TCGGAACCCGAATTACTTTGGTTCGGGGAGTCCCGACTACTGGGCCAGGGAACGCTGGTCAACCGTCTCCTC A
SLE1p1-c04h	202	CAGGTGCAGCTGCAGGAGTCGGGCCAGGACTGGTGAAGCCCTTCGGAGACCCCTGTCCCTCACCTGCACCTGTC TCTGGTGGCTCCATCAGTAGTCACTACTGGAGCTGGATCCGGCAGCCCCAGGAAAGGGACTGGAGTGGATT GGGTATATCTATCACAGTGGGATTAACAACCCCTCCCTCAAGAGTCGAGTCAACCATATCAATAGAC ACGTCCAAGAACCAGTACTCCCTGAAGCTGAGCTCTGTGACCCGCTGGGACACGGCCGTGTATTACTGTGGC AGAGTGTGGCTACAATTTCTTACTGGGCCAGGGAACGCTGGTCAACCCGTCCTCA
SLE1p1-e01h	203	GAGGTGCAGCTGGTGGAGTCTGGGGAGGGTGTGGTACGGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGC CTCTGGATTCACTTTGATGATTATGGCATGACCTGGGTCCGCCAAGCTCCAGGAAAGGGCTGGAGTGGAT CTCTGGTATTTGTGCAACGGTGGTGTGCTCAGGTTATGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGA GACAACGCCAAGAAGTCCCTGTTCTGTGTCATGAACAGTGTGAGAGCCGAGGACACGGCCCTGTATTACTGT GTGAGAGTGGCAGTACCAGCTGCTACATACACCCGAGGGAATGATGCTTTTGTGATATTTGGGGCCCAAGGGAC AATGTCACCCGTCCTCA
SLE1p1-f02h	204	GAGGTGCAGCTGGTGGAGTCTGGGGAGGGCTTGGTAGAGCCTGGGGGTCCCTCAGACTCTCCTGTGCAGTC TCTGGTTCACTTTCACTGACCCCTGGATGACCTGGTCCGCCAGGCTCCAGGAAAGGGCTAGATTGGGTT GGCCATGTAAAAGTAAATATGATGTTGCGACAACAGATCCGTGCACCCCTGCAACCCGAGGAGTTCACCAT CTCGAAGATGATTCAAAAGAAGACAATATATCTGCAAAATGAACAGCCTGAACACCCGAGGACACAGGGCTCT

SLE1 Heavy	Seq ID No.	
SLE1p1-g05h	205	<p>ATTTTGTACCACAGCTCATGGCCCGGTGGTGACCAATGGGGCCAGGGAAACAACACTGGTCACCCGTCTCCCTCA GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGTCCCTGAGACTCTCCTGTGCAGC CTCTGGATTACAGCTTGTATACCTTTGGATGACCTGGGTCCGCCAGGCTCCAGGGAAAGGGGCTGGAGTGGGT GGCCACCATAAACCCAGGTGGAAGTGACAAATACTATGTGGACTGTGAAAGGGCCGATCCACCATCTCCA GAGACAACGCCAAGAACTCACTGTACTGCAAAATGAACAGCCCTGGAGCCGAGACACGGCTGTATATTAC TGTGGAGAGCGGGGGTGTAGCTCTACCAGATGCCATACAACCCCGGATTTGACTACTGGGGCCAGGG AGCGCTGGTACCCGTCTCCTCA</p>
SLE1p2-a02h	206	<p>TGCAGTGCAGGAGTCCGGCCAGGACTGGTGAAGCCTTCGGAGACCCCTGTCCCTCACCTGCACCTGTCTCTG GTAGCTCCATCAGCAGTAGTAGTTACTACTGGGGTGGTCCGCCAGTCCCAAGGAAAGGGACTGGAGTGG ATTGGAGTATCTATCACAGTGGACCATCTACTACAACCCGTCCCTCAGGAGTGCAGTCCACCATATCCGTA GACACGTCCAAGAACCAGTCTCCCTGAAGTGAACCTGTGACCCGCCAGACACGGCTGTTTATTACTGT GCGAGTCTTAGTGGCACAAATGCTTTTGATATCTGGGGCCAAAGGACAATGGTCAACCCGTCTCTTCA</p>
SLE1p2-d04h	207	<p>GAGGTGCAGCTGTGGAGTCTGGGGGGGCTTGTACAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTACACCTTAGCAGCCATGACATGAGTTGGGTCCGCCCTGCCAGGAAAGGGCCGGAGTGGGTCTC TCAGCTCTTGGTGTGGAGATGCTTGGACACACTACGCAAACTCCGTGAGGGGCCGGTTCACCATCTCCAGA GACGATTCGAAGAACACCGTGTACTGCAAAATGAACAGCCTGAGAGCCGAAGACACACGGCTGTATTTCTGT GCGAAACCCCGTGGATACTCTATGGTACTTTGACTACTGGGGCCAAAGGAAACCGTGTCAACCCGTCTCCTCA</p>
SLE1p3-a02h	208	<p>GAGGTGCAGCTGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGGAGCC TCTGGATTACACCTTTAGTACCTATTGGATGACCTGGTCCGCCAGGCTCCAGGAAAGGGCTGGAGTGGGTG GCCAATATAAACCAAGATGGAAGTGAGAAACAATAATGTGGACTGTGAAAGGGCCGATCCACCATCTCCAG AGACAACGCCAAGAACTCACTGTATCTGCAGATGAACAAGCCTGAGAGTGCAGGATACGGCTATTTATTACTG TCCGAGACCCCGTCCCGACTTACTCTGGGGCCAGGATCGTGGTCAACCCGTCTCCTCA</p>
SLE1p3-a04h	209	<p>GAGGTGCAGCTGGTGGAGTCCGGGGAGGCTTAGTTCAAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGAAATTCACCTTCAGTGACTACTGGATGCACTGGTCCGCCAAGCTCCAGGAAAGGGCTGGTCTGGGTCTC TCACGTATTAATCTGACGGGAGTACCACAACCTACGGGACTCCGTGAAGGGCCGATCCACCATCTCCAGA GACAACGCCAAGAACACCGTGTATCTACAATGAACAGTCTGAGGGCCGAGACACGGCTGTGTATTACTG TCGAAGATCTAATCGGGGCCACGAAGCCTGGGGCCAGGAAACCGTGGTCAACCCGTCTCCTCA</p>
SLE1p3-b03h	210	<p>AGGTGCAGCTGGTGCAGTCTGGGGTGAAGTGAAGAAAGCCTGGGGCTCAGTGAGGTTTCTCTGCAAGGCA TCTGGATACACCTTCACCAACTACTGGATACACTGGGTGCACAGGCCCTTGACAAAGGCTTGAAGTGGATG GGAATGATCGCCCTAAGGAAGTTACACATTTACGCACAGCAATTACAGGCAAGATCCCGTGAACCCGATCCAG GGACACGTGCAGAGCGGTTACATGGAGCTGAACAGCCTGAGATCTGAGGACACGGCCGTATAATTTCTG TCGGAGAGACATTCACCCACGCTAATTTGGACTATTGGGGCCAGGGGACGCTGGTCAACCCGTCTCCTCA</p>
SLE1p3-c03h	211	<p>GAGGTGCAGCTGTGGAGTCTGGGGGAGGATGGTACAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTACACCTTAGCGATTATACCATGAATGGGCCCGCCAGGCTCCAGGAAAGGGCTGGAGTGGGTCTC TCAGCTATTAGAGAGAGTGGTACAGACATACACAGACTCCGTGACGGGCCGGTTCACCATCTCCAGG GACAATTCAGAAACACACTTTTATCTGCACATGAACAGCCTGAGAGCCGAGGACACGGCCATGTATTTTGT GTGAAAGACAGGTTGCCCGGGTGCAGCTGCCCCGGGTGACTTCTGGGGCCCGGAAACCGTGCACCCGTCTC CTCA</p>

SLE1 Kappa	Seq ID No.	
SLE1p1-a02k	212	GACATCCAGTTGACCCAGTCTCCATCCTTCCCTGCTGCATCTGTAGGAGACAGAGTCAACCATCACTTGGCCGGG CCAGTCAGGACATGACCCATTCTTTAGCCTGGTATCAGCAAAAACCAGGAAAGCCCTAACCTCCTGATCT ATAATGCATACACTTTGCAAAAGTGGGTCCCATCAAGTTTCAGGGCAGTGGATCTGGGACAGAAATTCACATC TCACAAATCAGCAGCCTGCAGCCTGAAAGATTTTGCAACTTATTACTGTCAACAGATTAATAGTTACCCCTCGAA CTTTTGGCCAGGGACCAAGTGGAGATCAAA
SLE1p1-a03k	213	GAAATTTGTTGACACAGTCTCCAGGCACCCCTGTCTTTGTCTCCAGGGGAAAAGAGCCACTCTCTCCGACAGG GCCAGTCAGAAATATTGGCACCCCTTAGCCTGGTACCAACAGAAAACCTGGCCAGGCTCCCAGACTCATCATC TATGAAACATCCAAACAGGGCCACTGACGTCCAGCCAGGTTCAAGTGGCAGTGGTCTGGGACAGACTTCACT CTCACCATCAGCAGCCTGGAGCGTGAAGATTTTGCCCTTTATTACTGTCAACAGCGTGGCCGACTGGCCGCTC ACTTTCGGCGGAGGACCAAGTGGAGATCAAA
SLE1p1-b05k	214	GAAATTTGTTGACACAGTCTCCAGGCACCCCTGTCTTTGTCTCCAGGGGAAAAGAGCCACTCTCTCCGACAGG GCCAGTCAGAGTGTAGCAGTACTTAGCCTGGTACCAACAGAGACCTGGCCAGGCTCCCAGGCTCCGTCATC TATGCTGCATCCAAACAGGGCCACTGGCATCCAGCCAGGTTCAAGTGGCAGTGGTCTGGGACAGACTTCACT CTCACCATCAGCAGCCTAGAGCCTGAAAGATTTTGCAAGTATTACTGTCTGCAGTGTAGCAACTGGCCCAATGT ACACTTTTGGCCAGGGACCAAGTGGAGATCAAA
SLE1p1-c04k	215	GACATCCAGTTGACCCAGTCTCCATCCTTCTCTGCTGCATCTGTAGGGGACAGAGTCAACCATCACTTGGCCGGG CCAGTCAGGACATTAACCGATTTCTTAGCCTGGTATCAGCAAAAACCAGGAAAGCCCTAACCTCCTGATCT ATACTGCATCCACTTTGCAAAAGTGGGTCCCATCAAGTTTCAGCCGAGTGGATCTGGGACAGAAATTCACATC TCACAAATCAGCAGCCTGCAGCCTGAAAGATTTTACAACCTTATTACTGTCAACAGATTAATAGTTACCCCTCGAA CTTTTGGCCAGGGACCAAGTGGAGATCAAA
SLE1p1-e01k	216	GACATCCAGATGACCCAGTCTCCATCCTTCTCTGCTGCATCTGTAGGAGACAGAGTCAACCATCACTTGGCCGG GCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAAACCAGGAAAGCCCTAACCCCTAAGCCCTGAT CTATGCTGCATCCAGTTTGCAAAAGTGGGTCCCATCAAGTTTCAGCCGAGTGGATCTGGGACAGAAATTCAC TCTCACAAATCAGCAGCCTGCAGCCTGAAAGATTTTGCAAGTATTACTGTCTACAGCATAGTAGTTTCCCGTGG ACGTTCCGGCCAGGGACCAAGTGGAAATCAAA
SLE1p1-f02k	217	GACATCCAGTGCACCCAGTCTCCAGACTCCCTGGCTGTCTCTGGCCGAGAGGGCCGCCATCAACTGCAAG TCCAGCCAGAGTGTCTTAGACAGCTCCAAACATGAAGAGTACTTAGCCTGGTATCAGCTGAAAGCAGGACA GCCTCCTAGGTTGCTCAATTTACTTGGCTCCACCCGGGAATCCGGGTCCCGGACCCGATTCAGTGGCAGCGG GTCCGGGACAGATTTCAATCTCAATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAAGCA ATATTATACAACCCCTTCGATCACTTCGGCCAAAGGACACGACTGGAGATTA
SLE1p1-g05k	218	GACATCCAGTGCACCCAGTCTCCAGACTCCCTGGCTGTCTCTGGCCGAGAGGGCCACCATCAACTGCAAG TCCAGCCAGAGTGTCTTAGACAGCTCCAAACAATAAGAACTACTTAGCTTGGTACCAGCAGAAAACCAGGTCAG CCTCCTAAGATGCTCAATTTACTGGCATCTACCCGGGAGTCCGGGTCCCTGACCGATTTCAGTGGCAGCGGG TCTGGGACAGATTTCACTCTCACTCAAGCAGCCTGCAGGCTGAAAGATGTGGCAGTTTATTACTGTCAAGCAA TATTATACTACTCCTCCCATCACTTCGGCCAAAGGACACGACTGGAGATTA
SLE1p2-a02k	219	GAAATTTGTTGACACAGTCTCCAGGCACCCCTGTCTTTGTCTCCAGGGGAAAAGAGCCACTCTCTCCGACAGG GCCAGTCAGAGTGTAGTATCTACTTAGCCTGGTACCAACAGAAAACCTGGCCAGGCTCCCAGGCTCCTCATC TATGATTCATCCAAACAGGGCCACTGGCATCCAGCCAGGTTCAAGTGGCAGTGGTCTGGGACAGACTTCACT CTCACCATCAGCAGCCTAGAGCCCGAAGATTTTGCCGTTTATTACTGTCAACAGCGTGGCCGACTGGCCGAAACG

SLE1 Kappa	Seq ID No.	
SLE1p2-d04k	220	<p>TTCGGCC AAGGACCAAGTGGAGATCAAA</p> <p>GAAATTGTGTTGAGCGAGTCTCCAGGCACCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG GCCAGTCAGACTGTTACCAACAATACTTAGCCCTGGTACCAACAACAACCTGGCCTGGCCGCCCCAGGCTCCTC ATCTTTGATGATCCATCAGGGCCACTGGCATCCAGACAGGTTCAAGTGGCAGTGGGTCTGGGGCAGACTTC ACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTACATTTACTACTGTCAAGCAATATGGTATTTTCAACCTC GAACTTTGGCCAGGGACCAAGTGGAGATCAAA</p> <p>GATATTGTGATGACCCAGACTCCACTCTCTCTCCCTGACCCCTGGACAGCCGGCCCTCCATCTCCTGCAAGT CTAGTCAGAGTCTCCCTGGATAGTATGGAAGGACCTATTTCTTTTGGTATTTGCAGAAAGCCAGCCAGTCTCC ACAACTCCTGATCTATGAAGTTTCCAAACCGGTTCTCTGGAGTCCAGATAGGTTCAAGTGGCAGCGGGTTCAGG GACAGATTTCAACTGAAAATCAGCCGGTGGAGTCTGAAGATGTTGGGTTTATTACTGCATGCAAGGTAC ACACCATCCGTGGACGTTCCGGCCAAAGGACCAAGGTGGAATCAAA</p> <p>GACATCGTGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGCGAGAGGGCCACCCTCAACTGCAAG TCCAGCCAGAGTGTTTTATACAGTCCACAGTAAGAACTACTTAGCTTGGTACCAGCAGAAACCAGGACAG CCTCTAAGCTGCTCAATTTACTGGCATCTACCCGGAAATCCGGGGTCCCTGACCGGATTCAGTGGCAGCGGG TCTGGACAGATTTCACTCTCACCATCAGCAGCCTGCAAGTGAAGATGTGGCAGTGTATTACTGTCAAGCAA TATTATAGTACTCTCTCACTTCCGGGAGGACCAAGTGGAGATCAAA</p> <p>GACATCCAGATGACCCAGTCTCCATCTCCCTGTCTGCATCTGTGGGAGACAGAGTCAACCATCACTTGGCCGG GCAAGTCAGGGCAATGGGAATGATTTAGCTGGTATCAGCATGAACACAGGGAAGCCCTAAGCCCTAAGCCCTGAT CTATGCAGCATCCAGTTTGCAAAGTGGGTCCCATCGAGTTCAGCGGCAAGTGCATCTGGGACAGAAATTCAC TCTCACAATCACCAGCCTGCAGCCTGAAGATTTTGCAACTTACTGTCTACAACATACTACTTTTCCCGTGG ACGTTCGGCCAAAGGACCAAGTGGAAATCAAA</p> <p>GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG GCCAGTCAGAGTGTGGCAGTCACTCCCTGGTACCACAGAAACCTGGCCAGGCTCCCAAGGCTCCCTCATC TATGGTGCATCCAAACAGGGCCCTGGCATCCCACTCCAGTTCAGTGGCCAGTGGATCTGGGACAGACTTCACT CTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAATTTTACTGTCAACAGCCTAGGACCTGGCCCTCCG CTAACCTTCGGCCAAAGGACCAAGTGGAGATTAAC</p>
SLE1p3-a02k	221	
SLE1p3-a04k	222	
SLE1p3-b03k	223	
SLE1p3-c03k	224	
SLE2 Heavy	Seq ID No.	
SLE2p1-a01h	225	<p>GAGGTGCAGCTGGTGGAGTCTGGGGAGGGCTTGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGTAGCC TCTGGATTCAGTTCAGTGGTCAATGAATGAATGAACTGGTCCCGCAGCCTCCAGGAAAGGGCTGGAGTGGGT TCACACATTTGGCAGTGGTGGTATATAGGTTACCGAGACTCTGTGAAGGGCCGATTCACCGTCTCTAGA GACAAACGCCAAGAAATTTACTCTATCTGCAATGAACAGCCTGAGAGCCGACAGACCGGTGTTTATTACTGT GCGACCTTGTCTTTGGGAGACAAACCAACTGGACGCTTGGGGCCAAAGGACCCAGGTCACCGTCTCCCTCA CAGGTGCAGCTGGTGGAGTCTGGGGAGGGCTGGTCCAGCCAGGAGGTCCTTAAGACTCTCCTGTGCAGC CTCTGGATTCAACCTCAGTAGTGTGGCATGCATGGATCCCGCCAGGCTCCAGGCAAGGGCTGGAGTGGGT GGCAGTTATAACATATGATGGACGAAATCACTCAACCGACCGCCGTGAAGGGCCGATTCACCATCTCCAG AGACAGATCCATGAACACGGTGTCTCTGCAATGGACAGCCTGAGACCCGACCCGAGACCGGCTGTTTATTACTG TGTCAAAGAACAAGGCTTTGGTTACTACCGGACCCCGGACTACTGGGGCCAGGGAACCCCTGTCAACCGTCTC</p>
SLE2p1-a06h	226	

SLE2p1-b01h	227	CTCA CAGGTGCAGCTGCAGGAGTCGGGGCCAGGACTGGTGAGGCCCTTCGGAGAGACCCCTGTCCCTCACTGCACCTGTC TCTGGTGGCTCCATCAGTAGTGACCACTGGAGTTGGATCCGGCAGCCCAAGGCAAGGCAAGGACTGGAGTGGATT GGGAATGTCTATTACAGTGGGGCCACCTACTACAACCCCTCTTCAAGAGTCGAGTCAACCATATCAGTAGCC ACGTCCAAGAACCAGTTCTCCCTGAAGGTGACCTCTGTGACCCGCCAGACACGGCCATTTTACTGTGGC AGGGAAAATGATTTTAAATATCTGGGGCCAGGGGACAATGGTCAACCGTCTCTTCA
SLE2p1-c03h	228	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCTGGGGGTCCCTGAGACTCTCCTGTGTCAGCC TCTGGATTCAACCTTAGTAAATATGCCGTGAGTGGGTCCGCCAGGCTCCAGGAAAGGGGTGGAGTGGGTTC TCAGCTGTCAGTGGTAAATGGTACTCCACATACTACGACAGACCCCGTGGAGGGCCGGTTCACCATCTCCAGA GACAATTCGAAGAACACCCCTGTATCTGCAATGAACAGCCTGAGAGCCGAGGACACGGCCCTATATTAAGT TCGATCTGGTGGGGACTTCAGTACAGTACCCATTGGTGTCTGACTACTGGGGCCTGGGAACCCCTGGTCAACC GTCTCCTCA
SLE2p1-c04h	229	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGGCTGGTCCAGCCTGGGAGGTCCCTAAGACTCCTGTGTGTCAGC CTCTGGATTCAACCTCAGTACTTGTGGCATGCCTGGATCCGCCAGACTCCTGGCAAGGGCTGGAGTGGGT GGCAGTTAAAACATATGACGGAAAGAGAGGAGTTCTACGCAGACTCCCGTGAAGGGCCGATTCACCAATTCCA GAGACGAGTCCATGAACACCGTGTCTTTGCAGATGAACAGCCTGAGACTGAGACTGAAGACACGGCTGTATATACT GTGTCAAAGAACAAGACTACGGTTACTACCCGGACCCCGACCCACTGGGGCCAGGGAAACCCCTGGTCAACCGTC
SLE2p1-d02h	230	CAGGTGCAGCTGCAGGAGGGGGCCAGGACTGGTGAAGCCTTACAGACCCCTGTCCCTCACTGCACCTGTC TCTGGTGGCTCCATCAGCAGTGTGGTTACTACTGGAGCTGGATCCGCCAGCACCAGGAAAGGGCCTGGAG TGGATTGGGTACATCTATTACAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTGGAGTCAACCATATCA GTAGACACGTCCAAGAACAGTATCCCTGAAGCTGAGTTCTGTGACCCGCCAGACACGGCCGTATATACT TGTGGAGAGGGCATGGCTCAACGCCTACTGGGGCCAGGAAACCCCTGGTCAACCGTCTCCTCA
SLE2p1-d04h	231	GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTGGTAAAGCCGGGGGAGTCCCTTAGACTCTCGTGTGCAAC CTCTGGAGTCAACTCAACATCGCCTGGATGACCTGGTCCGCCAGGCTCCAGGAAAGGACTGGAGTGGGT TGGCCGTATTAAAAGCAAAATTGGTGGTGGGACAAACAGACTATGCTGCAACCCGTGAAAGGCAGATTCAACA TGTCAAATAGATGATTCAAAAAATACCCTATATCTGCAAAATGAACAGCCTGAAAACCGAGGACACAGCCGTG TATTATTGTACCACAGTCCGCAATATGGCCGACTTGTCCCTTAAATCACTGGGGCCAGGGAAACCCCTGGTCAACC GTCTCCTCA
SLE2p2-a01h	232	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGAGCCTCCCTGACACTGTCAATGTGTAGTIC TCTGGATTCAACCTTCAATGGCACTGAAATGACCTGGATTCGCCAGGCTCCAGGAAAGGGCTGGAGGGACTT TCGTACATCAGTGGAGTGGGGGACAAATACCTACCGAGACTGTGTGAGGGCCGATTCACCATCTCCAG AGACAACCCAAAGAAATCACTGTTCTGCAAAATGACAGCCTGACAGCCGAGGACACCGGCTGTTACTACTG TGGACAGGCAACCCGGGATCACTTCCCGCCGTGGGGCCAGGAAACCCCTGGTCAACCGTCTCCTCA
SLE2p2-c04h	233	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCTGAGACTCTCCTGTGTAGCC TCTGGATTCAACCTTAGTTCCTTGGATGAGTGGTCCGCCAGGCTCCAGGAAAGGGCTGGAGTGGCTG GGCAACATAAAGCCGGATGCAAGTTGGTGTCTTGTGGACTGTGAAAGGGCCGATTCACCATCTCCAGA GACAACGCCAAGAATTCACCTGTTCTGGATATGAGCAGCTGAGAGTCGAGGACACGGCCCTACTACTGT GTGAGAGACGGGTGGGACACCTTCTTGTACTCTGGGGCCAGGAAACCCCTGGTCAACCGTCTCCTCA
SLE2p2-d03h	234	GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTACGCCGGGGGGTCCCTGAGACTCTCCTGTGTCAGC

SLE2p2-e04h	235	<p>CTCTGGATTCAACCTTTAGTAACTACTGGATGAGGTGGTCCGCCAAATCTCCAGGGAAGGGGCTGGTGTGGGT CTCACATATTAACCCCTGATGGAGTTTTACAAACTACGGGACTCCGTGAAGGCCGATTCACCATCTCCAG AGACAACACCAAGAACACACTGTATCTGCAAAATGAACAGTCTGAGAGCCGAGACACGGCTGTGTATTACT GTGTGAATTTTCAACTGGGGTGGGCCAGGGAAACCTGGTCAACCGTCTCCCTCA</p>
SLE2p2-f01h	236	<p>CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTAGTCCAGCCTGGGAGGTCCTTGAAACTCTCCTGTGCAGTC GCTGGATTCACCTTCAGGACCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAGGGGCTGGAGTGGGTG GCACTTATCAAAATGATGGAACCAAAATACTCCGCAGACTCCCGTGAAGGGGCCACTTCACCAATCTCCAGA GACAATTCAAAGGACACCGCTGTATCTGCAAAATGAACAGCCTGCGACCTGACGACACCGGCTGTCTATTACTGT GCGAGAGCGGAGTATTGTAGTCTCTGGTACTGCTTCCCTTATTGACACCTGGGGCCAGGGAAACCCCTGGTCAACCGTCTCCCTCA GTCTCCCTCA</p>
SLE2p2-g01h	237	<p>CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCTTGAGACTCTCCTGTGCAGTIG TCTGGATTCACCTTCAGTAGATAGGCATGCATGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTG GTAGTTATATGGCATGATGGAAGTAATACATACTATGCAGACTCCCGTGAAGGGCCGATTCACCAATCTCCAGA GACGACTCCAAGAACACCGTGTATCTGCAAAATGAACAGCCTCAGACTCAGAGTCGAGGACACCGGCTATGTATTACTGT CTGAGAGGCAACCCACTAGCAGCCCAACCGACTACTGGGGCCAGGGAAACCCCTGGTCAACCGTCTCCCTCA GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTGGTACAGCCTGGGGGTCCTTGAGACTCTCCTGTGAAAGTIC TCTGGATTCATCTTAGCAACTATGCCATGACCTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGCAGTGGGTG TCAGCTATTGGCACTAGTGGTGTGACACACACTACGACACTCCCGTGAAGGGCCGATTCACCAATCTCCAGA CACAATTCCCAGAACCCCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGGCTATATATTACTGT GCGAAAGTCTGTTATAGCAGGCCCTCTATGGACCTCTGGGGCCAGGGAAACCCCTGGTCAACCGTCTCCCTCA</p>
SLE2p2-g06h	238	<p>GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTGGTCCAGCCTGGGGGTCCTTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTAGTAATCTGGATGAGTGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAATGGGTG GCCAACATAAACGAAGATGGAAGTCAGAAACACTATGTGGACTCTGTGAGGGGCCGATTCACCAATCTCCAG AGACAACGCCAAGAACTCACTGCTCTGCAAAATGGACAGCCTGAGAGTCGAGGATACGGCCGTGTATTATTG CCGGAGAGCATCGAGGGAGACCCGTGAAACCTTACTGGGGCCAGGGAAACCCCTGGTCAACCGTCTCCCTCA</p>
<p>SLE2 Kappa SLE2p1-a01k</p>	239	<p>TTGTGATGACTCAGTCCACTCTCCCTGCCCGTCAACCCCTGGACAGTCGGCCTCCATCTCCTGCAGGTCTAG TCGAAGCCTCGTATTCAGTGTGAAACACCTACTTGAATTGGTTTCAGCAGAGGCCAGGCCGATCTCCAAG GCGCCTAATTTATAAGGTTTCAAGCGGACTCTGGGTCCAGACAGATTCAGCGGCACTGGTCCAGACAC TGATTCACACTGAAATCAGCAGGTGGAGGCTGAGGATGTTGGGTTTATTACTGCATGCAAGGTACACA CTGGCGACGTTCCGCCAAGGGACCAAGGTGGAGATCAAA</p>
SLE2p1-a06k	240	<p>GACATCCAGATGACCCAGTCTCCTTCCACACTGTCTGCATCTGTGGGAGACAGAGTCAACCTCCTTGCCGG GCCAGTCCAGAGTATTAATCTCTGGTTGGCTGGTATCAGCGGAAACCAGGAAACCCCTAAACTCCTCATC TATGAGCGTCCAGTTTAGAAAGTGGGTCCCATCAAGGTTCAGCGGCAAGTATCTGGGACAGAGTTCACC CTCACCATCAGCAGCTGCAGGCTGATGATTTTTCAACTTATTACTGCCACCCAGTATGATAAATAATCCCGTGG ACGTTCCGGCCAAGGGACCAAGGTGGAGATCAAA</p>
SLE2p1-b01k	241	<p>GAAAATTGTGTTGACGAGTCTCCAGGCAACCTGTCTTTGTCTCCAGGGGAAAGAGCCACCTCTCCTGCAGG GCCAGTCCAGAGTGTGACCAACAACATAATTGGTCTGGCACCAGCAGAAACCTGGCCAGGCTCCCAAGGCTCCTC ATTTCTGATGCATCCAAACAGGGCCACTGGCATCCAGACAGGTTCAAGTGGCAGTGGGCTGGGACAGACTTC</p>

		ACTCTCAACCATCAACAGACTGGAGCCTGAAGATTTCCGACAGTGTATTACTGTCAAGCAATAACGGTAGCTCACCTTTCACCTTCGGCCCTGGGACCAAAAGTGGATATCAAA
SLE2p1-c03k	242	GAAATAGTGATGACGCAGTCTCCAGCCACCCCTGTCTGTCTCCAGGGGAAAGAGTCAACCCCTCTCCCTGCAGGGCCAGTCAAGATATTGGCAGCAGCTTAGCCTGGTACCTGCAGAAACCTGGCCAGGCTCCACAGATCCCTCATCTATGGTGCATCCACAGGACCCCTGGCACCCAGCCAGGTTCAAGTGCAGTGGTCTGGGACAGAGTTCACCTCACCATCAGCAGCCTGCAGTCTGAAGATCTTGGGATTTATTATTGTCAACAGTATAGTAAAGTGGCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATAAA
SLE2p1-c04k	243	GACATCCAGATGACCCAGTCTCCCTCCATCCCTGTCTGCATCTGTAGGAGACAGAGTCAACCATCAAAATTTGCCGGGCCAGTCAAGAGTATTAATGCTGGCTGGCTGGTATCAGCAGAAACCAGGAAAGCCCTAAATTCCTAAATTTATAAGGGCTTAGTTTTAGAAAAGTGGGTCTCGTCAAAGTTTCAGCGGCAGTGGATCTGGGACAGAAATTCACCTCATATCAGCAGCCTGCAGCTGATGATTTTGGCAACTTATTACTGCCAACAGTATGATAAATATATCCGTGGACGTTCCGGCCGGGACCAAGGTGGAGATCAAA
SLE2p1-d02k	244	GAAAATTGTGTTGAGCGAGTCTCCAGGCACCCCTGTCTTCTCTCCAGGGGATAGAGCCACCCCTCTCCCTGCAGGGCCAGTCAAGTGTAGCAGCAGCTCTTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCACAGCCTCCTCATATGGTGCATCCACAGGGCCACTGGCATCCACAGACAGTTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCAACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTACTACTGTCAAGCAATATGATGACTCACCTCGGACGTTCCGGCCAAGGGACCAAGGTGGAGATCAAA
SLE2p1-d04k	245	GAAAATTGTGTTGAGCGAGTCTCCAGGCACCCCTGTCTTGTCTCCAGGGGAAAGAGCCACCCCTCTCCCTGCAGGGCCAGTCAAGTGTAGCAGCAGCTACTTAAACTGGTACCAGCAGAGACCTGGCCAGGCTCCACAGCCTCCTCATATGGTGGTCCACAGGGCCACTGGCATCCACAGACAGTTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTAAACCATCAGCAGACTGGAGCCTGAAGACTTTCAGTGTACTACTGTCAAGCAATATGATGACTCACGGTGGACGTTCCGGCCAAGGGACCAAGGTGGAAATCAAA
SLE2p2-a01kb	246	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGCTGGTCAAGAGCCTCCTGTATAGTATGATGATGAAACAACCTATTGGATTGGTATCTGCAAGCCAGGGCAGTCTCACAGCTCCTGATCTATTGGGTCTAAATCGGGCCTCCGGGTCCCTGACAGGTTCAAGTGGCAGTGAATCAGGCACAGATTTACACTGAAAATCAGCAGAGTGGAGGCTGGGGATGTTGGGATTTATTACTGCATGCAAGGCTCTACGAAATCCGTACACTTTTGGCCAGGGACCAAGGTGGAGATCAAA
SLE2p2-c04k	247	TTGTGATGACTCAGTCTCCACTCTCCCTGCCCCGTCACCCCTGGACAGCCGGCCTCCATCTCCTGCAGGCTCTAGTCAAAAGCCCCGTATACAGTGTATGGAAACAACCTACTGAATTTGGTTTCAGCAGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAGGTTTTCTAAACCGGACTCCGGGGTCCACAGACAGATTCAGCGGCAGTGGGTCAAGGCAC TGATTTCAACTGAATATCAGCGGGGTGGAGGCTGAGGACGTTGGGGTTTTATTACTGCATGCAAGGATAGATACTGGCCGTACACTTTTGGCCAGGGACCAAGGTGGAGATCAAA
SLE2p2-d03k	248	GAAAATTGTGTTGAGCGAGTCTCCAGGCACCCCTGTCTTCTCTCCAGGGGATAGAGCCACCCCTCTCCCTGCAGGGCCAGTCAAGTGAAGCAGCAGCCCTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCACAGCCTCCTCATATGGTGCATCCACAGGGCCACTGGCATCCACAGACAGTTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCAACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTACTACTGTCAAGCAATATGATGACTCACCTCGGACGTTCCGGCCAAGGGACCAAGGTGGAAATCAAA
SLE2p2-e04k	249	TTGTGATGACTCAGTCTCCACTCTCCCTGCCCCGTCACCCCTGGACAGTCCGCTCCATCTCCTGCAGGCTCTAGTCCGAAAGCCTCGTATTCAGTGTAGTGAACAACCTACTTGAATTTGTTTCAGCAGAGGCCAGGCCGATCTCCAAGGCGCCTAATTTATAAGGTTTTCTAAAGCGGGACTCTGGGGTCCACAGACAGATTCAGCGGCAGTGGGTTCAGAC

		<p>TGATTTCACTGAAAATCAGCAGGGTGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTACACA CTGGCGACGTTTCGGCCAAGGGACCAAGGTGGAATCAAAC</p>
SLE2p2-f01k	250	<p>GACATCCAGATGACCCAGTCTCCTTCCCTCACTGCTGCATCTGTAGGGGACAGAAATCACCATCACTTGTTCGG GCGAGTCAGGGCATTAAACAATTAATTAAGCCTGGTTTCAGCAGAAAGCCAGGAAAAGCCCTAAGACCCTGATC TACTTACATCCACTTTGCAAAAGTGGGTCCCATCAAAGTTCAGCGGCAGTGGATCTGGACACAGTTTTCACT CTCACCATCAGCAAACCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAATAATAATAGTTACCCCGCTCA CTTTCGGCGGAGGGACCAAGGTGGAGATCAAA</p>
SLE2p2-g01k	251	<p>GACATCCAGATGACCCAGTCTCCATCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTTCGGCGG GCAAAGTCAGACCAATTAGCAACTATTTAAATTGGTTTTTCAGCAGAAACCAGGAAAAGCCCTAGGCTCCTGATC TATGCTGCATCGAGTTTGCAAAAGTGGGTCCCATCAAAGTTCAGTGGCAGTGGATCTGTGACAGATTTCACT CTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTTCTGTCAACAGAGTTACAGCACCCCGGTGG ACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA</p>
SLE2p2-g06k	252	<p>TTGTGATGACTCAGTCTCCATTTCTCCCTGCCCCGTCAACCCTTGGACAGCCGCCCTCCATCTCCTGCAGGTTCTAG TCAAAGCCTCGTATACAGTGTATGGAAACACCTACTTGAATTTGTTTCAGCAGAGGCCAGGCCAAATCTCCAAAG GCGCCTGATTTATAAGCTTTCTAACCGGGACTCTGGGGTCCACAGATTCAGCGGCAGTGGGTCAAGGCAC TGATTTCACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTACACA CTGGCCTTGGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAA</p>

Antibodies were also tested for binding against five common lupus autoantigens: Ro, La, Sm, nRNP, and cardiolipin. Antibodies which bound to at least two of these five antigens were classified as poly-reactive (whether or not they bind polysaccharide). FIG. 2C shows the percentage of poly-reactive antibodies from each donor. SLE2 shows a remarkable 52% of antibodies showing polyreactivity. Graphs similar to those in FIG. 2A, but highlighting cross-reactive or poly-reactive antibodies from each donor are shown in FIGS. 7A-B.

A small but significant percentage of anti-polysaccharide antibodies produced from ASCs bind to the polysaccharides of two distinct serotypes. Although most of the antibodies are serotype specific, 12% of the antibodies characterized bind two serotypes. Of the antibodies that bind two serotypes, one pair of polysaccharides, 9N and 9V, were dually bound by several antibodies. These two carbohydrates have very similar non-branched structures with one of four D-Glc in a 9N chain repeat being replaced by a D-Gal in 9V. Thus, it is not unexpected that some antibodies will cross-react with both serotypes. However, the inventor observed a wide variety of 9N and 9V binding antibodies, some of which cross-react and some that do not. For example, *Conlp2D02* and *SLElplEOl* antibodies are mono-specific to 9N and 9V respectively (FIG. 3A), showing little to no cross-reactivity. *Conlp4B03*, however, binds to both serotypes, favoring 9N by an order of magnitude in affinity and by 5-times in avidity (FIG. 3B). One antibody to 9N, *SLElplA03*, does not bind to 9V, but rather cross-reacts to serotype 14 polysaccharide (FIG. 3C), with similar affinity and avidity, an observation which is difficult to explain examining only the carbohydrate sequence. Several of these cross-reacting antibodies are from the same donor, demonstrating a variety of antibodies to a certain serotype within a single individual. Serotypes 19A and 19F also have very similar structures with 19F having a D-Glc with a 1-2 linkage and 19A having a 1-3 linkage. The antibody *SLE2p2D03* binds to both 19A and 19F with nearly equivalent affinities (FIG. 3D), although four-fold different avidities (favoring 19A).

The inventor also detected cross-reactivity between serotypes 15B and 14 (FIG. 4C), as well as 17F and 33F (FIGS. 4A and 4B). The antibody *SLE2p1B01* slightly favors serotype 14 over serotype 15B in avidity, although not in affinity. While *SLE2p2G06* and *SLE2p2C04* are mono-specific for 17F and 33F respectively (FIG. 4A), *SLE2p1C03* (from the same donor; FIG. 4B) cross-reacts to both serotypes with similar avidity. Overall, it is evident that although serum may cross-react between two serotypes, 85% of the actual antibodies making up this response are specific to only one polysaccharide. The inventor

encountered no antibodies that reacted with more than two serotypes with a measureable affinity/avidity.

A high frequency of somatic hypermutation in these antibodies indicates frequent anamnestic anti-polysaccharide responses. As previously reported, the ASC recall response to the influenza vaccine is highly mutated, even more so than in the typical IgG germinal center memory cell. The inventor hypothesized that this was due to the repeated nature of the annual vaccine, as well as frequent exposure to various influenza strains. The antibodies obtained in this study have a similar mutation frequency (see FIG. 5). This is particularly interesting because for each donor, this was a primary vaccination. If the donors were truly naive to these polysaccharide antigens, the ASC response would have been smaller and the sequences of the antibodies would show less mutation. Thus, this vaccine is producing an anamnestic response which can only arise from previous infection or exposure to *S. pneumoniae* strains.

Each donor displays a unique anamnestic fingerprint of antibody serotype specificities. Each of the four donors showed a remarkably different antibody response, as demonstrated by the number of antibodies produced against each serotype or cell wall polysaccharide (FIG. 6A, non-binding antibodies not shown; antibodies that cross-react are counted in the bin of the serotype with the strongest affinity). A response to certain serotypes seems to predominate in each donor. Donor Con1 shows a strong response to serotype 8 (six total antibodies, three of which are clonal), Con2 shows a strong response to serotype 18C (nine antibodies, all clonal), SLE1 and SLE2 both exhibit a strong response to serotype 5 (six antibodies, two of which are clonal and six antibodies, four of which are clonal, respectively). The inventor hypothesizes that this is due to an infection (clinically evident or not) by that serotype at some point in that donor's lifetime.

The inventor's previous study of the immune response to influenza vaccination (Wrammert *et al*, 2008) highlighted the strong clonality of the ASC response to that vaccine, and this is also the case after immunization with Pneumovax®23. Thus, several of the antibodies the inventor characterized are clonally related, but show very similar binding characteristics (see Table 1 to compare affinities). When displaying all four donors on a single histogram graph and reducing clonally related antibodies to a count of 1 (FIG. 6B), it is quite evident that the hmAbs isolated from each donor create a unique fingerprint with three donors binding 9V, 15B, 17F, and only serotypes 8 and 33F being bound by all four donors. Also, no subject in the study produced an antibody that bound to serotypes 7F, 10A, or 12F. Although it is difficult to mathematically show that the histograms from each donor are

unique, the inventor is confident that producing 44 antibodies from Con2 gives a representative distribution of the serotypes to which this individual is having an anamnestic response and that this differs from donor to donor.

5

EXAMPLE 3 - DISCUSSION

This is the first comprehensive analysis of the human immune response to Pneumovax®23 immunization, on a per antibody basis, utilizing antibody secreting cells (ASCs) that emerge seven days post vaccination as a source for the production of monoclonal
10 antibodies. An analysis of these polysaccharide specific monoclonal antibodies allowed a detailed study of the human antibody repertoire to this vaccine. It also provided insight into the specificities of each antibody and surprisingly revealed an "anamnestic fingerprint" that the inventor interprets to reflect the prior infection history of each participant.

In an earlier study (Wrammert *et al*, 2008), the inventor found that the magnitude of
15 the anamnestic response after influenza vaccination was such that an average of 6% of total B cells were ASCs, yet some donors made poor to non-existent responses. Using these same techniques, some vaccines (notably Anthrax AVA) routinely result in a very poor induction of a protective response (Crowe *et al*, 2010). Here, the inventor reports that Pneumovax®23 invoked a two- to four-fold more robust response than the strongest responses induced in
20 some of the influenza donors, suggesting that these polysaccharides are exceptionally efficient at triggering a memory response. Earlier studies (2-4) also detected antibody secreting cells seven days post vaccination with both the polysaccharide and conjugate vaccines, averaging over 100 serotype specific cells per million PBMCs. The inventor's own ELISpot results were similar to these previous reports (data not shown), but the overall
25 magnitude of the IgG ASC response as determined by flow cytometry was still surprising. Interestingly, one of the SLE donors, SLE2 also participated in the previous influenza study and did not make a response to the influenza vaccine, yet produced an impressive ASC response to the polysaccharide vaccine. This provides a direct comparison, albeit with a small sample size, of the vast difference in potential immune response to vaccines, especially
30 in immunocompromised individuals.

There are several interesting differences in this study between the SLE donors and healthy controls. As discussed above, the percentage of ASCs that arose from the vaccination was considerably smaller in SLE1 and SLE2 (8.8% on average, as compared to 23.8% for Con1 and Con2). Although the percentage of high affinity antibodies generated from these

donors was not different, the antibodies generated from SLE2 do appear to be quite poly-reactive against non-carbohydrate antigens. It is also important to note that three of the four cross-reactive antibodies from SLE2 are also poly-reactive (see FIGS. 7A-B). It is remarkable that although they bind to multiple self-antigens, they are still specific for only one or two polysaccharide structures. These results likely indicate a defect in B cell tolerance in this donor which is allowing cross- and poly-reactive B cells, which would otherwise be deleted or anergized, to mature and secrete antibody. Although it is unknown if this manner of poly-reactive antibody has physiological effects, it is likely that any vaccination in this individual will result such poly-reactive antibodies.

This study has greatly increased the number of reported human monoclonal antibodies to *S. pneumoniae* that have been characterized both in terms of binding and repertoire usage. These anti-polysaccharide antibodies are as highly mutated as antibodies which arise from repeated seasonal influenza vaccination. In comparing V gene usage in these antibodies to the previous reports, the inventor observes similar trends. For example, Baxendale (Baxendale and Goldblatt, 2006; Baxendale *et al*, 2000) suggests that VH3-48 likely contributes to an antigen binding domain that prefers epitopes from serotypes 23F and 18C, as the two VH3-48 family antibodies they characterized bound those two serotypes and Zhou found VH3-48 in the 23F study (Zhou *et al*, 2002), but not the 6B study (Zhou *et al*, 2004). Similarly, three of four VH3-48 antibodies (Table 1) characterized in this study also bind these two serotypes. The inventor have also characterized a VH3-48 which binds serotype 2 (*Con2p5E05*), a case of a VH3-48 binding a different serotype. They have also observed remarkable similarity in the antibodies characterized which bind cell wall polysaccharide (CWPS). Comparing two unique donors, these antibodies use either VH3-30 or closely related VH3-33. The CDR3s even show remarkable similarity, (*Con2p6B03*, VKESATGWYRTADY (SEQ ID NO:57); *Con2p5A06*, VKEYSWGYYRTADY (SEQ ID NO:49); *SLE2plA06*, VKEQGFYRTADY (SEQ ID NO:101); *SLE2plC04*, VKEQDYGYRTADH (SEQ ID NO:107)). Thus, the chemical simplicity of repeated polysaccharide sequences seems to induce similar V gene family usage even in distinct individuals.

Although avidity has been shown to be an important correlate with protection (Anttila *et al*, 1999; Harris *et al*, 2007; Usinger and Lucas, 1999), thiocyanate ELISA is not commonly performed on monoclonal antibodies. The inventor utilizes it here because there are several complications in determining affinity by fitting simple ELISA curves. These include the magnified effects of small antibody concentration errors on affinities, uncertainty

whether or not the antigen binding interaction is univalent or bivalent, and coating plates with large units of repeating epitopes. It is also possible that poly-reactive antibodies from SLE donors (and occasionally healthy controls) may interact with antigens outside of the binding site. All of these effects are minimized in the thiocyanate avidity ELISA system. FIGS. 3D and 4C both represent an antibody for which affinity and avidity ELISA binding measurements do not correlate. Both of these antibodies are from SLE2 and both antibodies are poly-reactive. The inventor is currently exploring interesting antibodies such as these in more detail, but in these cases, thiocyanate avidity is a more reliable measure of the antibody-carbohydrate interaction.

Serum cross-reactivity is typically determined by depleting the serum with a particular serotype carbohydrate and then observing binding of the serotypes still present in the serum. Soininen *et al* (2000), for example, found remarkable cross-reactivity in the serum, especially in unvaccinated individuals. However, these assays require careful calibration, as well as pre-adsorption of CWPS and other polysaccharides to remove nonspecific reactivity, especially common in unvaccinated individuals (Marchese *et al*, 2006). Modern updates to this method, using microarray printing and reading technology (Pickering *et al*, 2007), for example, have greatly improved the reliability of these assays; yet until this study, one could not be definite whether observed cross-reactivity is due to actual cross-reactive individual antibodies, or the polyclonal nature of serum antibodies.

This study, focusing on cross-reactivity in monoclonal antibodies, has addressed such ambiguities. Park *et al* (2009) describes cross-serotype monoclonal antibodies, deducing the common linear carbohydrate structure to which the antibodies were binding. Other reports (Baxendale *et al*, 2006; Baxendale *et al*, 2000; Zhou *et al*, 2004) do not specify cross-reactive antibodies, although those produced from Fab libraries were only panned with the serotype of interest. These experiments are the first, however, that characterize a large number of anti-pneumococcal human monoclonal antibodies, and although most of the antibodies are serotype specific, 15% were not. Unlike the above report, explaining the cross-reactivity of several of the monoclonal antibodies the inventor characterized is clearly not as simple as finding similar primary polysaccharide structures. While 9N/9V and 19A/19F are quite similar, 17F and 33F, and 14 and 15B do not have similar primary structures. Pickering *et al* (2007), found that 9V could inhibit 9N binding, 15B inhibited 14 binding, 19F strongly inhibited 19A binding and 33F strongly inhibited 17F binding, all matching the observed results (FIGS. 3A-D and 4A-C). Interestingly, the converse is not typically the case (14 does not inhibit 15B and 17F does not inhibit 33F), but this is likely an

affinity issue. Using these results to illustrate this, it is unlikely that *Conlp4B03* binding to 9N could be inhibited by adding 9V polysaccharide because its affinity for 9N is over an order of magnitude higher. Overall, the inventor can say with confidence that the serum cross-reactivity observed in these studies is indeed due to individual monoclonal antibodies
5 that bind to at least two different serotypes.

The observation that each of the donors produced a unique panel of antibodies to each of the serotypes is quite interesting. One explanation of this phenomenon is that one is seeing an "anamnestic fingerprint," or that the memory response being observed is a product of the serotypes that each of the subjects had been exposed to in the past. It is difficult to
10 approximate how many of the 23 strains someone has been exposed to up to the time when they receive the Pneumovax®23 vaccine. The four donors whose serum was carefully examined by Pickering *et al* (2007) had appreciable IgG concentrations (higher than 1 µg/ml) for 5-12 of the 22 serotypes (the samples were depleted with CWPS and 22F) indicating active plasma cells and subsequently previous exposure to those serotypes. The
15 donors here showed antibodies to just over an average of 11 (13, 13, 9, and 10) serotypes, matching the serology in this previous study. Thus, one is observing that antibodies from the reactivation of memory cells seven days after vaccination is similar to those observed in the sera, likely from long-lived plasma cells.

While the generation of these human monoclonal antibodies elucidates basic
20 anamnestic response, it may also serve a therapeutic purpose. As many current treatments can become ineffective due to antibiotic resistance, it is important to consider passive immunotherapeutics that can safely target pathogens. Several previous reports (Casal *et al*, 2002; Yuste *et al*, 2002) have explored the effects of specific antibodies in a mouse sepsis model. Remarkably, administering hyperimmune serum after infection was able to reduce
25 the amount of antibiotic required for the mouse to recover by eight-fold. In addition, this synergistic effect might be effectively used in treating difficult or invasive infections, such as empyema, as well as bacteremia in immunocompromised individuals. In addition to the myriad of treatment options of fully human monoclonal antibodies, the drastically decreased risk of anaphylactic shock and of anti-treatment immune responses suggests that they will
30 become as important in infectious diseases as they are currently in autoimmune settings.

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

VIII. REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

U.S. Patent 2,653,899
U.S. Patent 3,817,837
U.S. Patent 3,850,752
U.S. Patent 3,939,350
U.S. Patent 3,996,345
U.S. Patent 4,196,265
U.S. Patent 4,275,149
U.S. Patent 4,277,437
U.S. Patent 4,366,241
U.S. Patent 4,472,509
U.S. Patent 4,554,101
U.S. Patent 4,680,338
U.S. Patent 4,816,567
U.S. Patent 4,867,973
U.S. Patent 4,938,948
U.S. Patent 5,021,236
U.S. Patent 5,141,648
U.S. Patent 5,196,066
U.S. Patent 5,563,250
U.S. Patent 5,565,332
U.S. Patent 5,856,456
U.S. Patent 5,880,270

"Antibodies: A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1988.

Anttila *et al.*, *Clin. Exp. Immunol.*, 118:402-407, 1999.

Atherton *et al.*, *Biol. of Reproduction*, 32:155-171, 1985.

Baxendale *et al.*, *Eur. J. Immunol.*, 30:1214-1223, 2000.

Baxendale *et al.*, *Infect. Immun.*, 74:1025-1031, 2006.

- Campbell, *In: Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology*, Vol. 13, Burden and Von Knippenberg, Eds. pp. 75-83, Amsterdam, Elsevier, 1984.
- Capaldi *et al*, *Biochem. Biophys. Res. Comm.*, 74(2):425-433, 1977.
- Casal *et al.*, *Antimicrob. Agents Chemother.*, 46:1340-1344, 2002.
- Chowdhry *et al*, *Arthritis Rheum.*, 52:2403-10, 2005.
- Clutterbuck *et al*, *Immunol*, 119:328-337, 2006.
- Crowe *et al*, *J. Infect. Dis.*, 202:251-60, 2010.
- De Jager *et al*, *Semin. Nucl. Med.* 23(2): 165-179, 1993.
- Dholakia *et al*, *J. Biol. Chem.*, 264:20638-20642, 1989.
- Doolittle and Ben-Zeev, *Methods Mol. Biol.*, 109:215-237, 1999.
- Elkayam *et al*, *Autoimmunity*, 38:493-496, 2005.
- Gefter *etal*, *Somatic Cell Genet*, 3:231-236, 1977.
- Goding, *In: Monoclonal Antibodies: Principles and Practice*, 2d ed., Orlando, Fla., Academic Press, 60-61, 65-66, 71-74, 1986.
- Gulbis and Galand, *Hum. Pathol.* 24(12): 1271-1285, 1993.
- Harris *et al*, *Clin. Vacc. Immunol*, 14:397-403, 2007.
- Khatoon *et al*, *Ann. of Neurology*, 26:210-219, 1989.
- King *et al*, *J. Biol. Chem.*, 269:10210-10218, 1989.
- Kobasa *et al*, *Nature*, 445:319-323, 2007.
- Kohler and Milstein, *Eur. J. Immunol*, 6:511-519, 1976.
- Kohler and Milstein, *Nature*, 256:495-497, 1975.
- Kyte and Doolittle, *J. Mol. Biol*, 157(1): 105-132, 1982.
- Lee *et al*, *J. Immunol*, 133:2706-2711, 1984.
- Marchese *et al*, *Clin. Vacc. Immunol*, 13:905-912, 2006.
- Morrison, *Science*, 229(4719):1202-1207, 1985.
- Nakamura *et al*, *In: Enzyme Immunoassays: Heterogeneous and Homogeneous Systems*, Chapter 27, 1987.
- Nieminen *et al.*, *Vaccine*, 16:313-319, 1998.
- Nieminen *et al.*, *Vaccine*, 16:630-636, 1998.
- O'Shannessy *et al*, *J. Immun. Meth.*, 99:153-161, 1987.
- Owens and Haley, *J. Biol. Chem.*, 259:14843-14848, 1987.
- Park *et al*, *Infect. Immun.*, 77:3374-3379, 2009.
- Persic *et al*, *Gene*, 187(1):1-8, 1997.

- Pickering *et al*, *Am. J. Clin. Pathol*, 128:23-31, 2007.
- Posner *et al*, *Hybridoma*, 6:61 1-625, 1987.
- Potter and Haley, *Meth. Enzymol*, 91:613-633, 1983.
- Smith *et al*, *Nat. Protoc.*, 4:372-384, 2009.
- Soininen *et al*, *Clin. Diagn. Lab. Immunol*, 7:468-476, 2000.
- Tang *et al*, *J. Biol. Chem.*, 271:28324-28330, 1996.
- Usinger *et al*, *Infect. Immun.*, 67:2366-2370, 1999.
- Wawrzynczak & Thorpe, In: *Immunoconjugates, Antibody Conuugates In Radioimaging And Therapy Of Cancer*, Vogel (Ed.), NY, Oxford University Press, 28, 1987.
- Wrammert *et al*, *Nature*, 453:667-671, 2008.
- Xu *et al*, *Anal. Biochem.*, 336:262-272, 2005.
- Yuste *et al*, *Clin. Exp. Immunol*, 128:41 1-415, 2002.
- Zhou *et al*, *Infect. Immun.*, 70:4083-4091, 2002.
- Zhou *et al*, *Infect. Immun.*, 72:3505-3514, 2004.

WHAT IS CLAIMED IS:

1. A human monoclonal antibody panel comprising a plurality of antibodies, wherein antibodies in said panel bind to at least 15 serotypes of *Streptococcus pneumoniae*.
2. The antibody panel of claim 1, wherein antibodies in said panel bind to at least 18 *S. pneumoniae* serotypes.
3. The antibody panel of claim 2, wherein antibodies in said panel bind to 21 *S. pneumoniae* serotypes.
4. The antibody panel of claim 3, wherein at least 15 antibodies are serotype specific.
5. The antibody panel of claim 4, wherein at least 17 antibodies are serotype specific.
6. The antibody panel of claim 5, wherein 19 antibodies are serotype specific.
7. The antibody panel of claim 1, wherein the antibody panel is attached to a support.
8. The antibody panel of claim 7, wherein the support is a bead, a dipstick, a filter, a membrane, a plate, or a chip.
9. The antibody panel of claim 1, wherein the serotypes are selected from 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 11B, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F and CWPS.
10. The antibody panel of claim 1, wherein at least one antibody reacts with two serotypes.
11. A method of assessing a *Streptococcus pneumoniae* in a subject comprising obtaining a first antibody-containing sample from said subject and assessing binding of antibodies in said sample to a human monoclonal antibody panel comprising a plurality of antibodies, wherein antibodies in said panel bind to at least 15 serotypes of *Streptococcus pneumoniae*.
12. The method of claim 11, wherein antibodies in said panel bind to at least 18 *S. pneumoniae* serotypes.
13. The method of claim 12, wherein antibodies in said panel bind to 21 *S. pneumoniae* serotypes.

14. The method of claim 13, wherein at least 15 antibodies are serotype specific.
15. The method of claim 14, wherein at least 17 antibodies are serotype specific.
16. The method of claim 15, wherein 19 antibodies are serotype specific.
17. The method of claim 11, wherein the antibody panel is attached to a support.
18. The method of claim 17, wherein the support is a bead, a dipstick, a filter, a membrane, a plate, or a chip.
19. The method of claim 11, wherein the serotypes are selected from 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 11B, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F and CWPS.
20. The method of claim 11, wherein at least one antibody reacts with two serotypes.
21. The method of claim 11, wherein said subject is immunocompromised and/or 60 years old or older.
22. The method of claim 11, wherein said subject is suspected of having a *Streptococcus pneumoniae*.
23. The method of claim 11, further comprising treating said subject with an anti-*Streptococcus pneumoniae* therapy if said first antibody-containing sample is found to be positive for one or more serotypes.
24. The method of claim 11, further comprising treating said subject with vancomycin or levofloxacin if first said antibody-containing sample is found to be positive for serotype 19A and/or 19F.
25. The method of claim 11, wherein said first antibody-containing sample is blood, serum, plasma, sputum, or saliva.
26. The method of claim 11, further comprising obtaining a second antibody-containing sample from said subject and assessing binding of antibodies in said second sample to a human monoclonal antibody panel comprising a plurality of antibodies, wherein antibodies in said panel bind to at least 15 serotypes of *Streptococcus pneumoniae*.

27. The method of claim 26, wherein said second antibody-containing sample is blood, serum, plasma, sputum, or saliva.
28. The method of claim 26, wherein said subject was treated with an *anti-Streptococcus pneumoniae* therapy after determining that said first antibody-containing sample was positive for one or more serotypes, and a reduction in antibody titer to serotypes from said first sample indicates that said *anti-Streptococcus pneumoniae* therapy is effective at treating *Streptococcus pneumoniae*.
29. The method of claim 26, wherein said subject was treated with an antibiotic after determining that said first antibody-containing sample was positive for one or more serotypes, and the absence of a reduction in antibody titer to serotypes from said first sample indicates that said *anti-Streptococcus pneumoniae* therapy is ineffective at treating *Streptococcus pneumoniae*.
30. The method of claim 29, further comprising treating said subject with a different *anti-Streptococcus pneumoniae* therapy.
31. An antibody that binds selectively to *Streptococcus pneumoniae*, wherein said antibody has heavy and light chain CDRs as set forth in Table 2.
32. The antibody of claim 31, wherein said antibody is a single chain antibody.
33. The antibody of claim 31, wherein said antibody is a single domain antibody.
34. The antibody of claim 31, wherein said antibody is a chimeric antibody.
35. The antibody of claim 31, wherein said antibody is a Fab fragment.
36. The antibody of claim 31, wherein said antibody is an IgG.
37. The antibody of claim 31, wherein said antibody further comprises an antibiotic linked thereto.
38. The antibody of claim 37, wherein said antibiotic is linked to said antibody through a photolabile linker.
39. The antibody of claim 37, wherein said antibiotic is linked to said antibody through an enzymatically-cleaved linker.

40. The antibody of claim 31, wherein said antibody is conjugated to a nanoparticle or a liposome.
41. A method of treating a *Streptococcus pneumoniae* infection in a subject comprising administering to said subject an antibody according to claim 31.
42. The method of claim 41, further comprising administering to said subject a second anti- *Streptococcus pneumoniae* treatment.
43. The method of claim 42, wherein said second *anti-Streptococcus pneumoniae* treatment is given at the same time as said antibody.
44. The method of claim 42, wherein said second *anti-Streptococcus pneumoniae* treatment is given before and/or after said antibody.
45. The method of claim 41, wherein said antibody is a single chain antibody.
46. The method of claim 41, wherein said antibody is a single domain antibody.
47. The method of claim 41, wherein said antibody is a chimeric antibody.
48. The method of claim 41, wherein said antibody a Fab fragment.
49. The method of claim 41, wherein said antibody is an IgG.
50. The method of claim 41, wherein said antibody further comprises an antibiotic linked thereto.
51. The method of claim 41, wherein said antibiotic is linked to said antibody through a photolabile linker.
52. The method of claim 41, wherein said antibiotic is linked to said antibody through an enzymatically-cleaved linker.
53. The method of claim 41, wherein said antibody is conjugated to a liposome or nanoparticle.
54. The method of claim 41, multiple *anti-Streptococcus pneumonia* antibodies are administered.

55. The method of claim 54, wherein said multiple *anti-Streptococcus pneumonia* antibodies bind to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 *Streptococcus pneumonia* serotypes.





FIG. 1A-B




FIG. 2A-C




FIG. 3A-D




FIG. 4A-C




FIG. 5




FIG. 6A-B




FIG. 7A-B

专利名称(译)	人肺炎链球菌抗体及其用途		
公开(公告)号	EP2810078A4	公开(公告)日	2016-02-17
申请号	EP2013744086	申请日	2013-01-14
[标]申请(专利权)人(译)	俄克拉荷马医学研究基金会		
申请(专利权)人(译)	俄克拉何马医学研究基金会		
当前申请(专利权)人(译)	俄克拉何马医学研究基金会		
[标]发明人	SMITH KENNETH		
发明人	SMITH, KENNETH		
IPC分类号	G01N33/68 C07K16/12 G01N33/53 G01N33/544 G01N33/551		
CPC分类号	G01N33/56944 C07K16/1275 C07K2317/21 C07K2317/33 C07K2317/92 G01N33/6854 G01N2469/10		
优先权	61/593654 2012-02-01 US		
其他公开文献	EP2810078A2		
外部链接	Espacenet		

摘要(译)

本发明涉及特定的单克隆抗体及其片段，其可用于检测，预防和治疗肺炎链球菌感染。特别是，这些抗体可以杀死肺炎链球菌或限制肺炎链球菌的复制。还公开了用于产生此类单克隆抗体的改进方法。